A Comprehensive Guide to Adipose-Derived MSC Characterization: Flow Cytometry from Basics to Clinical Translation

Abstract

This article provides a detailed guide for researchers and drug development professionals on the characterization of adipose-derived mesenchymal stromal cells (ADSCs) using flow cytometry. It covers the foundational principles of ADSC biology and marker expression as defined by the International Society for Cellular Therapy (ISCT). The content explores methodological approaches for panel design, sample preparation, and data analysis, alongside advanced techniques for identifying functionally distinct subpopulations. It addresses common challenges such as heterogeneity, marker instability during culture, and the effects of processing, offering practical troubleshooting and optimization strategies. Finally, it discusses the critical role of flow cytometry in validating ADSCs against other MSC sources and establishing release criteria for Good Manufacturing Practice (GMP)-compliant production, providing a holistic resource for preclinical and clinical development.

Understanding ADSC Biology and International Marker Standards

Adipose-derived mesenchymal stem cells (AD-MSCs), also referred to as adipose-derived stem cells (ADSCs), are multipotent progenitor cells found in adipose tissue. They are characterized by their ability to self-renew and differentiate into various cell lineages, including adipocytes, chondrocytes, osteoblasts, and neural cells [1] [2]. These cells were first isolated from lipoaspirates in 2001 [1] [3], sparking significant interest in the field of regenerative medicine. AD-MSCs are part of the broader family of mesenchymal stromal cells (MSCs) but are distinguished by their unique source and advantageous properties [4].

The isolation of AD-MSCs typically involves enzymatic digestion of liposuction-derived adipose tissue, followed by centrifugation to separate the stromal vascular fraction (SVF)—a heterogeneous mixture of cells—from mature adipocytes. AD-MSCs are then further purified and expanded from this fraction [1] [5]. Their discovery provided an abundant and easily accessible alternative to bone marrow-derived MSCs (BM-MSCs), positioning AD-MSCs as a cornerstone for developing innovative therapeutic strategies in tissue engineering and regenerative medicine [3].

Adipose tissue serves as a rich and readily available reservoir for harvesting MSCs. AD-MSCs are primarily sourced from subcutaneous white adipose tissue, commonly obtained from the abdomen and thighs through minimally invasive liposuction procedures [1] [6]. The therapeutic potential of these cells began to be fully appreciated with the understanding that the regenerative effects of grafted adipose tissue were not merely due to volume replacement but were driven by the biological activity of the AD-MSCs within the stromal vascular fraction [1].

Abundance in the Stromal Vascular Fraction (SVF)

The SVF is the cellular pellet obtained after enzymatic digestion and centrifugation of adipose tissue. It is a heterogeneous mix that contains AD-MSCs alongside other cell types. The composition of the SVF is detailed in [1]:

• 15–25% mesenchymal stromal cells (AD-MSCs)
• 10–20% endothelial progenitor cells
• 25–35% pericytes
• The remainder consists of endothelial cells, preadipocytes, smooth muscle cells, lymphocytes, and macrophages [1]

AD-MSCs constitute a significantly higher proportion of the nucleated cell population in their tissue source compared to BM-MSCs in bone marrow. Estimates indicate AD-MSCs represent 1% of SVF cells, a stark contrast to the 0.001–0.002% of BM-MSCs found in bone marrow aspirate [1] [6]. This high relative abundance is a fundamental advantage, reducing the need for extensive in vitro expansion to obtain clinically relevant cell numbers.

Quantitative Yield from Tissue Harvesting

The practical yield of AD-MSCs from adipose tissue underscores their abundance. Up to 1 billion cells can be potentially generated from processing 300 grams of adipose tissue [6]. This high yield is a direct result of the high density of MSCs within adipose tissue and the large volumes that can be safely harvested from patients. This makes adipose tissue a uniquely efficient and productive source for clinical and research applications.

When compared to MSCs derived from other tissues, AD-MSCs possess a collection of distinct advantages that make them particularly suitable for research and clinical use. The following table provides a direct comparison of AD-MSCs with other common MSC sources.

Table 1: Comparative Analysis of Mesenchymal Stem Cell (MSC) Sources

Feature	Adipose-Derived (AD-MSCs)	Bone Marrow-Derived (BM-MSCs)	Umbilical Cord (UC-MSCs)	Menstrual Blood (MenSCs)
Relative Abundance	Very high (~1% of SVF cells) [1]	Very low (0.001-0.002%) [6]	High concentration in Wharton's jelly [6]	Easily collectible [6]
Harvesting Procedure	Minimally invasive (liposuction) [6] [3]	Highly invasive (bone marrow aspiration) [3]	Non-invasive, but limited to birth [6] [7]	Non-invasive [6]
Proliferation Rate	High [6] [7]	Moderate [6]	High [6]	Very high (doubling every 20h) [6]
Key Advantages	Abundant tissue, high yield, easy access, strong immunomodulation [7] [2]	Most established source [6]	High purity, low immunogenicity [6]	High proliferation, few ethical concerns [6]
Major Limitations	Donor variability, need for purification [5] [3]	Low yield, painful harvest, donor age-dependent quality [6] [3]	Limited availability (single time collection) [3]	Relatively new, requires further research [6]

Specific Advantages Over Bone Marrow-Derived MSCs

The comparison to BM-MSCs, the historically "gold-standard" source, is particularly insightful:

• Less Invasive Harvesting: Bone marrow aspiration is a painful procedure associated with patient anxiety, whereas adipose tissue is obtained via liposuction, which is less invasive and better tolerated [3].
• Superior Proliferative Capacity: AD-MSCs tend to proliferate at a faster rate in vitro compared to BM-MSCs, allowing for quicker expansion to therapeutic doses [7].
• Enhanced Resilience: Recent studies suggest AD-MSCs exhibit greater resilience to harsh conditions like oxidative stress and hypoxia, showing enhanced survival rates and angiogenic potential under these conditions compared to BM-MSCs [7].

Immunological and Practical Benefits

AD-MSCs also offer significant immunological and practical benefits for therapy:

• Low Immunogenicity: They can be used in both autologous and allogeneic settings due to low expression of HLA class II molecules and the capacity to inhibit lymphocyte proliferation, reducing the risk of immune rejection [1] [7].
• Autologous Use: Unlike neonatal sources like umbilical cord tissue, which are typically allogeneic, AD-MSCs can be easily obtained for autologous transplantation, eliminating ethical concerns and the risk of transmitting infectious diseases [2] [3].

Characterization of AD-MSCs via Flow Cytometry

The accurate identification and characterization of AD-MSCs are critical for research reproducibility and clinical application. Flow cytometry serves as a powerful, high-throughput tool for this purpose, enabling multi-parameter analysis of specific cell surface markers at the single-cell level [8].

Standard Marker Profile for AD-MSCs

The International Society for Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics and Science (IFATS) have established consensus markers for the identification of human AD-MSCs [5]. The standard immunophenotypic profile is defined as follows:

Table 2: Standard Flow Cytometry Marker Profile for Human AD-MSCs

Marker Category	Markers	Expression	Purpose & Notes
Primary Positive Markers	CD73, CD90, CD105, CD13, CD29, CD44	>80% expression [5]	Define core MSC phenotype; crucial for identification.
Variable/Unstable Marker	CD34	Variable expression [5]	Often positive in freshly isolated SVF but decreases with in vitro culture.
Primary Negative Markers (Hematopoietic)	CD31, CD45, CD235a	<2% expression [5]	Exclusion of endothelial (CD31), pan-hematopoietic (CD45), and erythroid (CD235a) cells.
Secondary Positive Markers	CD10, CD26, CD36, CD49d, CD49e	Expressed [5]	Supplementary positive markers.
Secondary Low/Negative	CD3, CD11b, CD49f, CD106, PODXL	Low or negative [5]	Supplementary negative markers.

Murine AD-MSC Markers and a Purification Workflow

For preclinical research, characterizing mouse AD-MSCs requires a different set of markers. Stem cell antigen-1 (Sca-1) is a widely accepted marker for enriching mouse stem cell populations, including AD-MSCs [5]. A recent study optimized a protocol for purifying mouse AD-MSCs using Sca-1, comparing three different methods. The most effective method involved adherence culture followed by magnetic-activated cell sorting (MACS) [5].

The workflow for this optimal purification and characterization strategy can be visualized as follows, illustrating the key steps from tissue harvest to a purified cell population ready for analysis or experimentation:

This ADSC-AM method (Adherence followed by Magnetic sorting) produced a population with over 95% expression of Sca-1 and CD29, uniform morphology, enhanced proliferation, and superior trilineage differentiation potential, particularly in adipogenesis [5].

The Scientist's Toolkit: Essential Reagents and Materials

Successful isolation, culture, and characterization of AD-MSCs rely on a set of core reagents and materials. The following table details essential components of the research toolkit.

Table 3: Key Research Reagent Solutions for AD-MSC Work

Reagent/Material	Function/Application	Example & Notes
Collagenase Type I	Enzymatic digestion of adipose tissue to release the SVF.	0.3 PZU/mL used in [9]; critical for initial cell yield.
Culture Medium	Supports the growth and expansion of AD-MSCs in vitro.	Often Dulbecco's Modified Eagle Medium (DMEM) [9].
Platelet Lysate	Serum-free supplement for MSC culture; promotes growth.	Preferred over fetal bovine serum (FBS) for clinical translation [9].
Flow Cytometry Antibodies	Identification and characterization of AD-MSCs via cell surface markers.	Positive Panel: CD73, CD90, CD105. Negative Panel: CD31, CD45, CD34 [5].
Sca-1 Microbeads	Purification of mouse AD-MSCs using Magnetic-Activated Cell Sorting (MACS).	Essential for isolating high-purity Sca-1+ mouse AD-MSCs [5].
Tri-lineage Differentiation Kits	Functional validation of MSC multipotency (adipo-, osteo-, chondrogenesis).	Commercial kits available to confirm differentiation potential [5].
Paclitaxel (PTX)	Chemotherapeutic drug for loading into AD-MSCs or derived vesicles for drug delivery studies.	Used at 10 µg/mL to create EV-PTX for anti-tumor applications [9].

Adipose-derived mesenchymal stem cells, with their abundant availability, accessibility, and robust biological properties, present a superior source for MSCs compared to many alternative tissues. Their high yield from minimally invasive harvests and potent proliferative and immunomodulatory capacities make them exceptionally suitable for both basic research and clinical regenerative medicine. The rigorous characterization of AD-MSCs using flow cytometry, guided by international consensus markers, is fundamental to ensuring population purity and experimental reproducibility. As research progresses, overcoming challenges related to standardization and donor variability will further solidify the role of AD-MSCs in shaping the future of therapeutic development.

The therapeutic potential of human multipotent mesenchymal stromal cells (MSCs) has generated markedly increasing interest across diverse biomedical disciplines, with over 1,500 registered clinical trials by 2023 involving conditions ranging from cardiology to neurology [10]. This growing clinical application landscape necessitates robust, standardized criteria for defining MSCs to ensure consistent characterization and reliable comparison of research outcomes. The minimal criteria proposed by the International Society for Cellular Therapy (ISCT) represent the foundational standard for the field, providing a critical framework for identifying MSCs based on plastic adherence, differentiation potential, and specific surface marker expression patterns including CD73, CD90, CD105, and CD44 [11]. For researchers characterizing adipose-derived MSCs (AMSCs) using flow cytometry, these criteria provide the essential starting point for cell identification and isolation, though additional markers may offer further refinement of cellular subsets and functional properties [12].

The ISCT/IFATS Minimal Defining Criteria

The ISCT position statement established three minimal criteria for defining human MSCs. First, MSCs must be plastic-adherent when maintained in standard culture conditions. Second, ≥95% of the MSC population must express CD105, CD73, and CD90, while lacking expression (≤2% positive) of CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR surface molecules. Third, the cells must demonstrate multipotent differentiation potential, specifically the ability to differentiate into osteoblasts, adipocytes, and chondroblasts under standard in vitro differentiating conditions [11].

Core Positive Marker Profiles

The positive marker profile required by ISCT provides the essential signature for MSC identification. These markers have specific biological functions relevant to MSC identity:

• CD73 (ecto-5'-nucleotidase): Catalyzes the conversion of extracellular AMP to adenosine, playing a key role in purine metabolism and immunomodulatory functions.
• CD90 (Thy-1): A glycosylphosphatidylinositol (GPI)-anchored cell surface protein involved in cell-cell and cell-matrix interactions.
• CD105 (endoglin): A component of the TGF-β receptor complex with roles in angiogenesis and cardiovascular development.

While not included in the original ISCT minimal criteria, CD44 (hyaluronic acid receptor) is widely recognized as a characteristic marker of MSCs, particularly those of adipose origin, and is frequently included in characterization panels [12].

Table 1: Core Positive Markers for MSC Identification

Marker	Biological Function	ISCT Requirement	Typical Expression in AMSCs
CD73	Ecto-5'-nucleotidase, adenosine production	≥95% positive	>95% positive [12]
CD90	Cell adhesion, migration, signaling	≥95% positive	>95% positive [12]
CD105	TGF-β receptor complex, angiogenesis	≥95% positive	>95% positive [12]
CD44	Hyaluronic acid receptor, adhesion	Not in ISCT minimal criteria	>95% positive [12]

Negative Marker Profiles and Hematopoietic Exclusion

The absence of hematopoietic and endothelial markers is equally critical for proper MSC identification, ensuring the population is not contaminated with cells of other lineages.

Table 2: Negative Markers for MSC Identification

Marker	Cell Types Identified	ISCT Requirement	Purpose in MSC Identification
CD45	Pan-leukocyte marker	≤2% positive	Excludes hematopoietic cells [13]
CD34	Hematopoietic progenitors, endothelial cells	≤2% positive	Excludes hematopoietic and endothelial cells [13]
CD14/CD11b	Monocytes/macrophages	≤2% positive	Excludes monocyte/macrophage lineage
CD79α/CD19	B cells	≤2% positive	Excludes B lymphocytes
HLA-DR	MHC Class II antigen	≤2% positive	Excludes antigen-presenting cells

Extended Marker Profiles for Adipose-Derived MSCs

While the ISCT criteria provide the minimal standards, research has identified additional markers that offer further refinement of AMSC characterization, particularly for clinical-grade production. These non-classical markers may provide novel information about cellular heterogeneity and functional properties.

Table 3: Extended Marker Profiles for Adipose-Derived MSCs

Marker Category	Specific Markers	Expression in AMSCs	Research Application
Non-classical MSC Markers	CD36, CD163, CD271, CD200, CD273, CD274, CD146, CD248, CD140B	Variable across donors [12]	Assessing population heterogeneity, potentially informative for manufacturing
Perivascular Markers	PDGFR, CD10, α-SMA	PDGFR and CD10 consistently expressed; α-SMA variable [14]	Identifying tissue localization (perivascular adventitia)
Endothelial Progenitor Markers	CD31 (in CD45- fraction)	Positive in adipose-resident microvascular endothelial progenitor cells [13]	Distinguishing vascular progenitors in stromal vascular fraction

Experimental Protocols for Flow Cytometric Characterization

Sample Preparation and Cell Isolation

For adipose-derived MSC characterization, begin with lipoaspirate collection from human donors under approved IRB protocols. The standard isolation protocol involves:

• Tissue Processing: Extract floating adipose tissue layer after natural gravity sedimentation of lipoaspirate. Digest with an equivalent volume of collagenase-based enzyme solution (0.2% collagenase with 3 mM CaCl₂, with optional addition of 1000 U/mL DNase1 and 0.1% Poloxamer 188) at 37°C for 30-60 minutes with agitation [13].

• Stromal Vascular Fraction (SVF) Isolation: Centrifuge digested tissue at 400-800 × g for 5-10 minutes. Collect the resulting cell pellet (SVF) and wash with HBSS or PBS. Pass through sequential cell strainers (100μm followed by 40μm) to remove debris [13] [12].

• Erythrocyte Lysis: Treat SVF with buffered ammonium chloride solution (154 mM NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA) or commercial red blood cell lysis solution to remove erythrocytes [13] [12].

• Cell Counting and Viability Assessment: Determine nucleated cell count and viability using fluorescent cell counter with acridine orange/propidium iodide staining or similar viability dyes [13].

Flow Cytometry Staining Protocol

The following protocol provides a standardized approach for MSC immunophenotyping:

• Cell Preparation: Resuspend cells in FACS buffer (0.5% BSA, 2 mM EDTA in PBS). For cultured cells, dissociate with TrypLE Express Enzyme or similar non-enzymatic cell dissociation solution [13].

• Viability Staining: Treat cells with fixable viability dye (e.g., Fixable Viability Dye eFluor 780) to exclude dead cells from analysis [13].

• Fc Receptor Blocking: Incubate cells with human Fc block reagent (e.g., Human BD Fc Block) for 10 minutes on ice to prevent nonspecific antibody binding [13].

• Surface Marker Staining: React cells with fluorescent-conjugated specific antibodies for 30 minutes on ice, protected from light. Use antibody cocktails designed to include both positive and negative ISCT markers.

• Washing and Resuspension: Wash cells twice with FACS buffer to remove unbound antibody, then resuspend in fresh buffer for acquisition.

• Controls: Include isotype controls and universal negative controls for proper gating and compensation [13].

Instrument Setup and Data Acquisition

Proper instrument configuration is essential for reproducible results:

• Instrument Optimization: Adjust photomultiplier tube (PMT) voltages to produce optimal resolution of dim populations while ensuring bright populations remain within dynamic range [15].

• Compensation: Set compensation using single-stain controls for each fluorochrome in the panel [16].

• Acquisition Parameters: Collect forward scatter (FSC) and side scatter (SSC) to assess cell size and granularity. Acquire a sufficient number of events (typically 10,000-100,000 viable cells) for robust population analysis.

• Gating Strategy:

  • Exclude debris based on FSC/SSC characteristics
  • Exclude doublets using FSC-H vs FSC-A
  • Select viable cells based on viability dye exclusion
  • Analyze marker expression on viable single cells

Flow Cytometry Gating Strategy

Research Reagent Solutions for MSC Characterization

A standardized set of reagents is essential for reproducible MSC characterization. The following toolkit outlines essential materials for flow cytometric analysis of adipose-derived MSCs.

Table 4: Essential Research Reagents for MSC Flow Cytometry

Reagent Category	Specific Examples	Function/Purpose
Digestion Enzymes	Collagenase Type I (0.075-0.2%) [13] [12]	Tissue dissociation to isolate stromal vascular fraction
Cell Separation	MACS CD45 and CD31 microbeads [13]	Magnetic-activated cell sorting for progenitor enrichment
Viability Stains	Fixable Viability Dye eFluor 780 [13]	Exclusion of dead cells during flow analysis
Fc Block	Human BD Fc Block Reagent [13]	Prevent nonspecific antibody binding
Positive ISCT Markers	Anti-CD73, CD90, CD105 antibodies [11] [12]	Confirmation of MSC phenotype per ISCT criteria
Negative ISCT Markers	Anti-CD45, CD34, CD14, CD19, HLA-DR antibodies [11] [13]	Exclusion of hematopoietic lineages
Extended Characterization	Anti-CD36, CD163, CD271, CD200, CD146, CD140b [12]	Assessment of MSC heterogeneity and subpopulations
Culture Media	EGM-2MV BulletKit [13]	Expansion and maintenance of purified cell populations

Methodological Considerations and Technical Challenges

Characterizing freshly isolated MSCs presents specific technical challenges that researchers must address. The inherent rarity of MSCs in source tissues (0.001-0.01% in bone marrow; 1-10% in adipose SVF) necessitates careful experimental design and appropriate controls [10] [12]. Additionally, MSC heterogeneity across donors, tissues, and cell subpopulations requires multiparameter approaches for comprehensive characterization [10].

The enzymatic digestion process during cell isolation may potentially affect surface epitopes, necessitating careful validation of antibody binding post-digestion [10]. Furthermore, changes in MSC phenotype during in vitro expansion highlight the importance of standardized passage number reporting and comparison of cells at similar population doublings [10] [17].

For clinical-grade applications, growing AMSCs in human platelet lysate (hPL) rather than fetal bovine serum provides a xeno-free alternative that may influence marker expression profiles and growth characteristics [12].

Experimental Workflow for Adipose-Derived MSC Characterization

The ISCT/IFATS criteria provide the essential foundation for MSC identification, with CD73, CD90, CD105, and CD44 serving as core positive markers for adipose-derived populations. Standardized flow cytometry protocols implementing these criteria enable consistent characterization across laboratories and studies. As the field advances, incorporating extended marker panels that account for MSC heterogeneity while maintaining adherence to these core standards will enhance both basic research and clinical translation of adipose-derived MSC therapies. Proper implementation of these protocols with attention to technical details in cell preparation, instrument optimization, and data analysis ensures reliable, reproducible characterization of these clinically valuable cell populations.

The accurate characterization of adipose-derived mesenchymal stromal/stem cells (ASCs) via flow cytometry is a cornerstone of reproducible research in regenerative medicine and drug development. The foundational step in this process is the exclusion of hematopoietic lineages to isolate a pure stromal cell population. The critical markers for this negative selection—CD45, CD34, CD31, and HLA-DR—form an essential immunophenotypic signature. The dynamic nature of CD34 expression, which can be positive in native ASCs but is often lost in culture, adds a layer of complexity that researchers must navigate [18]. This technical guide details the role of these exclusion markers, provides standardized protocols, and frames their use within the broader context of characterizing adipose-derived MSCs for robust scientific outcomes.

The Core Hematopoietic Exclusion Markers

The International Society for Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics and Science (IFATS) have established consensus panels for characterizing stromal cells. The following table summarizes the core hematopoietic exclusion markers and their roles in identifying ASCs.

Table 1: Core Hematopoietic Exclusion Markers for ASC Characterization

Marker	Common Name	Expression on ASCs	Primary Function	Lineage Excluded
CD45	Leukocyte Common Antigen	Negative [18] [19]	Receptor-linked protein tyrosine phosphatase	All hematopoietic cells (except erythrocytes) [18]
CD31	PECAM-1	Negative [18] [14]	Cell adhesion, angiogenesis, platelet function	Endothelial cells, platelets, some leukocytes [18]
HLA-DR	MHC Class II	Negative (on cultured ASCs) [18]	Antigen presentation	Antigen-presenting cells (e.g., B cells, macrophages)
CD34	-	Variable (Positive in situ/SVF, often lost in culture) [18]	Cell adhesion, hematopoiesis	Used with others to exclude hematopoietic stem cells

CD34 requires special consideration. In the stromal vascular fraction (SVF) of adipose tissue, native ASCs are defined as CD45-/CD31-/CD34+ [18]. One study found this population represents approximately 51.1% ± 5.3% of viable SVF cells [20]. However, during in vitro culture and expansion, ASCs frequently lose CD34 expression, and long-term cultured ASCs are typically CD34- [18]. This dynamic expression necessitates reporting both the passage number and culture conditions for accurate interpretation.

Experimental Protocols for Flow Cytometry Analysis

Sample Preparation from Adipose Tissue

The initial isolation of cells from adipose tissue is a critical step that impacts all downstream analyses.

• Reagents & Equipment: Collagenase IV, DNAse I, Dulbecco's Phosphate-Buffered Saline (PBS), Fetal Bovine Serum (FBS), RPMI 1640 medium, Ficoll-Paque, RBC lysis buffer, sterile scissors, 70 µm cell strainer, centrifuge, and sterile bench [21].
• Step-by-Step Protocol:
  • Digestion: Mince approximately 1-2 cm³ of adipose tissue into tiny pieces (1-2 mm) and transfer to a digestion buffer containing 0.2 mg/mL Collagenase IV and 0.05 mg/mL DNAse I in RPMI 1640 with 10% FBS [21].
  • Incubation: Incubate the mixture for 1 hour at 37°C with gentle agitation [21].
  • Suspension Creation: Gently pipette the digested tissue up and down 6-8 times using a serological pipette to achieve a single-cell suspension [21].
  • Filtration and Washing: Filter the suspension through a 70 µm cell strainer into a 50 mL tube. Wash the well with PBS and add it to the filtered suspension. Centrifuge at 365 × g for 5 minutes at 25°C [21].
  • Density Gradient Centrifugation: Resuspend the cell pellet in PBS and carefully layer it over a 10 mL room-temperature Ficoll-Paque gradient. Centrifuge at 1,800 × g for 25 minutes at room temperature with low acceleration and brake settings [21].
  • Harvesting Mononuclear Cells: Collect the mononuclear cell layer at the PBS-Ficoll interface, transfer to a new tube, and top up with PBS. Centrifuge at 365 × g for 5 minutes at 4°C to pellet the cells, which constitute the Stromal Vascular Fraction (SVF) [21].

Staining and Flow Cytometry Gating Strategy

The gating strategy is a systematic process to isolate the target ASC population from a complex cell mixture.

Diagram 1: Flow cytometry gating strategy for ASCs.

• Reagents: Fluorochrome-conjugated monoclonal antibodies against CD45, CD31, HLA-DR, and CD34. A viability dye, such as ViaKrome or CALCEIN-AM, is essential to exclude dead cells and debris [20].
• Staining Procedure:
  • Preparation: Resuspend the prepared SVF or cultured ASCs in an appropriate buffer.
  • Viability Staining: Incubate cells with a viability dye for 15-30 minutes, protected from light [20].
  • Surface Marker Staining: Incubate cells with a pre-titrated antibody cocktail for 15-20 minutes at room temperature, protected from light [20].
  • Washing and Analysis: Wash cells twice to remove unbound antibody, resuspend in buffer, and analyze immediately on a flow cytometer.

The Scientist's Toolkit: Essential Research Reagents

The following table outlines key reagents required for the reliable characterization of ASCs using flow cytometry.

Table 2: Essential Research Reagents for ASC Characterization

Reagent / Equipment	Function / Specificity	Application Note
CD45-APC [20]	Pan-hematopoietic cell marker	Critical for the initial exclusion of all leukocytes.
CD31-PE [20]	Endothelial cell marker	Excludes endothelial cells and their progenitors.
CD34-PC7 [20]	Hematopoietic stem/progenitor & ASC marker	Used as a positive marker for native ASCs in SVF; expression is culture-dependent.
Viability Dye [20]	Distinguishes live/dead cells	Excludes debris and dead cells induced by the isolation protocol; ensures analysis of live cells only.
Collagenase IV [21]	Digests collagen in tissue	Essential for breaking down the extracellular matrix of adipose tissue to release SVF cells.
Ficoll-Paque [21]	Density gradient medium	Separates mononuclear cells (including ASCs) from other components like adipocytes and red blood cells.

The precise identification of adipose-derived MSCs hinges on a rigorous flow cytometry strategy centered on the hematopoietic exclusion markers CD45, CD31, and HLA-DR, coupled with a nuanced understanding of CD34's dynamic expression. Adherence to standardized protocols for sample preparation, staining, and gating, as outlined by international societies, is paramount for generating reliable, comparable data across different laboratories. As the field advances, these foundational practices will continue to underpin high-quality research and the successful translation of ASC-based therapies from the bench to the clinic.

The characterization of adipose-derived mesenchymal stromal cells (ASCs) has long relied on a set of classical surface markers defined by international societies. According to the International Society for Cellular Therapy (ISCT) and the International Federation of Adipose Therapeutics and Sciences (IFATS), cultured ASCs are typically identified by the expression of CD73, CD90, CD105, and CD44, along with the absence of hematopoietic and endothelial markers such as CD45, CD31, and CD34 (though CD34 expression in native ASCs remains a subject of discussion) [18]. While these markers provide a basic framework for identifying MSC populations, they offer limited insight into the functional heterogeneity, tissue origin, or therapeutic potential of specific ASC subpopulations. The growing application of ASCs in regenerative medicine demands more sophisticated characterization methods that link surface marker profiles to biological function [22] [12].

The isolation of ASCs from the stromal vascular fraction (SVF) of adipose tissue yields a heterogeneous cell population containing stem cells, endothelial cells, pericytes, fibroblasts, and blood cells [23]. This heterogeneity presents a significant challenge for clinical applications, as undefined cell populations may lead to inconsistent therapeutic outcomes. Furthermore, the distinction between ASCs and fibroblasts remains particularly challenging due to their similar morphology, plastic adherence, and overlapping surface marker expression [24] [25]. This technical guide explores the emerging landscape of non-classical and functionally relevant markers that provide enhanced resolution for characterizing ASC subpopulations, predicting their functional capabilities, and ensuring product quality for clinical applications.

A Deeper Dive into Non-Classical and Functionally Relevant Markers

Research over the past decade has identified numerous non-classical markers that offer insights beyond basic ASC identification. These markers can help distinguish ASCs from other cell types, identify subpopulations with enhanced therapeutic potential, and monitor changes during in vitro expansion. The table below summarizes key non-classical markers, their expression patterns, and potential functional significance.

Table 1: Non-Classical and Functionally Relevant Markers for Adipose-Derived MSCs

Marker	Expression in ASCs	Reported Functional Associations	Utility in Characterization
CD36	Variable expression [22] [23]	Fatty acid uptake, metabolic functions [18]	Distinguishes ASCs from bone marrow MSCs (BM-MSCs) [18]
CD146	Variable expression; defines subpopulations [22] [24] [23]	Perivascular origin, angiogenic potential [24]	Helps discriminate ASCs from fibroblasts [24] [25]
CD271	Variable expression [22] [23]	Neural differentiation potential, more specific marker for BM-MSCs [24]	Helps discriminate adipose-derived MSCs from fibroblasts [24] [25]
CD106 (VCAM-1)	Typically low/absent [18]	Activation marker, cell adhesion	Key negative marker to distinguish ASCs (CD106-) from BM-MSCs (CD106+) [18]
CD200	Variable expression [22] [23]	Immunomodulatory functions [22]	Potential role in immune regulation
CD274 (PD-L1)	Variable expression; defines subpopulations [22] [23]	Immunosuppressive activity [22] [23]	Identifies subpopulations with enhanced wound healing and angiogenic potential [23]
CD248	Variable expression [22] [23]	Proliferative state, perivascular origin [22]	Marker for specific ASC lineages
CD34	Expressed in native ASCs/SVF, often lost in culture [18]	Progenitor cell status [18]	Distinguishes uncultured SVF-derived ASCs; expression diminishes with expansion

Functional Correlations of Key Markers

• CD146 and CD271 in Fibroblast Discrimination: A 2021 study systematically comparing MSCs from multiple tissues to fibroblasts identified CD146 and CD271 as particularly useful for distinguishing adipose-derived MSCs from dermal fibroblasts [24] [25]. These markers showed significant differential expression, providing a tool to authenticate cell populations and reduce the risk of fibroblast contamination in therapeutic products.

• CD274+ Subpopulations with Enhanced Therapeutic Potential: Recent high-resolution immunophenotyping has revealed that the co-expression pattern of CD274 (PD-L1) and CD146 defines a subpopulation (CD274+CD146+) with superior growth rates, clonogenic activity, and wound healing potential in vitro [23]. This subpopulation also demonstrated enhanced capacity for endothelial tube formation, suggesting strong angiogenic potential.

• CD36 as a Discriminatory Marker: The consistent presence of CD36 on ASCs and its general absence on BM-MSCs makes it a valuable tool for verifying the tissue origin of MSC preparations [18]. This is particularly important in manufacturing settings where source validation is a critical quality parameter.

Experimental Protocols: Flow Cytometric Characterization of Non-Classical Markers

Multicolor Panel Design for High-Resolution Phenotyping

Comprehensive characterization of ASC subpopulations requires carefully designed multicolor flow cytometry panels that account for marker expression levels and spectral overlap. The following protocol, adapted from contemporary research, enables precise resolution of complex co-expression patterns [23].

Table 2: Research Reagent Solutions for Multicolor Flow Cytometry

Reagent Category	Specific Product/Example	Function in Protocol
Bright Marker Antibody Panel	Anti-CD73, CD90, CD105, CD166, CD201 [23]	Identifies classical and bright positive markers
Dim Marker Antibody Panel	Anti-CD34, CD36, CD146, CD200, CD248, CD271, CD274, Stro-1 [23]	Resolves weakly expressed but functionally relevant markers
Viability Stain	Fixable Viability Stain 570 (FVS570) [23]	Distinguishes live from dead cells during analysis
Staining Buffer	Brilliant Stain Buffer [23]	Mitigates fluorochrome interactions and improves staining quality
Sheath Fluid & Cleaning	Flow Clean Reagent, 70% Ethanol [23]	Maintains instrument fluidics and prevents sample carryover

Procedure:

• Cell Preparation: Harvest subconfluent ASCs (≤80% confluence) at passage 3-4 using 0.25% trypsin [24]. Wash cells with PBS containing 1% penicillin/streptomycin.
• Viability Staining: Resuspend cell pellet in PBS and incubate with Fixable Viability Stain 570 at room temperature for 15 minutes, protected from light [23].
• Surface Marker Staining: Centrifuge cells and resuspend in Brilliant Stain Buffer containing pre-titrated antibody cocktails. Two separate panels are recommended:
  • Panel A (Bright Markers): CD73, CD90, CD105, CD166, CD201 [23].
  • Panel B (Dim Markers): CD34, CD36, CD146, CD200, CD248, CD271, CD274, Stro-1 [23]. Incubate at 4°C for 30 minutes in the dark.
• Sample Processing: Pass stained cell suspensions through a 70 µm mesh filter to ensure single-cell formation [23].
• Flow Cytometry Analysis: Acquire data on a flow cytometer equipped with at least 3 lasers (488nm, 561nm, 640nm). Use single-stained compensation beads (e.g., BD CompBeads) for each fluorochrome to create a compensation matrix [23].
• Data Analysis: Analyze co-expression patterns using advanced flow cytometry software (e.g., Kaluza). Focus on identifying subpopulations based on combinatorial marker expression rather than just individual marker positivity.

Figure 1: Experimental workflow for high-resolution ASC immunophenotyping.

Fluorescence-Activated Cell Sorting (FACS) of Functional Subpopulations

To isolate specific subpopulations for functional validation, the following FACS protocol can be implemented [23]:

Procedure:

• Cell Preparation and Staining: Follow steps 1-4 of the flow cytometry protocol, using only the dim marker panel (Panel B) for sorting.
• Buffer Preparation: Use a sorting buffer based on PBS supplemented with 50% Accumax and 25mM HEPES to prevent cell aggregation [23].
• Instrument Setup: Decontaminate the sorter sheath line with 70% ethanol for 1.5 hours prior to sorting. Clean the sample line sequentially with Flow Clean reagent, 70% ethanol, and MilliQ water [23].
• Sorting Gates: Define sorting gates based on the desired marker combination (e.g., CD274+CD146+ vs. CD274+CD146-). Use collection tubes containing growth medium with 10% human platelet lysate and 25mM HEPES [23].
• Post-Sort Culture: Plate sorted cells under standard culture conditions and assess functional properties including proliferation, clonogenic activity, trilineage differentiation, and wound healing potential [23].

Marker Selection Logic and Integration into Manufacturing

The selection of appropriate markers should be guided by the specific application and the biological questions being addressed. The following diagram illustrates a logical framework for marker selection in both research and clinical manufacturing contexts.

Figure 2: Logical framework for marker selection strategy in ASC characterization.

The integration of non-classical and functionally relevant markers into standard ASC characterization protocols represents a significant advancement in the field. Moving beyond the basic panel of CD73, CD90, and CD105 to include markers such as CD36, CD146, CD271, CD274, and CD248 provides researchers and clinicians with powerful tools to address critical challenges. These include authenticating cell populations, discriminating against fibroblasts, predicting therapeutic potential, and monitoring product consistency during manufacturing.

The future of ASC characterization lies in the development of standardized, high-resolution immunophenotyping panels that correlate specific marker profiles with functional outcomes. As research continues to elucidate the biological significance of these non-classical markers, their implementation will enhance both fundamental understanding of ASC biology and the efficacy and safety of ASC-based therapies in regenerative medicine.

Adipose-derived stromal/stem cells (ADSCs) represent a promising tool for regenerative medicine and cell therapy, yet their inherent cellular heterogeneity presents a significant challenge for both basic research and clinical application. ADSCs are not a uniform population but rather a mixture of functionally distinct subpopulations with varying differentiation potentials, proliferative capacities, and secretory profiles [26]. This heterogeneity stems from multiple sources, including differences in tissue origin, donor variability, and the complex cellular composition of the stromal vascular fraction (SVF) from which they are derived [27] [28].

The recognition of this heterogeneity is crucial for advancing ADSC characterization through flow cytometry research. The minimal criteria proposed by the International Society for Cellular Therapy (ISCT) for defining mesenchymal stromal cells—including plastic adherence, specific surface marker expression (CD73+, CD90+, CD105+, CD45-, CD34-, CD11b-, CD19-, HLA-DR-), and trilineage differentiation potential—provide a foundational framework but fail to capture the full spectrum of ADSC diversity [26]. Within the adherent ADSC population exist multiple subpopulations with distinct functional attributes, which can be identified and isolated through sophisticated flow cytometric analysis of specific surface markers [27] [29].

Quantitative Profiling of ADSC Subpopulations

Surface Marker Expression Across Studies

Comprehensive flow cytometric analysis has revealed remarkable diversity in surface marker expression patterns among ADSC populations from different sources. The table below summarizes key quantitative findings from recent investigations:

Table 1: Surface Marker Expression Profiles in ADSC Populations

Study Model	CD34+	CD31+	CD45-	CD29+	CD44+	CD90+	CD105+	Sca-1+	Reference
Human SVF (Freshly isolated)	51.06% ± 5.26%	-	>97% (negative)	-	-	-	-	-	[20]
Human ADRCs (Clinical trial)	-	13.9% ± 8.4%	-	-	-	-	-	-	[29]
Mouse ADSC-AM (Purified)	-	-	-	>95%	-	-	-	>95%	[27]
Human P2 ASCs (Culture expanded)	-	-	Weakly positive	-	90.7%	-	Positive	-	[30]

Functional Correlations of Specific Subpopulations

The identification of specific surface markers enables not only population characterization but also correlation with functional outcomes:

Table 2: Functionally Distinct ADSC Subpopulations and Their Characteristics

Subpopulation	Primary Markers	Localization in Tissue	Key Functional Attributes	Clinical/Experimental Correlation
Perivascular ASCs	CD34+/CD31-/CD90+	Outer adventitial ring of vasculature	Multilineage differentiation, tissue stabilization	Proposed as native ASCs in situ [28]
CD31+ ADRCs	CD31+	Vascular endothelium	Potent angiogenic activity, paracrine signaling	Positive correlation with restored erectile function in clinical trial (r=0.5195, p=0.0495) [29]
Sca-1+ Mouse ADSCs	Sca-1+/CD29+	Perivascular region	Enhanced proliferation, adipogenic potential, immune regulation	Superior in angiogenesis and immune regulation assays [27]
Culture-Expanded ASCs	CD44+/CD105+/CD45-	Plastic-adherent fraction from SVF	Immunomodulation, multi-lineage differentiation	Standardized population for therapeutic applications [30]

Experimental Protocols for Subpopulation Characterization

Flow Cytometry Analysis of Freshly Isolated SVF

The immunophenotypic characterization of ADSCs begins with proper isolation and analysis of the stromal vascular fraction. The following protocol has been validated for human adipose tissue:

• Tissue Processing: Process lipoaspirate adipose tissue (50-100ml) through centrifugation at 1,200 × g for 10 minutes to separate the infranatant from mature adipocytes and lipids [20] [30].

• Enzymatic Digestion: Digest adipose tissue fragments in 0.075% collagenase I solution at 37°C for 30-45 minutes with continuous agitation [30].

• SVF Collection: Centrifuge digestate at 1,200 × g for 10 minutes to pellet SVF cells. Resuspend in erythrocyte lysis buffer if necessary, then wash with PBS [27] [30].

• Antibody Staining: Aliquot 1×10^6 cells per tube and incubate with fluorochrome-conjugated antibodies against target surface markers (CD31, CD34, CD45, CD44, CD105) for 20 minutes at 4°C in the dark [20] [30].

• Viability Assessment: Include viability dye (e.g., ViaKrome or CALCEIN-AM) to exclude apoptotic cells and debris [20].

• Flow Cytometry Analysis: Analyze samples using a flow cytometer with appropriate laser configurations and filters. Collect a minimum of 10,000 events per sample [20].

• Gating Strategy:

  • Exclude debris based on forward and side scatter properties
  • Exclude dead cells using viability dye
  • Identify specific subpopulations through sequential gating based on marker combinations

This protocol typically yields SVF with ≥70% viability, with ASCs (CD34+CD31-CD45-) representing approximately 51% of viable cells [20].

Magnetic-Activated Cell Sorting (MACS) for Subpopulation Isolation

For functional studies of specific subpopulations, MACS provides an efficient purification method:

• Cell Preparation: Obtain single-cell suspension from SVF or cultured ADSCs [27] [29].

• Antibody Labeling: Incubate cells with magnetic microbead-conjugated antibodies against target surface markers (e.g., CD31 for angiogenic subpopulation) [29].

• Magnetic Separation: Pass cell suspension through MACS column placed in magnetic field. Retain both positive and negative fractions for comparative studies [27].

• Purity Assessment: Analyze sorted fractions by flow cytometry to confirm enrichment efficiency. CD31+ sorts typically achieve >90% purity [29].

• Functional Validation: Subject sorted subpopulations to functional assays including tube formation assays, differentiation potential assessments, and proteomic analysis of conditioned media [29].

Sca-1-Based Murine ADSC Purification Methods

For mouse studies, Sca-1 represents a key marker for ADSC subpopulation isolation. The following comparative methods have been systematically evaluated:

• Direct Adherence (ADSC-A): Traditional method involving collagenase digestion of inguinal fat pads from C57BL/6J mice (4-6 weeks old), followed by centrifugation and plating of SVF. Non-adherent cells are removed after 24 hours [27].

• Magnetic Sorting Then Adherence (ADSC-M): SVF is first magnetically sorted for Sca-1+ cells before adherence culture [27].

• Adherence Then Magnetic Sorting (ADSC-AM): SVF undergoes initial adherence culture until third passage, followed by magnetic sorting for Sca-1+ cells [27].

Among these methods, ADSC-AM demonstrated superior performance with >95% Sca-1 and CD29 expression, uniform morphology, enhanced proliferation, and unique potential in angiogenesis and immune regulation based on RNA sequencing analysis [27].

Signaling Pathways and Functional Mechanisms

The functional specialization of ADSC subpopulations is governed by distinct molecular pathways that can be visualized through the following diagram:

ADSC Subpopulation Signaling Pathways

The CD31+ ADSC subpopulation demonstrates potent angiogenic effects through secretion of specific proteins including DKK3, ANGPT2, ANAX2, and VIM, which collectively promote tube formation and vascular network stabilization [29]. Concurrently, Sca-1+ murine ADSCs exhibit enhanced proliferative activity and adipogenic potential through distinct signaling pathways that remain to be fully elucidated [27]. These functional specializations enable different ADSC subpopulations to contribute uniquely to tissue repair processes.

Research Reagent Solutions for ADSC Characterization

Table 3: Essential Research Reagents for ADSC Subpopulation Analysis

Reagent/Category	Specific Examples	Research Application	Technical Notes
Collagenase Enzymes	Collagenase Type II (0.25%), Collagenase I (0.075%)	Tissue dissociation for SVF isolation	Concentration optimization required based on tissue source and age [27] [30]
Flow Cytometry Antibodies	CD31-PE, CD34-PC7, CD45-APC, CD44-FITC, CD105-PE, Sca-1-FITC	Immunophenotypic characterization	Include viability dye (ViaKrome) to exclude debris and dead cells [27] [20]
Magnetic Sorting Systems	Magnetic cell sorting (MACS) kits for CD31, Sca-1	Subpopulation isolation for functional studies	Enables separation of specific functional subsets (e.g., CD31+ angiogenic cells) [27] [29]
Cell Culture Media	DMEM-F12 with 10% FBS, adipogenic/osteogenic induction media	Expansion and differentiation assays	Serum lots should be standardized for experimental consistency [30]
Functional Assay Kits	CCK-8 proliferation assay, Oil Red O staining, ALP staining	Assessment of differentiation potential	Quantitative differentiation assays essential for functional validation [30]

The recognition that ADSCs comprise multiple functionally distinct subpopulations has profound implications for both basic research and clinical applications. Flow cytometry serves as an indispensable tool for deconstructing this heterogeneity, enabling researchers to identify and isolate subpopulations with enhanced therapeutic potential for specific applications. The emerging paradigm suggests that future ADSC-based therapies may leverage specific subpopulations rather than heterogeneous mixtures—CD31+ cells for vascular regeneration, Sca-1+ cells for enhanced proliferation and adipogenesis, and specific perivascular subsets for tissue stabilization [27] [29].

Standardization of isolation protocols, characterization methods, and functional validation assays across different laboratories will be essential to advance our understanding of ADSC heterogeneity. The integration of single-cell RNA sequencing technologies with flow cytometric analysis offers promising approaches to further dissect this complexity and identify novel markers for subpopulation isolation [31]. Through continued refinement of these techniques, the field moves closer to harnessing the full therapeutic potential of specific ADSC subpopulations for targeted regenerative applications.

Designing and Executing a Robust Flow Cytometry Assay for ADSCs

Flow cytometry serves as an indispensable tool for the precise characterization of adipose-derived mesenchymal stromal cells (MSCs), a cell population of significant interest in regenerative medicine and therapeutic development [32]. The stromal vascular fraction (SVF) of adipose tissue contains a heterogeneous assembly of cells, including MSCs and endothelial colony-forming cells (ECFCs), which are being investigated for their vasculogenic potential in treating chronic wounds and other conditions [32]. Multicolor flow cytometry enables researchers to dissect this complexity by simultaneously measuring multiple cell surface antigens on individual cells, providing critical immunophenotypic data that defines cellular identity and function. However, the accuracy of this data hinges on proper panel design—a process encompassing strategic fluorochrome selection, thorough spillover compensation, and implementation of appropriate controls. This technical guide outlines core principles and best practices for building robust flow cytometry panels specifically tailored for adipose-derived MSC research, ensuring the generation of reliable, publication-quality data.

Fluorochrome Selection and Panel Design

The selection of fluorochromes is a critical first step in panel design that directly impacts data quality. The primary goal is to minimize spectral overlap between fluorochromes while ensuring sufficient signal intensity for detecting markers of interest.

Strategic Fluorochrome Allocation

The fundamental principle for fluorochrome assignment is to match fluorophore brightness with antigen density [33]. Bright fluorophores such as PE and APC should be paired with antibodies targeting low-abundance antigens, while dimmer fluorophores like FITC can be used for highly expressed markers [33]. For adipose-derived MSC immunophenotyping, this means allocating brighter fluorochromes to key markers that may have low expression levels or require precise discrimination, such as certain differentiation markers or receptors with variable expression.

Additionally, spectrally distinct fluorophores should be used for co-expressed markers to facilitate clear population resolution, whereas spectrally similar fluorophores can be allocated to markers expressed on mutually exclusive cell subpopulations that will be gated separately [33]. This strategy is particularly relevant when analyzing heterogeneous cultures of adipose-derived cells, where distinct subpopulations may coexist [34].

Quantitative Fluorochrome Performance Metrics

The table below summarizes key characteristics of common fluorochromes used in flow cytometry panels for MSC characterization:

Table 1: Common Fluorochromes and Their Characteristics in Flow Cytometry

Fluorochrome	Relative Brightness	Laser Excitation (nm)	Spectral Spillover Considerations	Suitability for MSC Markers
FITC	Moderate	488	Long emission tail; significant spill into PE detector [35]	Highly expressed markers (e.g., CD90, CD105)
PE	Very High	488	High spillover into yellow/green detectors [33]	Low-abundance antigens (e.g., early differentiation markers)
PE-Cy7	High	488, 561	Significant spreading error in multiple channels [33]	Critical subpopulation markers
APC	Very High	633, 640	Minimal spillover with properly selected filters	Low-abundance antigens
APC-Cy7	High	633, 640	Spillover into far-red detectors [33]	Secondary markers
Brilliant Violet 711	High	405, 407	Noticeable spread into PerCP-Cy5.5, APC, PE channels [33]	Mid-to-high abundance antigens

Tandem dyes like PE-Cy7 and APC-Cy7, while bright, can exhibit significant spreading error due to unstable chemical bonds and lot-to-lot variability, complicating data interpretation [33]. The newer "Brilliant" polymer dye series offers high brightness and improved stability but may still contribute to spillover spreading and require careful validation [33].

Panel Design Workflow for Adipose-Derived Cells

The process of building an effective flow cytometry panel follows a logical sequence from marker selection to final validation, with particular considerations for adipose-derived cell populations.

This workflow emphasizes several critical steps specific to adipose-MSC research. Researchers must first define the biological question, which may involve characterizing heterogeneous cultures where immunophenotype adaption occurs during in vitro expansion [34]. When assigning fluorochromes, consider that adipose-derived MSC cultures are often dominated by clones expressing patterns like CD166+CD34- or CD166+CD34+, with minor subsets showing donor-dependent variation [34]. This heterogeneity directly impacts fluorochrome allocation decisions.

Understanding and Managing Spillover

Spectral spillover occurs because fluorochromes emit photons across a range of wavelengths, not just at their peak emission [35]. This overlap must be quantitatively measured and corrected to ensure accurate data interpretation.

Spillover Spread Matrix and Measurement

In conventional flow cytometry, compensation is the mathematical process used to correct for spillover, while in spectral flow cytometry, unmixing algorithms perform a similar function [36] [37]. Both methods rely on high-quality single-stain controls to determine the degree of spectral overlap.

The Spillover Spread Matrix (SSM) is a valuable tool for visualizing how much signal from each fluorophore spills into other detectors [36] [33]. However, with ultra-high parameter panels (up to 50 colors), current SSM versions may have limitations in accurately predicting spillover spread [36]. The Median Mismatch Index (MMI) and robust Standard Deviation (rSD) are additional metrics used to evaluate unmixing accuracy and population spread in complex panels [36].

Table 2: Troubleshooting Spillover and Signal Resolution Issues

Problem	Potential Cause	Solution
Poor population resolution	Excessive spillover spreading	Reassign marker to different fluorochrome; use brighter fluorochrome-antigen pair [33]
Over-compensation	Incorrect compensation values; poor single-stain controls	Use automated compensation; verify control quality [35]
High background in all channels	Dead cells; antibody aggregation; insufficient blocking	Include viability dye; Fc receptor blocking; filter antibodies [38] [39]
Inconsistent spillover between experiments	Tandem dye degradation; lot-to-lot variability	Use fresh tandem dyes; validate new lots [37] [39]

Compensation Methodologies

Three primary compensation methodologies exist, with automated compensation being the recommended approach for multicolor panels:

• Non-pensation: Not recommended as it does not correct for spillover, relying instead on fixed-voltage instruments with wide dynamic range detectors [35].
• Manual Compensation: Error-prone and not recommended for panels with more than 2-3 colors [35]. This "Cowboy Compensation" approach often leads to overcompensation, especially with FCS 2.0 data format limitations [35].
• Automated Compensation: The gold standard for polychromatic flow cytometry, automated compensation uses matrix algebra to solve for actual fluorescence values based on measurements from single-stain controls [35]. This method ensures consistent and accurate compensation when proper controls are used.

Essential Controls for Robust Data

Implementing appropriate controls is fundamental for validating flow cytometry data, particularly when characterizing complex populations like adipose-derived MSCs.

Technical Controls for Signal Resolution

Technical controls address the instrument and reagent-related aspects of data quality:

• Unstained Cells: Determine cellular autofluorescence, which varies by cell type and can be altered by treatment, activation, or fixation [37] [39]. This control is essential for setting baseline fluorescence levels.
• Single-Stain Controls: Required for both compensation (conventional cytometry) and unmixing (spectral cytometry) [37]. These controls must follow four critical rules: (1) positive and negative populations must have identical autofluorescence; (2) the positive signal must be as bright or brighter than experimental samples; (3) the identical fluorophore (including tandem dye lot) must be used; and (4) all controls should receive the same treatment as experimental samples [37].
• Fluorescence Minus One (FMO) Controls: Samples stained with all antibodies in the panel except one [38] [37]. FMO controls are particularly valuable for setting gates for dimly expressed markers or when expression exists on a continuum, as they account for the spread of all other fluorophores into the channel of interest [37] [33].
• Viability Controls: Dead cells exhibit increased autofluorescence and nonspecific antibody binding, potentially leading to inaccurate results [38] [33]. Cell-impermeable dyes like 7-AAD, propidium iodide, or fixable viability dyes allow exclusion of dead cells during analysis [38] [39].

Biological and Reagent Controls

Biological and reagent controls address specificity and experimental variability:

• Biological Controls: Include positive controls (samples known to express the target antigen) and negative controls (samples known not to express the antigen) [37]. These help establish what positive and negative populations should look like under the experimental conditions.
• Isotype Controls: Antibodies with the same immunoglobulin class and subclass as the experimental antibody but with irrelevant specificity [38] [39]. While historically common, their utility is limited unless precisely matched to the experimental antibody in concentration, fluorophore-to-antibody ratio, and formulation [37].
• Fc Receptor Blocking: Particularly important for myeloid cells and macrophages present in adipose-derived SVF, Fc receptors can cause nonspecific antibody binding [37] [39]. Adding excess IgG or specific Fc blocking reagents before staining reduces this nonspecific binding [37].

Experimental Protocols for Panel Validation

Antibody Titration Protocol

Antibody titration is essential for optimizing signal-to-noise ratio and minimizing spillover spreading [37] [33].

• Preparation: Start with the manufacturer's recommended concentration and perform serial 2-fold dilutions in buffer identical to what will be used experimentally [37] [33].
• Staining: Stain a constant number of cells (preferably including both positive and negative populations) with each antibody dilution under standard conditions [33].
• Analysis: Calculate the Stain Index (SI) for each dilution using the formula: SI = (Mean fluorescence of positive population - Mean fluorescence of negative population) / (2 × Standard deviation of negative population) [33].
• Interpretation: Identify the "separating concentration" where the SI is highest, providing optimal distinction between positive and negative cells [33]. The saturation concentration (where all antigen binding sites are occupied) may be higher but can increase spillover spreading.

Voltage Optimization Protocol

Proper detector voltage settings ensure optimal signal resolution without sacrificing linear range.

• Preparation: Use dimly fluorescent beads and brightly fluorescent beads or cells [33].
• Acquisition: Run beads at a series of increasing voltage settings, recording the signal spread (coefficient of variation) at each voltage [33].
• Analysis: Plot the percentage of robust coefficient of variation (%rCV) and robust standard deviation (rSD) against voltage [33].
• Determination: Identify the minimum voltage requirement (MVR) as the lowest voltage on the %rCV curve before the rSD increases significantly [33].

The Scientist's Toolkit: Research Reagent Solutions

Table 3: Essential Reagents for Flow Cytometry of Adipose-Derived MSCs

Reagent Category	Specific Examples	Function & Application
Viability Dyes	7-AAD, Propidium Iodide, Fixable Viability Stains [38] [39]	Distinguish live/dead cells; exclude dead cells with autofluorescence and nonspecific binding from analysis
Fc Blocking Reagents	Human IgG, FcR Blocking Solution [37]	Reduce nonspecific antibody binding to Fc receptors on monocytes/macrophages in adipose tissue
Compensation Beads	Anti-mouse/rat Ig κ beads [37] [34]	Create consistent single-stain controls for compensation, especially when cell numbers are limited
Cell Staining Buffer	PBS with BSA or FBS, azide [39]	Provide protein block to reduce nonspecific binding; maintain cell viability during staining
Enzymatic Cell Dissociation	Collagenase, TrypLE [32] [34]	Generate single-cell suspensions from adipose tissue (SVF) or culture flasks
Fixation Reagents	Paraformaldehyde [39]	Preserve stained samples for delayed acquisition; note: fixation can increase autofluorescence

Building a robust flow cytometry panel for adipose-derived MSC research requires meticulous attention to fluorochrome selection, spillover management, and appropriate control implementation. The dynamic nature of adipose-derived cell immunophenotypes during in vitro expansion [34] necessitates particularly careful panel design and validation. By following the systematic approaches outlined in this guide—including strategic fluorochrome allocation, comprehensive spillover compensation, and rigorous validation protocols—researchers can generate reliable, high-quality data that accurately captures the complexity of these therapeutically promising cell populations. As flow cytometry technology continues to advance, with spectral analyzers enabling higher parameter panels [40], these fundamental principles of panel design will remain essential for scientific rigor and experimental reproducibility.

The isolation and characterization of adipose-derived mesenchymal stem/stromal cells (MSCs) represent a cornerstone of regenerative medicine research. This technical guide details the standardized protocols for processing adipose tissue, from initial extraction of the stromal vascular fraction (SVF) to the preparation of single-cell suspensions optimized for flow cytometry analysis. The precise characterization of these cells via flow cytometry is critical for ensuring population purity, validating therapeutic potential, and fulfilling the identity criteria set by the International Society for Cellular Therapy (ISCT) [25] [41]. This document provides an in-depth framework for researchers and drug development professionals, complete with quantitative data summaries and detailed methodologies to ensure reproducibility and reliability in adipose-derived MSC research.

Adipose Tissue Processing and SVF Isolation

The initial step in obtaining adipose-derived MSCs involves the mechanical and enzymatic breakdown of adipose tissue to liberate the heterogeneous stromal vascular fraction (SVF). The chosen isolation method significantly impacts the yield, viability, and cellular composition of the resulting SVF [42] [43].

Isolation Methodologies

There are three primary approaches for SVF isolation, each with distinct advantages and drawbacks:

• Enzymatic Digestion (L-SVF): This method, considered the traditional standard, involves incubating adipose tissue with collagenase to dissociate the extracellular matrix. The process typically uses a 0.1% collagenase I solution in a 37°C shaker for 30-60 minutes [42] [44]. The digest is then centrifuged, filtered, and treated with a red blood cell lysis buffer to obtain the SVF suspension. While this method yields a high number of cells, it is more expensive, time-consuming, and raises potential regulatory concerns due to the introduction of xenoproteins [42] [45] [43].

• Mechanical Emulsification (M-SVF): This non-enzymatic approach relies solely on physical forces. The adipose tissue is centrifuged, and the intermediate layer is mechanically emulsified by repeatedly passing it between syringes with Luer connectors (e.g., 50 times), followed by centrifugation to pellet the SVF cells [42]. This method is faster, avoids enzyme-related regulatory issues, and is considered a "minimal manipulation" technique in many jurisdictions. Its main drawback is a relatively lower total cell yield compared to enzymatic protocols [43].

• Commercial Closed Systems (C-SVF): Systems like the Celution 800 automate the SVF isolation process within a sterile, closed environment. They often use a proprietary enzyme reagent (e.g., Celase) and integrate standardized washing and centrifugation steps. These systems offer a balance, providing cell yields comparable to laboratory enzymatic digestion while offering enhanced reproducibility, rapid processing, and improved compliance with Good Manufacturing Practice (GMP) standards [42].

Quantitative Comparison of Isolation Methods

The choice of isolation technique directly influences critical initial cell parameters, as summarized in the table below.

Table 1: Quantitative Outcomes of Different SVF Isolation Methods

Parameter	Mechanical Emulsification (M-SVF)	Lab Enzymatic Digestion (L-SVF)	Commercial System (C-SVF)
Average Cell Yield (x10⁴ cells/ml lipoaspirate)	Data not specified in search results	Higher than mechanical methods [43]	Comparable to L-SVF [42]
Cell Viability	Retained viability (up to 98%) [43]	Data not specified	Enhanced proliferation; reduced apoptotic cells [42]
Key Advantages	Simplicity, speed, regulatory compliance [43]	High cell yield [43]	Reproducibility, sterility, viable cell yield [42]
Key Limitations	Lower total cell yield [43]	Cost, processing time, regulatory concerns [42] [43]	System cost, proprietary reagents [42]

SVF to Cultured MSCs: Expansion and Characterization

The freshly isolated SVF is a heterogeneous mixture containing adipose-derived stem cells (ADSCs), vascular cells, immune cells, and other stromal components [43]. To obtain a more homogeneous population of MSCs, the SVF must be cultured and expanded in vitro.

Cell Culture and Maintenance

Freshly isolated SVF cells are plated on standard tissue culture plastic in a basal medium such as Dulbecco's Modified Eagle's Medium (DMEM) or α-MEM, supplemented with 10% Fetal Bovine Serum (FBS) and antibiotics (e.g., 100 U/ml penicillin-streptomycin) [42] [46]. The cultures are maintained at 37°C in a humidified 5% CO₂ atmosphere. Non-adherent cells are removed during the first medium change after 48-72 hours. The adherent, fibroblast-like cells are then allowed to proliferate until they reach 70-90% confluence, after which they are passaged using trypsin/EDTA or enzyme-free cell dissociation solutions [46] [41] [47].

Flow Cytometry Immunophenotyping

Flow cytometry is an indispensable tool for authenticating the identity of the cultured MSCs and ensuring they meet established criteria. The ISCT defines human MSCs by positive expression (≥95%) of CD73, CD90, and CD105, and negative expression (≤2%) of hematopoietic markers CD45, CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR [25] [41]. It is crucial to note that marker expression can vary based on tissue origin and passage number [25].

Table 2: Key Surface Markers for Characterizing Adipose-Derived MSCs and Discriminating from Fibroblasts

Marker Category	Marker	Expression in Adipose-Derived MSCs	Function / Significance
Positive Markers	CD73	Positive (≥95%) [25]	Ecto-5'-nucleotidase; ISCT defining marker.
	CD90	Positive (≥95%) [46] [25]	Thy-1 glycoprotein; ISCT defining marker.
	CD105	Positive (≥95%) [46] [25]	Endoglin; ISCT defining marker.
Negative Markers	CD34	Often negative, but can be positive in native SVF [25] [43]	Hematopoietic progenitor cell marker.
	CD45	Negative (≤2%) [46] [25]	Pan-leukocyte marker; excludes hematopoietic cells.
Additional/MSC-Associated	CD44	Positive [44]	Hyaluronic acid receptor.
	CD106 (VCAM-1)	Can be positive; helps differentiate from fibroblasts [25]	Cell adhesion molecule.
	CD146	Can be positive; helps differentiate from fibroblasts [25]	Pericyte marker.
Fibroblast-Associated	CD26	Reported as fibroblast-specific in some studies, but this is contested [25]	Dipeptidyl peptidase-4.

Preparation of Single-Cell Suspensions for Flow Cytometry

The accuracy of flow cytometry analysis is entirely dependent on the quality of the single-cell suspension. The following protocol is optimized for cultured MSCs.

Detailed Staining Protocol

• Cell Harvesting: Remove culture medium and wash the adherent cells (at ~80% confluence, passage 3-4) with phosphate-buffered saline (PBS). Detach the cells using 0.25% trypsin/EDTA or a non-enzymatic cell dissociation solution, and incubate at 37°C for 3-5 minutes. Neutralize the trypsin with a complete culture medium containing serum [25] [47].
• Washing and Counting: Transfer the cell suspension to a conical tube and centrifuge at 300-400 × g for 5 minutes. Decant the supernatant and resuspend the cell pellet in an appropriate buffer (e.g., PBS with 1% BSA). Perform a viable cell count using a hemocytometer or automated cell counter, adjusting the concentration to 1 × 10⁶ cells/100 µl [25] [47].
• Antibody Staining: Aliquot 100 µl of cell suspension into flow cytometry tubes. Add fluorochrome-conjugated antibodies at the manufacturer's recommended concentrations. Include isotype-matched control antibodies for each fluorochrome to set negative populations and compensate for non-specific binding. Vortex the tubes gently and incubate for 20-30 minutes in the dark at room temperature [25] [47].
• Fixation (Optional): For immediate analysis, cells can be analyzed live. If analysis must be delayed, fix the cells after staining by resuspending them in a 1-4% formaldehyde solution in PBS for 15 minutes, followed by two washes in buffer [47].
• Data Acquisition: Resuspend the final cell pellet in 0.5-1 ml of flow cytometry buffer or PBS. Filter the suspension through a 35-70 µm cell strainer cap into a flow cytometry tube to remove cell clumps. Acquire data immediately on a flow cytometer, analyzing at least 10,000 events per sample [8] [47].

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagent Solutions for Adipose-Derived MSC Research

Reagent / Material	Function / Application	Example
Collagenase Type I	Enzymatic digestion of adipose tissue to extract SVF.	0.1% solution in PBS [42] [44]
Culture Medium	In vitro expansion and maintenance of MSCs.	DMEM or α-MEM + 10% FBS + 1% Pen/Strep [42] [46]
Fluorochrome-Conjugated Antibodies	Immunophenotyping of MSCs via flow cytometry.	Anti-CD73, CD90, CD105; and corresponding isotype controls [25] [47]
Cell Dissociation Solution	Harvesting adherent MSCs to create single-cell suspensions.	Trypsin/EDTA or enzyme-free alternatives [25] [41]
Flow Cytometry Staining Buffer	Provides medium for antibody staining and cell resuspension.	PBS supplemented with 1% BSA or FBS [25] [47]

Experimental Workflow and Characterization Diagrams

The entire process, from raw tissue to characterized cells, can be visualized in the following workflow.

Diagram 1: Workflow from tissue to characterized MSCs.

The subsequent characterization of MSCs relies on a multi-parametric flow cytometry approach to confirm identity and purity, as outlined below.

Diagram 2: Flow cytometry characterization pipeline.

The characterization of adipose-derived mesenchymal stromal cells (AD-MSCs) through flow cytometry is a critical methodology in regenerative medicine and cellular therapy research. The identification and purification of MSCs expanded in culture is crucial for improved yield and optimal therapeutic results, as fibroblasts—the most common cell type in connective tissue—frequently contaminate MSC cultures, potentially affecting cell yield and causing complications after transplantation [25]. AD-MSCs are of particular interest due to their wide accessibility and high regenerative potential, making them promising candidates for stem cell therapy [48]. However, their similarity to fibroblasts in morphology, plastic adherence, immunomodulatory properties, differentiation potential, and surface marker expression creates a significant challenge for researchers seeking to obtain pure populations for experimental and clinical applications [25] [49].

Establishing robust gating strategies is therefore fundamental to accurate AD-MSC characterization. Flow cytometry measures multiple parameters including fluorescence intensity, forward scatter (FSC), and side scatter (SSC) to analyze different cell populations within heterogeneous mixtures [50]. These parameters enable researchers to identify and characterize specific cell populations based on their light-scattering properties and marker expression. The process involves the photomultiplier tube (PMT) detecting emitted light as fluorescing cells pass through the laser beam and converting it to a voltage pulse, with each distinct event corresponding to a single cell or particle [50]. This technical guide provides a comprehensive, step-by-step framework for developing effective gating strategies specifically tailored to AD-MSC research, ensuring accurate identification and characterization of these therapeutically valuable cells.

Critical Surface Markers for AD-MSC Identification

The International Society for Cellular Therapy (ISCT) has proposed minimal criteria for defining MSCs, including adherence to plastic, specific differentiation potential, and expression of particular surface markers [25] [51]. According to these standards, MSCs should express CD105, CD73, and CD90 while lacking expression of hematopoietic markers such as CD45, CD34, CD14 or CD11b, CD79alpha or CD19, and HLA-DR [25]. However, research has revealed complexities in these expression patterns, with CD34—declared by ISCT as a negative surface marker—showing expression in native AD-MSCs [25]. This underscores the importance of tissue-specific marker knowledge.

Advanced studies have identified additional markers that can differentiate AD-MSCs from fibroblasts, a common challenge in MSC research. For AD-MSCs derived from adipose tissue, CD79a, CD105, CD106, CD146, and CD271 have shown utility in distinguishing them from fibroblasts [25]. The expression of CD106 and CD146 appears to be particularly significant, with some studies indicating that CD146 expression occurs in MSCs but not in fibroblasts, while CD106 expression in MSCs is at least tenfold higher than in fibroblasts [25]. Contradicting some previous research, recent evidence suggests that CD26 is not fibroblast-specific, highlighting the evolving nature of marker identification [25].

Table 1: Key Surface Markers for AD-MSC Characterization

Marker	Expression in AD-MSCs	Function/Role	Utility in Fibroblast Discrimination
CD105	Positive	Endoglin; part of TGF-β receptor complex	Higher expression in AD-MSCs [25]
CD73	Positive	Ecto-5'-nucleotidase	Positive in both AD-MSCs and fibroblasts [25]
CD90	Positive	Thy-1 cell surface antigen	Positive in both AD-MSCs and fibroblasts [25]
CD44	Positive	Hyaluronic acid receptor	Positive in both AD-MSCs and fibroblasts [25]
CD34	Variable (positive in native AD-MSCs)	Hematopoietic progenitor cell antigen	Can be positive in AD-MSCs, contrary to ISCT criteria [25]
CD45	Negative	Protein tyrosine phosphatase	Negative in both AD-MSCs and fibroblasts [25]
CD146	Positive	Melanoma cell adhesion molecule	Higher expression in AD-MSCs [25]
CD106	Positive	VCAM-1; vascular cell adhesion protein	Higher expression in AD-MSCs [25]
CD271	Positive	Nerve growth factor receptor	Useful for adipose tissue-derived MSC identification [25]
CD26	Variable	Dipeptidyl peptidase-4	Not fibroblast-specific as previously thought [25]

Recent single-cell RNA sequencing studies have further elucidated distinctions between AD-MSCs and fibroblasts, identifying 30 genes with significant expression differences between these cell types. Genes such as MMP1, MMP3, S100A4, CXCL1, PI16, IGFBP5, and COMP show promise for reliably differentiating between AD-MSCs and fibroblasts [49]. These molecular insights provide additional validation tools for surface marker analyses.

Step-by-Step Gating Strategy

Sample Preparation and Initial Setup

Proper sample preparation begins with the isolation of the stromal vascular fraction (SVF) from adipose tissue. For murine adipose tissue, researchers should dissect the tissue of interest (e.g., perigonadal white adipose tissue) and place it in collection media such as RPMI with 10% FBS [52]. The tissue must be carefully cleaned to remove any contaminating tissues like lymph nodes or gonads, as these will lead to inconclusive findings [52]. Enzymatic digestion is then performed using a collagenase-based solution—for example, collagenase II at 228 U/mL in HBSS supplemented with calcium chloride, magnesium chloride, and zinc chloride [52]. The digestion should occur at 37°C with constant shaking for optimal tissue dissociation.

Following digestion, researchers should process the samples through a series of steps to obtain a single-cell suspension. The protocol involves centrifugation steps to separate the stromal vascular fraction from adipocytes and debris, filtration through cell strainers (typically 100μm and 40μm), and red blood cell lysis if necessary [52] [53]. For flow cytometry staining, cells are resuspended in an appropriate stain buffer such as PBS with 0.5% BSA and 10 mM EDTA [52]. Before antibody staining, cell counts and viability assessments should be performed to ensure sample quality.

Comprehensive Gating Hierarchy

A systematic gating strategy is essential for accurate identification of AD-MSCs within heterogeneous cell populations. The following hierarchy ensures proper identification of viable, single cells expressing characteristic MSC markers:

Diagram 1: Sequential Gating Hierarchy for AD-MSC Identification

Step 1: Elimination of Doublets and Cell Aggregates The initial gating step focuses on identifying single cells by plotting forward scatter-area (FSC-A) against forward scatter-height (FSC-H) [50]. This critical step removes doublets and cell aggregates from analysis, as these can cause inaccurate marker expression interpretation. In this plot, single cells form a diagonal population with proportional FSC-A and FSC-H values, while doublets and aggregates deviate from this population due to their irregular size and signal characteristics [50]. Applying a tight gate around the diagonal population ensures that subsequent analysis is performed only on single cells, significantly improving data accuracy.

Step 2: Viability Gating After selecting single cells, the next step involves excluding dead cells using viability dyes such as Ghost Dye Red 780 or similar membrane-impermeant dyes that distinguish intact from compromised membranes [52]. Live cells with intact membranes exclude these dyes and appear negative, while dead cells with compromised membranes take up the dye and show positive fluorescence [50]. This step is crucial because dead cells can non-specifically bind antibodies, leading to false-positive results and inaccurate characterization of surface marker expression.

Step 3: Identification of Putative MSC Population The putative MSC population is identified by negative selection for hematopoietic and endothelial markers. Researchers should gate on cells negative for CD45 (pan-hematopoietic marker) and CD31 (endothelial marker) [53] [48]. This enriched population contains MSCs and potentially fibroblasts, which share these negative markers. At this stage, light scattering properties can provide additional information—MSCs typically exhibit intermediate forward scatter (size) and side scatter (complexity) characteristics [50].

Step 4: Confirmation of MSC Phenotype The final gating step confirms the MSC phenotype through positive expression of characteristic markers. According to ISCT guidelines, bonafide MSCs should express CD73, CD90, and CD105 [51] [53]. Researchers should create two-dimensional plots displaying combinations of these markers (e.g., CD73 vs CD90, CD105 vs CD90) and gate on populations positive for all three markers [50]. The percentage of cells within this gate represents the proportion of characterized AD-MSCs in the original sample.

Data Visualization and Interpretation

Flow cytometry data can be visualized through various plot types, each offering unique advantages for different analysis stages. Histograms display a single parameter and work best when most cells express a marker of interest with bright staining [50]. Dot plots enable researchers to delineate cell populations using two parameters simultaneously and are particularly useful for establishing hierarchical gating strategies [50]. Density plots and contour plots can help highlight smaller cell populations that might not appear significant in dot plot form, as they visualize population density rather than individual events [50].

When quantifying populations, researchers must understand the relationship between sequential gates. If analyzing a subpopulation within a previously gated population, it's necessary to back-calculate percentages to reflect the proportion of the total original population [50]. For example, if 30.1% of the total population are neutrophils, and 14.5% of neutrophils express IL-17a, then 4.36% (30.1 × 0.145) of the total sample are IL-17a-expressing neutrophils [50]. This approach ensures accurate quantification throughout the gating hierarchy.

Table 2: Key Research Reagent Solutions for AD-MSC Flow Cytometry

Reagent/Resource	Function/Application	Examples/Specifications
Collagenase Enzymes	Tissue digestion to obtain stromal vascular fraction	Collagenase II at 228 U/mL for adipose tissue digestion [52]
Viability Dyes	Discrimination of live/dead cells	Ghost Dye Red 780, cisplatin; used at 1:1000 dilution [52]
Fc Receptor Block	Reduce nonspecific antibody binding	Anti-Mouse CD16/CD32 (clone 93); used at 1:200 dilution [52]
Positive Marker Antibodies	Identification of MSC-characteristic markers	CD105, CD73, CD90, CD44 antibodies [25] [53]
Negative Marker Antibodies	Exclusion of non-MSC populations	CD45, CD34, CD31, CD14 antibodies [25] [53]
Discrimination Antibodies	Distinguish MSCs from fibroblasts	CD106, CD146, CD271 for adipose-derived MSCs [25]
Stain Buffer	Antibody dilution and cell resuspension	PBS with 0.5% BSA and 10 mM EDTA; stable for 6 months at 4°C [52]
Flow Cytometry Instrument	Multi-parameter cell analysis	5-laser systems capable of detecting 17+ fluorescent parameters [54]

Advanced Technical Considerations

Multicolor Panel Design and Optimization

Modern flow cytometry instruments can measure up to 17 fluorescent colors simultaneously, enabling comprehensive immunophenotyping [54]. When designing multicolor panels for AD-MSC characterization, researchers must consider fluorophore brightness, antigen density, and potential spectral overlap. Brighter fluorophores should be paired with markers expressed at lower densities, while dimmer fluorophores can be used with highly expressed markers [54]. Comprehensive compensation controls are essential for accurate signal separation in multicolor experiments, particularly when using fluorophores with overlapping emission spectra.

Antibody titration is a critical yet often overlooked step in panel optimization. Researchers should perform titrations for each antibody lot to determine the optimal concentration that provides the best signal-to-noise ratio. Using excessive antibody can increase background fluorescence and non-specific binding, while insufficient antibody may result in weak signal intensity and poor population resolution [52]. Most commercial antibodies provide recommended starting concentrations, but these should be verified for each specific application.

Troubleshooting Common Issues

Several technical challenges can arise during AD-MSC flow cytometry analysis. Low cell yield after digestion often results from incomplete tissue dissociation or enzymatic activity variability between collagenase lots [52]. Researchers should verify enzyme activity and consider adjusting digestion time or enzyme concentration. High background fluorescence can stem from insufficient washing, inadequate Fc receptor blocking, or antibody concentrations that are too high [52]. Implementing additional wash steps, optimizing blocking conditions, and titrating antibodies can mitigate these issues.

Poor population resolution in scatter plots may indicate problems with cell viability or single-cell suspension quality. Researchers should ensure viability is maintained throughout processing by working quickly on ice, using proper media formulations, and processing samples within 24 hours of dissection [52]. If population resolution remains problematic, using additional discriminatory markers such as CD106 and CD146 can help distinguish AD-MSCs from fibroblasts within the CD45⁻CD31⁻ population [25].

Experimental Protocols for AD-MSC Characterization

Standardized Protocol for Flow Cytometric Analysis of AD-MSCs

Materials and Equipment:

• Stain buffer (PBS with 0.5% BSA and 10 mM EDTA)
• Fc receptor blocking solution (e.g., anti-CD16/CD32 for murine cells)
• Viability dye (e.g., Ghost Dye Red 780)
• Antibody cocktail against target markers
• Flow cytometer with appropriate laser and detector configuration
• Centrifuge capable of 400 × g
• Ice bucket or refrigerated centrifuge

Procedure:

• Sample Preparation: Harvest AD-MSCs at subconfluency (≤80%) after reaching passage 3 [25]. Use 0.25% trypsin for cell detachment, followed by washing with PBS containing 1% penicillin/streptomycin [25].

• Cell Counting and Viability Assessment: Count cells using a hemocytometer or automated cell counter. Adjust concentration to 1×10⁴ to 1×10⁶ cells per 100μL of stain buffer for antibody staining [53].

• Fc Receptor Blocking: Resuspend cell pellet in Fc block solution diluted in stain buffer (1:200 dilution) [52]. Incubate for 20 minutes at 4°C to prevent nonspecific antibody binding.

• Viability Staining: Add viability dye at recommended dilution (typically 1:1000) [52]. Incubate for 10-15 minutes at 4°C protected from light. Wash cells with 2mL stain buffer and centrifuge at 400 × g for 5 minutes.

• Surface Marker Staining: Prepare antibody cocktail in stain buffer using pre-optimized concentrations. Resuspend cell pellet in antibody solution and incubate for 20 minutes in the dark at 4°C [25]. Include unstained and single-color compensation controls as needed.

• Washing and Acquisition: Wash cells twice with 2mL stain buffer, centrifuging at 400 × g for 5 minutes between washes. Resuspend in 300-500μL stain buffer for immediate acquisition on flow cytometer. Keep samples on ice and protected from light until acquisition.

• Data Collection: Acquire data using flow cytometer, collecting a minimum of 10,000 events within the live, single-cell gate. Adjust instrument settings using compensation controls to ensure proper spectral unmixing.

Data Analysis Workflow

The analysis of acquired flow cytometry data follows a structured approach to ensure accurate population identification and quantification:

Diagram 2: Flow Cytometry Data Analysis Workflow

• Compensation: Apply compensation matrices to correct for spectral overlap between fluorophores using single-stained controls [54].

• Preprocessing: Transform data if necessary (e.g., logarithmic or biexponential transformation) to better visualize populations with broad expression ranges.

• Hierarchical Gating: Apply the sequential gating strategy outlined in Section 3.2, progressing from singlets to live cells to fully characterized AD-MSCs.

• Population Quantification: Record percentages and absolute counts for each population of interest. Calculate the percentage of parent and percentage of total populations as appropriate.

• Statistical Analysis: Perform appropriate statistical tests based on experimental design. Compare marker expression levels between different conditions, donors, or tissue sources.

• Data Visualization: Create publication-quality figures showing representative gating strategies and quantitative comparisons between experimental groups.

Mastering flow cytometry gating strategies is essential for researchers characterizing AD-MSCs in both basic research and clinical applications. The step-by-step approach outlined in this guide—progressing from FSC/SSC through viability staining to definitive marker expression—provides a robust framework for accurate AD-MSC identification and quantification. As the field advances, incorporating new discriminatory markers such as those identified through single-cell RNA sequencing studies will further enhance our ability to distinguish AD-MSCs from contaminating fibroblasts [49]. Additionally, researchers must remain aware of how technical factors such as culture conditions [51] [55] and tissue source inflammation [48] can influence surface marker expression, potentially requiring adjustments to standard gating approaches. By implementing these comprehensive gating strategies and maintaining attention to technical details, researchers can ensure the reliability and reproducibility of their AD-MSC flow cytometry data, advancing both scientific understanding and therapeutic applications of these versatile cells.

The characterization of Adipose-Derived Mesenchymal Stem Cells (ADSCs) through flow cytometry is a critical methodology in regenerative medicine and drug development. This technical guide addresses the core principles of data interpretation—specifically quantifying positivity, Median Fluorescence Intensity (MFI), and population purity—within the context of ADSC research. Accurate interpretation of these parameters is essential for ensuring experimental reproducibility, validating cell product identity, and meeting regulatory standards for therapeutic applications [16] [5]. The inherent heterogeneity of freshly isolated ADSCs necessitates rigorous analytical approaches to distinguish target populations from contaminating cells such as endothelial progenitors, hematopoietic cells, and pericytes [5]. By establishing standardized interpretation frameworks, researchers can advance the clinical translation of ADSC-based therapies with enhanced reliability and predictive value.

Quantitative Data Standards for ADSC Characterization

Marker Expression Profiles and Purity Thresholds

The International Society for Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics and Science (IFATS) have established consensus markers for human ADSCs. These standards provide the foundation for quantifying population purity, with primary positive markers (CD13, CD29, CD44, CD73, CD90, CD105) expected in >80% of the population and primary negative markers (CD31, CD45, CD235a) in <2% [5]. For murine ADSC research, which lacks a formal consensus, Sca-1 (Ly-6A/E) has emerged as a critical enrichment marker, with recent studies demonstrating populations achieving >95% Sca-1 positivity alongside high expression of CD29 [5]. The tabulated data below summarizes key quantitative standards for interpreting ADSC flow cytometry data.

Table 1: Quantitative Marker Expression Standards for ADSC Characterization

Marker Category	Specific Markers	Expression Threshold	Interpretation Guide
Primary Positive Markers	CD73, CD90, CD105	>80% positivity [5]	Confirms MSC identity and population purity
Additional Positive Markers	CD29, CD44, Sca-1 (mouse)	>80-95% positivity [5]	Species-specific identity confirmation
Primary Negative Markers	CD31, CD45, CD235a	<2% positivity [5]	Excludes hematopoietic/endothelial contamination
Unstable Marker	CD34	Variable expression [5]	Context-dependent (useful in SVF, declines in culture)

Control-Based Parameters for Data Interpretation

Appropriate controls establish the foundation for accurate quantification of positivity and MFI. The table below outlines critical control measurements and their specific roles in data interpretation for ADSC flow cytometry.

Table 2: Control-Based Parameters for Flow Cytometry Data Interpretation

Control Type	Measurement Purpose	Interpretation Role in ADSC Analysis
Unstained Cells	Quantifies cellular autofluorescence [38] [37]	Sets baseline for negative population identification
Isotype Controls	Assesses nonspecific antibody binding [38] [37]	Not for gate setting; identifies Fc receptor-mediated binding
FMO Controls	Defines spillover spreading error [38] [37]	Determines accurate positive/negative boundaries for low-expression markers
Biological Controls	Positive: Known antigen-expressing cellsNegative: Knock-out cells or antigen-negative tissues [37]	Validates staining specificity and serves as reference for marker expression status

Experimental Protocols for ADSC Flow Cytometry

Cell Preparation and Staining Protocol

The following protocol outlines the standard methodology for flow cytometric analysis of ADSCs, incorporating critical controls for accurate data interpretation:

• ADSC Isolation and Culture: Isolate ADSCs from adipose tissue lipoaspirates via enzymatic digestion with 0.3 PZU collagenase type I, followed by centrifugation and plating in DMEM supplemented with 5% human platelet lysate and 2mM L-glutamine [56] [5]. Culture cells at 37°C with 5% CO2, expanding until passage 4 maximum to maintain differentiation potential. For murine studies, use Sca-1-based magnetic sorting followed by adherence (ADSC-AM method) to achieve >95% purity [5].
• Sample Preparation for Staining: Harvest cells at 80% confluence using TrypLE Select enzyme detachment [56]. Wash twice with PBS and resuspend in flow cytometry buffer. Determine cell count and viability using impermeable DNA-binding dyes (e.g., 7-AAD, propidium iodide) or enzymatic viability dyes (e.g., calcein AM) to exclude dead cells during analysis [38].
• Antibody Titration and Staining: Prior to full experiment, titrate all antibody conjugates to determine optimal staining concentration that provides the best signal-to-noise ratio [37]. Include Fc receptor blocking step using purified IgG, serum, or specific blocking reagents for 10-15 minutes before antibody addition, particularly important for ADSCs which may express Fc receptors [38] [37]. Stain cells with predetermined antibody concentrations for 20-30 minutes in the dark at 4°C [37].
• Control Sample Preparation: Prepare unstained cells (autofluorescence control), isotype controls (matched to primary antibodies), and FMO controls for each channel in multicolor panels [38] [37]. For spectral flow cytometry, prepare single-stain controls using either beads or cells stained with each individual antibody conjugate [37].

Gating Strategy for Quantifying Positivity and Purity

Implement a sequential gating strategy to accurately identify target ADSC populations and quantify marker expression:

• Forward Scatter (FSC) vs. Side Scatter (SSC) Gating: Create an initial gate on the FSC-A vs. SSC-A plot to exclude debris and select the intact cell population based on light scattering properties [57].
• Singlets Gating: Plot FSC-A vs. FSC-H to gate on single cells, excluding doublets and aggregates that can cause inaccurate fluorescence measurements [16].
• Viability Gating: Select viable cells using viability dye staining (e.g., 7-AAD-negative or calcein AM-positive populations) to eliminate artifacts from dead cells [38].
• Phenotypic Gating for Population Purity: Apply consecutive gates using positive and negative marker combinations to establish population purity. For human ADSCs: CD73+/CD90+/CD105+ and CD31-/CD45- [5]. For murine ADSCs: Sca-1+/CD29+/CD44+ and CD31-/CD45- [5].
• Quantification of Positivity: Using the pre-gated viable, single ADSC population, create histogram overlays or biparametric plots to quantify marker positivity. Set positive/negative boundaries based on FMO controls, not isotype controls, particularly for markers with continuous expression patterns or low expression levels [38] [37].

Diagram 1: Gating strategy for ADSC analysis.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Essential Research Reagent Solutions for ADSC Flow Cytometry

Reagent Category	Specific Examples	Function in ADSC Characterization
Digestive Enzymes	Collagenase Type I (0.3 PZU) [56]	Liberates ADSCs from adipose tissue matrix
Culture Supplements	Human Platelet Lysate (5%) [56] [58]	Xeno-free expansion medium for clinical applications
Positive Marker mAbs	CD73, CD90, CD105 (human)Sca-1, CD29, CD44 (mouse) [5]	Confirms MSC identity and species-specific markers
Negative Marker mAbs	CD31, CD45, CD235a [5]	Detects hematopoietic/endothelial contamination
Viability Indicators	7-AAD, Propidium Iodide, DRAQ7 [38]	Impermeable dyes that identify dead cells
Fc Blocking Reagents	Purified IgG, FcR Blocking Serum [38] [37]	Reduces nonspecific antibody binding
Compensation Beads	Anti-Ig Compensation Beads [38]	Creates consistent single-stain controls for compensation

Advanced Data Interpretation Techniques

Interpreting Median Fluorescence Intensity (MFI)

Median Fluorescence Intensity provides quantitative information about antigen density on the cell surface, which can reflect functional status or differentiation state. When interpreting MFI:

• Relative Fluorescence Intensity: Calculate relative MFI by comparing the MFI of the stained sample to the MFI of the FMO control or biological negative control. This normalized value allows for comparisons across different samples and experiments [57].
• MFI Ratio for Low Abundance Markers: For markers with low expression levels, use the ratio of MFI of the positive population to MFI of the negative population (as defined by FMO controls) rather than relying solely on percentage positive [37].
• MFI Trends in Culture: Monitor MFI trends across passages for specific markers. For instance, decreasing CD34 MFI in human ADSCs during in vitro expansion confirms expected phenotypic changes [5].

Statistical Analysis and Reporting Standards

Robust statistical analysis is essential for reliable interpretation of flow cytometry data:

• Replicate Strategy: Include technical replicates (multiple aliquots of same sample) and biological replicates (different donor samples) to account for both technical variability and biological diversity [5].
• Reporting Flow Cytometry Data: When publishing, include representative scatter plots and histograms that show the gating strategy and FMO controls for critical markers [57]. Clearly state the number of events acquired, the percentage of parent population for each gate, and the MFI values with appropriate measures of dispersion.
• Data Reprodubility: Follow the MIFlowCyt standards to ensure data reproducibility, including detailed descriptions of instrument settings, reagent clones, and gating strategies [16].

Diagram 2: MFI data processing workflow.

The stromal vascular fraction (SVF) of adipose tissue represents a highly heterogeneous mixture of cells, containing not only adipose-derived mesenchymal stromal/stem cells (ASCs) but also endothelial progenitor cells, pericytes, preadipocytes, endothelial cells, smooth muscle cells, lymphocytes, macrophages, and other cell types [27]. This inherent heterogeneity presents a significant challenge for functional studies, as unpurified cell populations can yield inconsistent and unpredictable experimental outcomes in both preclinical models and clinical applications [27]. Flow cytometric cell sorting (FACS) has emerged as a powerful technological solution to this problem, enabling researchers to isolate highly pure subpopulations of adipose-derived MSCs based on specific cell surface markers for downstream functional analyses.

The biological source of this cellular heterogeneity lies in the native structure of adipose tissue. When adipose tissue is separated, it divides into mature adipocytes and a stromal vascular fraction containing a heterogeneous mesenchymal cell population that includes hematopoietic stem cells, endothelial cells, erythrocytes, fibroblasts, pericytes, myeloid and lymphoid cells, and adipose stromal cells [59]. When this heterogeneous SVF is cultured, the adherent cells form a more homogeneous population of mesenchymal stem/progenitor cells referred to as adipose-derived stromal/stem cells (ASCs) [59]. However, even these adherent cultures often retain significant heterogeneity without further purification steps.

Marker Identification: Defining the Surface Proteome of Adipose-Derived MSCs

Established and Novel Surface Markers

The International Society for Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics and Science (IFATS) have established fundamental criteria for defining MSCs, including specific surface marker profiles. For human adipose-derived MSCs, the consensus recommends positive expression (>80%) of CD73, CD90, and CD105, along with negative expression (<2%) of CD31, CD45, and CD235a [27]. CD34 is classified as a primary unstable positive marker due to its variable expression levels during in vitro culture [27].

However, research has identified numerous non-classical markers that may provide more robust characterization and purification criteria. Studies utilizing quantitative PCR, flow cytometry, and RNA-sequencing have validated nine non-classical markers that may potentially discriminate adipose-derived MSCs from other cell types: CD36, CD163, CD271, CD200, CD273, CD274, CD146, CD248, and CD140B [12]. These markers exhibit variability in cell surface expression among different cell isolates from a diverse cohort of donors, including freshly prepared, previously frozen, or proliferative state adipose-derived MSCs, and may provide novel information for manufacturing cells for clinical applications [12].

For murine adipose-derived MSCs, Sca-1 (Stem cell antigen-1 or Ly-6A/E) has emerged as a particularly valuable marker. Sca-1 is a glycosylphosphatidylinositol-anchored cell surface protein initially identified as a marker for murine hematopoietic cells but now recognized as being expressed in various tissues where it is linked to self-renewal and pluripotency [27]. Sca-1+ adipose-derived MSCs demonstrate enhanced stemness, proliferative capacity, and adipogenic potential compared to unsorted populations [27].

Anatomical Localization and Marker Expression

Immunohistochemical staining of adipose tissue has revealed that cells with immunophenotypic characteristics identical to those of cultured human adipose-derived MSCs are located mainly in the perivascular adventitia rather than the smooth muscle area [14]. These perivascular cells consistently express PDGFR and CD10 regardless of passage number, while expression levels of other markers such as α-SMA, CD68, Oct4, and c-kit vary [14]. This anatomical localization supports the theory that adipose-derived MSCs may represent perivascular precursor cells located near adipose tissue vessels, contributing to angiogenesis and tissue regeneration.

Table 1: Key Surface Markers for Identifying and Isulating Adipose-Derived MSC Subpopulations

Marker	Expression in ASCs	Biological Function	Species Specificity	Utility in FACS
CD73	>80% (Positive)	Ecto-5'-nucleotidase enzyme	Human	Definitive positive marker
CD90	>80% (Positive)	Cell-cell and cell-matrix interactions	Human	Definitive positive marker
CD105	>80% (Positive)	TGF-β receptor component	Human	Definitive positive marker, downregulated in tumour contexts [60]
Sca-1	High in purified populations	Self-renewal and pluripotency	Mouse (Ly-6A/E)	Primary purification marker
CD34	Variable/Unstable	Hematopoietic progenitor cell marker	Human	SVF characterization, unstable in culture
CD31	<2% (Negative)	Endothelial cell adhesion	Human & Mouse	Definitive negative marker
CD45	<2% (Negative)	Leukocyte common antigen	Human & Mouse	Definitive negative marker
CD36	Variable	Fatty acid transporter	Human	Non-classical, functional marker
CD163	Variable	Scavenger receptor	Human	Non-classical, macrophage association
CD271	Variable	Nerve growth factor receptor	Human	Non-classical, primitive population

Technical Approaches: FACS Strategies and Workflow Optimization

Comparative Purification Methodologies

Recent research has systematically compared different methodological approaches for obtaining pure adipose-derived MSC populations. A 2025 study evaluated three purification methods for isolating mouse adipose-derived MSCs based on Sca-1 positivity: direct adherence (ADSC-A), magnetic cell sorting followed by adherence (ADSC-M), and adherence to the third generation followed by magnetic cell sorting (ADSC-AM) [27]. The findings demonstrated significant differences in outcomes based on the purification strategy employed.

The ADSC-AM method (adherence to the third generation followed by magnetic cell sorting) yielded superior results, including uniform morphology, enhanced proliferation, and over 95% expression of Sca-1 and CD29 [27]. While all methods supported trilineage differentiation, ADSC-AM demonstrated particularly enhanced adipogenesis [27]. Furthermore, RNA sequencing and pathway enrichment analysis revealed that ADSC-AM possessed unique potential in angiogenesis and immune regulation, suggesting that this purification method isolates a functionally distinct subpopulation with enhanced therapeutic characteristics [27].

Table 2: Comparison of Murine ASC Purification Methods Based on Sca-1 Positivity

Method	Purity (Sca-1+)	Proliferation Rate	Adipogenic Potential	Key Advantages	Limitations
Direct Adherence (ADSC-A)	Variable (60-85%)	Standard	Moderate	Simple, minimal processing	High heterogeneity
Magnetic Sorting + Adherence (ADSC-M)	High (>90%)	Enhanced	Good	Rapid initial purification	Potential cell activation
Adherence + Magnetic Sorting (ADSC-AM)	Highest (>95%)	Significantly Enhanced	Excellent	Uniform morphology, enhanced functionality	Time-consuming

Comprehensive FACS Workflow

The isolation of pure adipose-derived MSC subpopulations requires a meticulously optimized workflow from tissue harvest through cell sorting and validation. The following diagram illustrates the complete experimental workflow for tissue processing, stromal vascular fraction isolation, and FACS purification:

Critical Technical Considerations for FACS Isolation

Several technical factors significantly impact the success and reproducibility of FACS isolation for adipose-derived MSC subpopulations:

• Collagenase Digestion Parameters: The digestion solution typically consists of 0.075-0.25% collagenase type I or II dissolved in HBSS, supplemented with DNase I and MgCl2, followed by incubation at 37°C for 60 minutes with shaking at 100 rpm until the tissue appears smooth on visual inspection [59] [12]. The concentration and duration of collagenase treatment must be optimized to balance cell yield against potential surface marker degradation.

• Viability Preservation: Maintaining cell viability throughout the isolation process is paramount. The use of calcium-free and magnesium-free HBSS during processing helps prevent cell aggregation [59]. Additionally, including EDTA in the sorting buffer (typically at 1-2 mM) further reduces cell clumping and ensures the formation of a single-cell suspension essential for efficient sorting.

• Antibody Panel Validation: Comprehensive validation of antibody specificity and titers is necessary before FACS isolation. Fc receptor blocking (using anti-mouse CD16/CD32 for murine cells) should be performed prior to antibody staining to minimize non-specific binding [59]. Compensation controls must include all fluorochromes used in the panel, and fluorescence minus one (FMO) controls are essential for establishing accurate gating boundaries, particularly when working with novel marker combinations.

• Sorting Parameters Optimization: Nozzle size (typically 70-100μm), sheath pressure, sort mode (purity vs. yield), and collection tube conditions significantly impact post-sort viability and function. Collection tubes should contain complete medium with higher serum concentrations (20-30% FBS) or addition of DNase I (10-50μg/mL) to prevent cell clumping during extended sort durations.

Functional Validation: Assessing Purified Subpopulations In Vitro and In Vivo

In Vitro Differentiation Capacity

The functional characterization of FACS-isolated adipose-derived MSC subpopulations must include comprehensive differentiation assays. The standard approach involves evaluating trilineage differentiation potential—adipogenic, osteogenic, and chondrogenic—using well-established staining methods [27] [61].

For adipogenic differentiation, the optimized protocol involves a two-phase induction system. Cells are first treated with a basal adipogenic differentiation cocktail typically containing insulin, dexamethasone, and 3-isobutyl-1-methylxanthine (IBMX) [61]. Subsequently, specific factors such as rosiglitazone (a PPARγ agonist) and triiodothyronine (T3) can be added to promote particular adipocyte phenotypes. Research has demonstrated that the combination of 1000 nM rosiglitazone and 0.2 nM T3 optimally induces brown adipocyte differentiation from adipose-derived MSCs, evidenced by multilocular lipid droplets and significant upregulation of UCP1 (19-fold), PPARγ (7.5-fold), and PGC1α (3.8-fold) [61].

Molecular Characterization Techniques

Beyond differentiation capacity, molecular characterization provides critical insights into the functional properties of purified subpopulations:

• Gene Expression Profiling: Quantitative PCR analysis of key markers (UCP1, PPARγ, PGC1α for adipogenesis; RUNX2, osteocalcin for osteogenesis; SOX9, collagen II for chondrogenesis) validates lineage commitment at the molecular level [61].
• RNA-Sequencing: Transcriptomic analysis can reveal unique pathway enrichment in specific subpopulations. For instance, Sca-1+ murine adipose-derived MSCs purified via the ADSC-AM method demonstrated unique potential in angiogenesis and immune regulation pathways [27].
• Immunophenotypic Stability: Longitudinal assessment of surface marker expression across multiple passages confirms the stability of the purified population and ensures consistent experimental results.

In Vivo Functional Studies

The therapeutic potential of FACS-isolated adipose-derived MSC subpopulations must be validated in relevant animal models. A study investigating the effect of murine adipose-derived MSCs on mammary tumour growth and formation of lung metastases found that MSC treatment produced anti-tumour effects with increased necrosis specifically in lung metastatic tumours, associated with decreased CD163+ anti-inflammatory macrophages [60]. This highlights the importance of considering the tissue microenvironment when evaluating MSC functions and demonstrates how purified subpopulations can exert distinct effects in different biological contexts.

In obesity research, transplantation of brown adipocytes differentiated from purified adipose-derived MSCs has demonstrated significant anti-obesity effects. In overweight mice, transplantation of these brown adipocytes increased core temperature by 1.5°C and reduced body weight by 18% and BMI by 14% compared to control groups [61], underscoring the therapeutic potential of functionally defined adipose-derived MSC subpopulations.

Essential Research Reagents and Technical Solutions

Table 3: Research Reagent Solutions for FACS Isolation of Adipose-Derived MSCs

Reagent Category	Specific Products	Application Purpose	Technical Notes
Digestion Enzymes	Collagenase Type I/II (0.075-0.25%)	Tissue dissociation to obtain SVF	Supplement with DNase I (3.3 units/mL) and MgCl2 (1mM) [59]
Cell Staining Reagents	Fc Receptor Block (anti-mouse CD16/CD32)	Reduce non-specific antibody binding	Critical for murine cells; use prior to surface marker staining [59]
Viability Maintenance	Fatty Acid Free BSA (0.1%) in PBS	FACS staining buffer	Prevents cell aggregation during sorting [59]
Selection Markers (Mouse)	Anti-Sca-1 (Ly-6A/E) antibodies	Primary positive selection marker	Yields >95% purity when combined with adherence pre-selection [27]
Positive Markers (Human)	CD73, CD90, CD105 antibodies	Definitive positive identification	Must be expressed >80% in human ASCs [27]
Negative Markers	CD31, CD45, CD235a antibodies	Exclusion of non-MSC populations	Must be expressed <2% in purified populations [27]
Sort Collection Medium	DME/F-12 with 15-30% FBS	Maintain viability during sorting	Higher serum concentration protects cells during collection

The implementation of FACS technologies for isolating pure adipose-derived MSC subpopulations represents a critical advancement in mesenchymal stem cell research. By moving beyond heterogeneous cell populations to defined cellular reagents, researchers can achieve greater experimental reproducibility, develop more predictive disease models, and accelerate the translation of basic research findings into clinical applications. The continued refinement of surface marker panels, coupled with optimized sorting methodologies, will further enhance our understanding of adipose-derived MSC biology and their therapeutic mechanisms across diverse pathological conditions.

Solving Common Challenges in ADSC Flow Cytometric Analysis

The therapeutic potential of adipose-derived mesenchymal stromal cells (AD-MSCs) is significantly hampered by their inherent heterogeneity, which presents a substantial challenge for reproducible clinical applications. AD-MSCs represent a heterogeneous cell population distributed throughout adipose tissue, demonstrating remarkable adaptability to microenvironmental cues but resulting in problematic variability in therapeutic outcomes [62]. This heterogeneity manifests at multiple levels, including molecular variations (transcriptomics, proteomics, secretomics) and functional differences in differentiation potential, immunomodulatory capabilities, and regenerative activities [62] [26].

The critical need to address this heterogeneity is underscored by the transition of AD-MSCs from laboratory research to clinical trials for conditions ranging from immunological and neurological disorders to regenerative medicine applications [31]. As the field advances toward standardized clinical applications, strategies for achieving higher population purity through multi-marker panels have become essential for ensuring consistent, reproducible, and predictable therapeutic outcomes. This technical guide examines current methodologies and emerging approaches for characterizing and purifying AD-MSC subpopulations within the context of flow cytometry research, providing researchers with practical frameworks for addressing cellular heterogeneity.

Biological Foundations of Heterogeneity

The heterogeneity observed in AD-MSC populations arises from multiple biological and technical factors that researchers must recognize when designing purification strategies. Donor-specific variations represent a significant source of heterogeneity, with AD-MSC properties influenced by age, gender, health status, and genetic background [62] [26]. Studies have demonstrated that MSCs from adult and neonatal sources show significant differences in differentiation potential, with aging associated with functional decline, telomere shortening, accumulation of DNA damage, and elevated reactive oxygen species [26].

Tissue-specific characteristics further contribute to heterogeneity, as AD-MSCs from different adipose depots (subcutaneous versus visceral) demonstrate distinct functional properties and marker expression profiles [63]. The anatomical and functional distinctions between white adipose tissue (energy storage) and brown adipose tissue (thermogenesis) further complicate the isolation of consistent AD-MSC populations [63].

Technical Factors Influencing Heterogeneity

Isolation and culture methodologies introduce substantial technical variability in AD-MSC populations. The common approach of using plastic-adherent culture to isolate AD-MSCs from the stromal vascular fraction (SVF) typically requires 2-3 weeks, during which cells undergo significant molecular and functional changes [64]. Research demonstrates that cultured AD-MSCs show rapid alterations in gene expression profiles compared to their ex vivo counterparts, potentially affecting clinical utility [64].

The composition of the starting material presents additional challenges, as the SVF itself is a highly heterogeneous mixture containing AD-MSCs, preadipocytes, fibroblasts, endothelial cells, CD45+ hematopoietic-lineage cells, CD146+ pericytes, and smooth muscle cells [63]. This complex cellular landscape necessitates sophisticated strategies to isolate precisely defined AD-MSC subpopulations for research and clinical applications.

Marker Panels for AD-MSC Characterization and Purification

Established Marker Panels for MSC Identification

The International Society for Cell & Gene Therapy (ISCT) has established minimum criteria for defining MSCs, including plastic adherence, specific surface marker expression, and trilineage differentiation potential [26]. According to these standards, MSCs must express CD105, CD73, and CD90 (≥95% of population), while lacking expression of hematopoietic markers (CD45, CD34, CD14, CD11b, CD79a, CD19, and HLA-DR) [26].

For adipose-derived cells specifically, the International Federation for Adipose Therapeutics and Science (IFATS) has proposed that freshly isolated, uncultured adipose stromal cells containing native AD-MSCs should be characterized as CD45−, CD235a−, CD31−, and CD34+ [63]. After culture, AD-MSCs typically demonstrate a CD45−, CD31−, CD73+, CD90+, CD105+ and/or CD13+, CD44+ profile [63].

Table 1: Core Marker Panels for AD-MSC Characterization

Marker Category	Markers	Expression in AD-MSCs	Functional Significance
Positive Markers (ISCT)	CD73, CD90, CD105	≥95% expression required	Mesenchymal lineage commitment
Negative Markers (ISCT)	CD45, CD34, CD14, CD19, HLA-DR	≤2% expression permitted	Exclusion of hematopoietic, endothelial cells
Adipose-Specific Positive Markers	CD34, CD13, CD29, CD44	Variable based on isolation method and culture	Progenitor status, adhesion, homing
Discriminatory Markers	CD36, CD106	CD36+, CD106- (vs. BM-MSCs: CD36-, CD106+)	Distinction from bone marrow MSCs

Advanced Multi-Marker Panels for Subpopulation Isolation

Beyond the standard characterization panels, researchers have identified numerous additional markers that enable isolation of functionally distinct AD-MSC subpopulations. CD271 (nerve growth factor receptor) has emerged as a particularly promising marker for purifying AD-MSCs with enhanced therapeutic potential. Studies demonstrate that CD271+ AD-MSCs express angiogenic genes at higher levels and inflammatory genes at lower levels compared to CD271− populations, with a greater proportion possessing the typical complement of stem cell markers and demonstrating superior ability to promote effective neoangiogenesis [65].

STRO-1 represents another well-studied marker, with expression levels varying significantly across tissues and species. In human bone marrow, STRO-1 expression typically ranges from 5-66.5%, while in dental tissues, expression varies from 10% in dental follicles to 20% in dental pulp [62]. Other significant markers for subpopulation isolation include CD146 (melanoma cell adhesion molecule), CD106 (vascular cell adhesion molecule-1), and SSEA3 (for multilineage-differentiating stress-enduring [Muse] cells) [62] [63].

Table 2: Specialized Markers for AD-MSC Subpopulation Isolation

Marker	Alternative Names	Reported Expression in AD-MSCs	Functional Associations
CD271	NGFR, p75NTR, LNGFR	4-20% of extracted AD-MSC population [65]	Angiogenic potential, reduced inflammation, self-renewal
STRO-1	-	5-66.5% (bone marrow); 10-20% (dental tissues) [62]	Primitive progenitor status, multipotency
CD146	MCAM, MUC18	12-25% (umbilical cord); variable in other tissues [62]	Perivascular localization, migratory potential
SSEA3	-	Subpopulation (Muse cells) [63]	Multilineage differentiation, stress endurance
CD34	-	High in SVF, decreases with culture [63]	Progenitor status, adhesion/migration

Technical Approaches for High-Purity AD-MSC Isolation

Flow Cytometry-Based Purification Strategies

Fluorescence-activated cell sorting (FACS) represents the gold standard for high-purity isolation of AD-MSC subpopulations based on multi-marker panels. This technology enables simultaneous assessment of multiple surface markers, allowing researchers to isolate highly specific cellular subsets with precision.

A recommended experimental protocol for FACS-based AD-MSC purification includes the following steps:

• Prepare single-cell suspension from stromal vascular fraction (SVF) using collagenase digestion and centrifugation [64]
• Incubate cells with fluorescently-conjugated antibodies targeting specific marker combinations (e.g., CD45−/CD31−/CD34+ for native AD-MSCs)
• Include viability dyes (e.g., DAPI or propidium iodide) to exclude dead cells
• Use appropriate isotype controls and fluorescence-minus-one (FMO) controls to establish gating parameters
• Sort cells using a high-speed cell sorter with appropriate nozzle size (70-100μm) to maintain cell viability
• Collect sorted populations in collection tubes containing culture medium with high serum content
• Assess sort purity by re-analyzing an aliquot of sorted cells

For intracellular markers or transcription factors, researchers may need to employ intracellular staining protocols following cell permeabilization, though this approach typically compromises cell viability and recovery.

Alternative Purification Methodologies

While FACS provides exceptional purity, several alternative methods offer advantages for specific applications. Magnetic-activated cell sorting (MACS) provides a valuable alternative when ultra-high purity is not required, offering benefits of scalability, speed, and maintenance of sterility. The MACS protocol for CD271+ AD-MSC isolation involves incubating SVF with CD271 microbeads and FcR blocking reagent, followed by separation through a magnetic column [65]. The positive population (CD271+ AD-MSCs) is retained on the column and eluted after removal from the magnetic field.

Membrane-based isolation methods present antibody-free alternatives for AD-MSC purification. The membrane migration method involves filtering SVF through porous membranes (11-80μm pore sizes), followed by culture that allows adhered AD-MSCs to migrate out from the membranes [66]. Research demonstrates that cells isolated using the membrane migration method with 11μm pores show higher MSC surface marker expression and more efficient osteogenic differentiation compared to conventional culture methods [66].

Diagram 1: Comprehensive workflow for AD-MSC purification and characterization, integrating multiple methodological approaches for achieving population purity.

Experimental Design and Quality Control

Optimization of Multi-Marker Panels

Designing effective multi-marker panels requires careful consideration of several factors. Panel validation should include titration of antibodies to determine optimal concentrations, assessment of spectral overlap with fluorescence minus one (FMO) controls, and verification of marker stability throughout the isolation process [64]. Researchers should prioritize markers that demonstrate consistent expression patterns with minimal donor-to-donor variability when possible.

Compensation controls are essential when designing multi-color flow cytometry panels, particularly when incorporating markers with overlapping emission spectra. Single-stain controls should be prepared using the same cell type (ideally AD-MSCs) rather than compensation beads, as cellular autofluorescence can significantly impact results.

Quality Assessment of Isolated Populations

Rigorous quality control measures must be implemented to validate the purity and functionality of isolated AD-MSC subpopulations. Purity assessment should include re-analysis of sorted populations to confirm enrichment efficiency, with most applications requiring ≥90% purity for meaningful results. Viability assessment using dyes such as DAPI or propidium iodide should be performed post-sort to ensure isolation methods haven't compromised cellular integrity.

Functional validation represents a critical component of quality control, particularly when isolating subpopulations for therapeutic applications. Standardized differentiation assays should demonstrate trilineage potential (adiopogenic, osteogenic, chondrogenic) according to ISCT guidelines [26]. For specific therapeutic applications, additional functional assays such as tubule formation assays for angiogenic potential [65] or immunomodulation assays may be appropriate.

Diagram 2: Sequential gating strategy for AD-MSC purification and associated quality control metrics to ensure population purity and functionality.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Research Reagent Solutions for AD-MSC Purification and Characterization

Reagent Category	Specific Examples	Application/Function	Technical Notes
Collagenase Enzymes	Collagenase Type I [64] [66]	Tissue dissociation for SVF isolation	Concentration (0.1-0.2%), incubation time (60-90min), temperature (37°C) critical for viability
Surface Antibodies	CD73, CD90, CD105, CD34, CD45, CD31, CD271, STRO-1 [62] [65] [67]	Phenotypic characterization and sorting	Titrate antibodies; use class III CD34 antibodies for consistent results [63]
Magnetic Sorting Reagents	CD271 microbeads, FcR blocking reagent [65]	MACS separation of subpopulations	Maintain sterility; use pre-separation filters to remove clumps
Viability Markers	DAPI, propidium iodide, 7-AAD	Exclusion of non-viable cells	Concentration critical to avoid toxicity; DAPI compatible with UV laser systems
Cell Culture Media	αMEM, DMEM/F12 [65] [64]	Cell expansion and maintenance	Serum lot validation essential; consider defined, xeno-free media for clinical applications
Differentiation Kits	Adipogenic, osteogenic, chondrogenic induction media [26] [67]	Functional validation of trilineage potential	Include appropriate controls; monitor differentiation with specific stains (Oil Red O, Alizarin Red)

The pursuit of higher population purity in AD-MSC research through multi-marker panels represents an essential step toward reproducible and efficacious cellular therapies. As single-cell technologies continue to advance, our understanding of AD-MSC heterogeneity will become increasingly refined, enabling the identification of novel markers for even more precise subpopulation isolation [31].

Future directions in the field will likely focus on the correlation of specific surface marker profiles with distinct therapeutic functionalities, potentially enabling custom isolation of AD-MSC subpopulations tailored to particular clinical applications. Additionally, the development of closed-system, automated isolation platforms compatible with current good manufacturing practices (cGMP) will be essential for clinical translation of defined AD-MSC populations [63].

As standardization efforts progress through organizations including ISCT and IFATS, the implementation of robust multi-marker panels for AD-MSC purification will play a crucial role in unlocking the full therapeutic potential of these versatile cells while ensuring consistent, predictable clinical outcomes.

The phenotypic stability of Adipose-derived Mesenchymal Stromal/Stem Cells (ASCs) represents a critical consideration in translational research and therapeutic development. Surface markers like CD34 serve as essential tools for cell identification, isolation, and characterization. However, researchers frequently encounter a significant challenge: CD34 expression rapidly diminishes during standard in vitro culture. This phenomenon underscores a critical disconnect between the native state of ASCs within adipose tissue and their behavior in artificial culture environments. Understanding this marker instability is not merely academic; it directly impacts experimental reproducibility, cell characterization protocols, and the safety and efficacy of cell-based therapies [18] [68].

The CD34 marker presents a particular paradox. The International Society for Cellular Therapy (ISCT) once classified CD34 as a negative marker for cultured MSCs. However, emerging evidence convincingly demonstrates that native, tissue-resident ASCs are CD34-positive. This discrepancy arises because the original ISCT criteria were established primarily using long-term cultured, plastic-adherent cells, not freshly isolated tissue-resident populations [68] [69]. This technical guide examines the mechanisms behind this phenotypic shift and provides researchers with methodologies to navigate this complexity within adipose-derived MSC flow cytometry research.

The Dynamics of CD34 Expression: From Tissue to Culture

Native State vs. Cultured Phenotype

In their physiological niche within adipose tissue, ASCs exhibit a distinct CD34-positive signature. The stromal vascular fraction (SVF) freshly isolated from adipose tissue contains native ASCs characterized as CD45-/CD235a-/CD31-/CD34+; this population constitutes a significant proportion, representing approximately 20% of the entire SVF [18]. These cells are intimately associated with the vascular stroma, localizing to capillaries and the adventitia of larger blood vessels [68].

The transition to in vitro culture conditions triggers a profound phenotypic shift. During initial passages, the previously strong CD34 expression drastically decreases and often disappears entirely. In contrast, canonical MSC markers like CD73, CD90, and CD105 are upregulated [18] [70]. One study on human facial and abdominal ASCs confirmed this pattern, reporting that "expression of hematopoietic markers CD34 and CD45 [was found] in less than 1.3% of cells," while mesenchymal markers were highly expressed after culture [70]. This conversion from a CD34+ native state to a CD34- cultured phenotype is one of the most consistent observations in ASC biology.

Quantitative Data on CD34 Loss During Culture

The following table summarizes key quantitative findings from recent studies on CD34 expression dynamics in ASCs:

Table 1: Quantitative Dynamics of CD34 Expression in Adipose-Derived Stromal/Stem Cells

Culture Stage	CD34 Expression Level	Key Supporting Findings	Research Context
Native State (in SVF)	High (≈20-37% of specific cell populations)	Native ASCs in SVF characterized as CD45-/CD235a-/CD31-/CD34+ [18]. A study on umbilical cord cells showed 37% of non-cultured cells had CD34/CD105 co-expression [71].	Analysis of freshly isolated stromal vascular fraction from human adipose tissue [18].
Early Passage	Decreasing	Expression is lost rapidly during initial plating and early subculturing [68] [69].	Observation across multiple studies on cultured ASCs.
Long-Term Culture (>P4)	Very Low/Absent (<1.3%)	Flow cytometry analysis revealed CD34 expression in less than 1.3% of both facial and abdominal ASCs after culture [70].	Human subcutaneous ASCs isolated from facial and abdominal fat depots [70].

This phenotypic instability is not limited to CD34. Similar dynamics have been observed with other markers, though the CD34 shift is particularly pronounced and well-documented.

Underlying Mechanisms and Contributing Factors

Impact of Passaging and Culture Duration

The process of serial passaging represents a significant selective pressure that directly influences phenotypic stability. As passaging progresses, ASCs not only lose CD34 expression but also undergo other functional changes. Studies demonstrate that ASCs from both facial and abdominal depots enter a state of replicative senescence around passage 12 (P12), accompanied by progressive morphological alterations, reduced proliferative capacity, and increased SA-β-galactosidase expression [70].

Perhaps more critically, long-term culture compromises genetic integrity. Research shows a higher proportion of cells exhibit nuclear alterations and γ-H2AX expression (a marker of DNA double-strand breaks) at higher passages. This loss of genetic fidelity presents a substantial safety concern for therapeutic applications [70].

The Plastic Adherence Selection Pressure

The very foundation of traditional MSC isolation creates the conditions for phenotypic shift. The standard protocol relies on plastic adherence to separate MSCs from hematopoietic cells in the initial stromal vascular fraction. This process inadvertently selects for a subpopulation of cells that can adapt to artificial surfaces, a characteristic not necessarily reflective of the native state [68] [69].

Furthermore, the artificial culture environment itself—including oxygen tension, nutrient availability, and removal from natural physiological cues—triggers fundamental changes in cell behavior and marker expression. The loss of CD34 is now understood not as a defining feature of ASCs, but rather as a consequence of in vitro adaptation [68].

Donor and Tissue Source Variability

The source of adipose tissue can also influence phenotypic stability. Comparative studies of ASCs from different anatomical depots reveal source-dependent variations. For instance, abdominal ASCs (aASCs) demonstrated a higher proliferative potential, while facial ASCs (fASCs) displayed fewer mitotic errors at higher passages [70]. These findings indicate that intrinsic biological differences based on tissue origin can modulate how ASCs respond to in vitro expansion.

Experimental Approaches and Methodologies

Standardized Characterization Workflow

To ensure reproducible characterization of ASCs across different passages, researchers should implement a standardized workflow that accounts for phenotypic dynamics. The following diagram illustrates the key decision points in this process:

Diagram 1: Experimental workflow for ASC characterization across passages

Detailed Protocol: Flow Cytometry Analysis Across Passages

Objective: To quantitatively track the expression dynamics of CD34 and other MSC markers during in vitro expansion of ASCs.

Materials and Reagents:

• Collagenase Type I (e.g., Sigma, USA): For enzymatic digestion of adipose tissue to isolate the stromal vascular fraction (SVF) [71] [72].
• Flow Cytometry Antibodies: Fluorescently labeled monoclonal antibodies against CD34, CD45, CD31, CD235a, CD73, CD90, and CD105 [71] [70].
• Culture Medium: DMEM supplemented with L-glutamine, glucose, and Fetal Bovine Serum (FBS) [71] [72].
• Trypsin-EDTA (0.25%): For cell detachment during passaging [73].

Procedure:

• SVF Isolation: Minced adipose tissue is digested with collagenase type I solution (e.g., 10 mg/30 ml) for 2-3 hours at 37°C. The digest is rinsed, centrifuged, and passed through a 100-μm sieve to obtain the SVF [71].
• Baseline Characterization (Day 0): Reserve an aliquot of the freshly isolated SVF. Stain cells with antibodies for CD34, CD45, CD31, and CD235a. Analyze via flow cytometry to establish the baseline percentage of native ASCs (CD45-/CD235a-/CD31-/CD34+) [18].
• Cell Culture and Passaging: Plate the remaining SVF cells in culture flasks. Culture in appropriate medium at 37°C with 5% CO₂. Subculture cells (using trypsin-EDTA) when they reach approximately 80% confluence, maintaining consistent seeding density [70] [72].
• Passage-Monitored Characterization: At each passage (e.g., P1, P2, P3, P5, P8, P10), harvest a sample of cells. Perform flow cytometry analysis using antibodies against CD34, CD73, CD90, and CD105. Include isotype controls for accurate gating [70].
• Data Analysis: Calculate the percentage of positive cells for each marker at every passage. Graph the expression dynamics over time to visualize the loss of CD34 and the gain of standard MSC markers.

Expected Results: Researchers should observe a rapid decline in CD34-positive cells concurrent with a stable, high percentage of CD73, CD90, and CD105-positive cells across passages.

Protocol: Assessing Genetic Stability During Long-Term Culture

Objective: To evaluate the maintenance of genetic integrity in ASCs through extended in vitro passaging.

Materials:

• Antibody against γ-H2AX (Phospho-Histone H2A.X, Ser139): A marker for DNA double-strand breaks [70] [74].
• SA-β-galactosidase Staining Kit: For detection of senescent cells.
• Materials for Karyotyping or Advanced Genomic Analysis (e.g., chromosomal microarray, next-generation sequencing) [74].

Procedure:

• Long-Term Culture: Continue passaging ASCs as described in Section 4.2 until later passages (e.g., beyond P10).
• Senescence-Associated β-Galactosidase Staining: Perform SA-β-gal staining at early (e.g., P3), middle (e.g., P8), and late (e.g., P12) passages following kit instructions. Quantify the percentage of blue-stained senescent cells [70].
• DNA Damage Assay: At the same passage timepoints, seed cells on coverslips. Fix, permeabilize, and stain with anti-γ-H2AX antibody and a fluorescent secondary antibody. Use DAPI for nuclear counterstaining. Analyze via fluorescence microscopy or flow cytometry to quantify the proportion of cells with DNA damage foci [70].
• Genomic Analysis: For a comprehensive assessment, submit cell samples from critical passages for high-resolution karyotyping, chromosomal microarray analysis, or next-generation sequencing to detect copy number alterations (CNAs) and single-nucleotide variations (SNVs) [74].

Table 2: Research Reagent Solutions for Phenotype and Genotype Tracking

Reagent/Category	Specific Examples	Primary Function in Experiment
Tissue Dissociation	Collagenase Type I	Enzymatic digestion of adipose tissue to isolate the stromal vascular fraction (SVF) [71].
Cell Culture Medium	DMEM + FBS	Basic nutrient medium for in vitro expansion and maintenance of ASCs [71] [72].
Flow Cytometry Antibodies	Anti-human CD34, CD73, CD90, CD105, CD45, CD31, CD235a	Cell surface immunophenotyping to track marker expression stability across passages [18] [70].
Senescence Detection	SA-β-galactosidase Staining Kit	Histochemical detection of senescent cells in culture [70].
DNA Damage Detection	Anti-γ-H2AX Antibody (Ser139)	Immunofluorescence marker for identifying DNA double-strand breaks [70].

Implications for Research and Therapeutic Development

Standardization and Reproducibility

The passage-dependent nature of ASC phenotype poses a significant challenge to experimental reproducibility. Studies that fail to report the specific passage number of cells used or that compare results from different passage ranges risk generating conflicting data. The field must adopt more rigorous reporting standards, including:

• Documenting exact passage numbers for all experiments
• Establishing passage windows for specific applications
• Characterizing phenotype at both early and late passages for comparative studies

Safety Considerations for Cell Therapy

For clinical applications, the genetic instability observed in long-term cultured ASCs presents substantial safety concerns. The accumulation of DNA damage and chromosomal abnormalities in later passages increases the potential oncogenic risk [70] [74]. Therefore, therapeutic protocols should:

• Establish safe passage limits (typically not exceeding P4-P5 for clinical use)
• Implement rigorous genomic quality control measures at critical manufacturing stages
• Consider using early-passage cells whenever possible for clinical applications

The instability of CD34 expression during in vitro expansion is not an anomaly but rather a representative example of the broader phenotypic dynamics that characterize ASCs in artificial culture environments. This phenomenon directly reflects the complex adaptation of tissue-resident cells to conditions fundamentally different from their native niche.

Moving forward, the field must prioritize several key areas:

• Development of Culture Conditions that better mimic the native ASC niche to preserve original phenotype.
• Implementation of Standardized Characterization Protocols that account for passage-dependent changes.
• Establishment of Validated Passage Windows for specific research and clinical applications.

Researchers should explicitly report passage numbers in all publications and carefully consider passage-dependent phenotypic changes when designing experiments and interpreting results. By acknowledging and systematically addressing marker instability, the scientific community can enhance reproducibility, improve therapeutic safety, and advance our fundamental understanding of adipose-derived MSC biology.

The characterization of adipose-derived mesenchymal stromal/stem cells (AD-MSCs) through flow cytometry is a cornerstone of research in regenerative medicine and drug development. However, this technique presents significant technical challenges that can compromise data integrity and experimental reproducibility. This technical guide addresses three critical pitfalls in AD-MSC flow cytometry: managing cell loss during preparation, detecting low-abundance populations, and pushing detection resolution limits. AD-MSCs, characterized by their expression of CD73, CD90, and CD105 and absence of hematopoietic markers like CD45 and CD31, possess immense therapeutic potential due to their multipotent differentiation capacity and immunomodulatory properties [75] [18]. The accuracy of their flow cytometric characterization is therefore paramount, not only for basic research but also for preclinical and clinical development. This whitepaper provides an in-depth analysis of these technical hurdles and offers evidence-based strategies to overcome them, ensuring reliable and reproducible data in the context of adipose-derived MSC research.

Managing Cell Loss in AD-MSC Processing

Cell loss during sample preparation is a critical yet often overlooked variable that can significantly impact the accuracy of AD-MSC characterization. This loss can occur at multiple stages, from the initial tissue dissociation to the final flow cytometric analysis, potentially introducing bias and compromising data quality.

Isolation and Pre-Analytical Processing

The journey of AD-MSCs for flow cytometry begins with the extraction of adipose tissue and isolation of the stromal vascular fraction (SVF). The initial tissue digestion is a delicate balance; insufficient digestion yields low cell numbers, while over-digestion compromises cell viability. A standardized protocol recommends using a collagenase solution (Type I or II) at a concentration of 0.5 mg/ml to 1 mg/ml, with digestion in a 37°C shaking water bath for 30-60 minutes until the tissue appears smooth and homogenous [59] [76]. It is critical to neutralize the collagenase activity promptly with a culture medium containing serum [76]. Following digestion, the cell suspension must be filtered through 100 μm and 40 μm cell strainers to remove undigested tissue fragments and ensure a single-cell suspension [59] [77]. The subsequent steps of red blood cell lysis using Ammonium-Chloride-Potassium (ACK) buffer and multiple centrifugation steps are further points of potential cell loss [59]. To minimize loss during these washes, researchers should avoid overly vigorous pipetting and ensure supernatant aspiration is performed carefully without disturbing the cell pellet.

Strategic Enrichment and Staining

For the adherent AD-MSC population, which is typically expanded in vitro, cell loss during passaging and staining can skew population representations. Using gentle cell dissociation reagents like enzyme-free solutions or low-concentration trypsin/EDTA, followed by meticulous neutralization with serum-containing medium, is essential. When preparing for flow cytometry, staining should be performed in sterile, pre-cooled U-bottom or V-bottom plates that minimize cell adherence to well surfaces. A key strategy to reduce loss is to implement a "dump channel" in the flow cytometry panel—a channel that collects signals from unwanted dead cells (using a viability dye) and contaminating hematopoietic cells (e.g., CD45, CD31) [78]. This allows for the electronic gating of viable, target AD-MSCs, effectively retrieving these cells from the analysis even if they cannot be physically preserved during processing. Furthermore, consistent cell counting and concentration adjustment before acquisition ensure that the sample is within the ideal range for the flow cytometer, preventing the instrument from clogging and the unnecessary waste of precious samples.

Table 1: Key Reagents and Their Functions in Minimizing AD-MSC Loss

Research Reagent	Function in Workflow	Technical Consideration
Collagenase Type I/II	Digests extracellular matrix in adipose tissue to release SVF	Concentration and digestion time must be optimized; over-digestion harms cell viability [59] [76].
Cell Strainers (100μm, 40μm)	Removes tissue aggregates and creates a single-cell suspension	Sequential use prevents clogging and ensures a smooth sample for the flow cytometer [59] [77].
ACK Lysis Buffer	Lyses contaminating red blood cells in the SVF	Incubation time should be limited (e.g., 10 min) to avoid damaging nucleated cells [59].
Viability Dye (e.g., Fixable Viability Stain)	Identifies and permits gating-out of dead cells	Crucial for assay accuracy; must be used prior to fixation for best results [78].
Fc Receptor Block	Binds to Fc receptors on cells to prevent non-specific antibody binding	Reduces background fluorescence, improving signal-to-noise ratio [59].
FACS Staining Buffer	Diluent for antibodies and wash buffer for cells	Should contain protein (e.g., 0.1-1% BSA) to support cell stability [59].

Detecting Low-Abundance and Rare Populations

The analysis of rare cell populations, defined as those with a frequency of 0.01% or less, is a common requirement in advanced AD-MSC research, such as tracking specific progenitor subsets or genetically modified cells [78]. Success in this endeavor demands a rigorous statistical and experimental approach.

Acquisition and Statistical Considerations

The fundamental principle of rare cell detection is that the number of events that must be acquired is inversely proportional to the frequency of the population of interest. According to Poisson statistics, to achieve a coefficient of variation (CV) below 5% for a population representing 0.01%, a minimum of 4 million total events must be acquired [78]. Acquiring fewer events leads to higher statistical noise and unreliable data. The following table outlines the relationship between acquisition volume and statistical confidence:

Table 2: Event Acquisition Requirements for Rare Population Analysis

Total Events Acquired (N)	Number of Positive Cells (R) at 0.01%	Coefficient of Variation (CV)
100,000	10	31.62%
500,000	50	14.14%
1,000,000	100	10.00%
4,010,000	401	4.99%
10,000,000	1,000	3.16%
20,000,000	2,000	2.24%

To manage these high event counts, sample concentration and flow rate must be optimized. Using a high-speed flow cytometer can drastically reduce acquisition time. However, it is critical to maintain an event rate below the instrument's maximum specification to avoid coincidence, which is the simultaneous detection of two cells as a single event, thereby polluting the data [78].

Enrichment Strategies and High-Sensitivity Detection

For extremely rare populations, simply acquiring more events may be impractical. In these cases, pre-enrichment strategies are invaluable. Magnetic-activated cell sorting (MACS) can be used to positively or negatively select target cells from a large initial sample, thereby increasing their relative frequency before flow cytometric analysis [78]. For example, a population of interest could be negatively enriched by depleting CD45+ hematopoietic cells from the SVF, thereby concentrating the AD-MSCs.

Pushing the boundaries of detection resolution also involves leveraging novel technologies. For instance, the RNAScope detection platform has been adapted for flow cytometry to detect low-abundance RNA molecules within individual cells [79] [80]. This method uses novel target-specific probes with a unique "z-design" that suppresses background signals and allows for sequential hybridization-mediated signal amplification. This enables the specific detection of RNA transcripts even at very low copy numbers, a capability that could be applied to AD-MSCs for tracking specific differentiation markers or responses to therapeutic agents at a single-cell level [80].

Optimizing Detection Resolution and Panel Design

Maximizing the resolution of flow cytometry assays is essential for accurately resolving dimly expressed markers and clearly distinguishing positive populations from negative ones. This is a function of both instrumental configuration and thoughtful experimental design.

Signal-to-Noise Optimization

The cornerstone of high-resolution detection is a high signal-to-noise ratio. This begins with the careful selection of bright fluorochromes for markers expressed at low levels. Tandem dyes, while bright, can be prone to degradation and increased spillover; therefore, their use requires strict light exposure control and validation. Furthermore, the use of viability dyes is non-negotiable, as dead cells exhibit high levels of non-specific antibody binding and autofluorescence, which dramatically increases background noise [78]. Titrating all antibodies and using Fc receptor blocking solutions are simple yet highly effective steps to minimize non-specific staining [59]. For intracellular targets like transcription factors or cytokines, the permeabilization and fixation steps must be optimized to preserve both the epitope of interest and the light-scatter properties of the cells.

Panel Design for AD-MSC Characterization

A well-designed multicolor panel is critical for the comprehensive and resolved characterization of AD-MSCs. The panel must account for the dynamic nature of AD-MSC markers; for instance, CD34 is expressed on native ASCs in the SVF but is often lost in culture, while CD73, CD90, and CD105 are consistently expressed on cultured AD-MSCs [18] [75]. The following workflow outlines a robust strategy for panel design and validation specifically for AD-MSC analysis:

Implementing full minus one (FMO) controls is particularly crucial for setting accurate gates for dim populations and in complex multicolor panels. These controls contain all antibodies in the panel except one, allowing researchers to distinguish true positive signal from background and spillover spreading error [78]. Finally, electronic or physical compensation must be performed meticulously using single-stained controls to correct for the spectral overlap of fluorochromes, which is a prerequisite for high-resolution multiparameter analysis.

The successful characterization of adipose-derived MSCs via flow cytometry hinges on a meticulous and informed approach to technical execution. As detailed in this guide, mitigating cell loss requires optimized protocols from tissue dissection to final sample acquisition. The reliable detection of low-abundance populations demands rigorous statistical planning and, when necessary, strategic enrichment. Finally, maximizing detection resolution is achieved through intelligent panel design and stringent control procedures. By systematically addressing these technical pitfalls, researchers can generate robust, reproducible, and high-quality data that will advance the field of AD-MSC research and accelerate its translation into clinical applications.

The characterization of Adipose-Derived Stem Cells (ADSCs) via flow cytometry is a cornerstone of their application in regenerative medicine and drug development. A critical, yet often underexplored, factor that can significantly influence experimental and therapeutic outcomes is the processing of these cells—specifically, the cryopreservation and thawing cycle. For research to be reproducible and for cell-based therapies to be reliable, it is paramount to understand how these standard laboratory procedures affect the immunophenotype of ADSCs. This technical guide synthesizes current evidence to delineate the effects of cryopreservation on the surface marker profile of ADSCs, providing detailed methodologies and data to inform robust experimental design and data interpretation within the broader context of ADSC characterization.

The Immunophenotype of ADSCs: A Primer

Adipose-Derived Stem Cells are defined by a specific set of cell surface markers, as established by the International Society for Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics and Science (IFATS). The consensus defines ADSCs by a consistent immunophenotype: they must be plastic-adherent under standard culture conditions and must express (≥95% positive) specific surface markers including CD73, CD90, and CD105 while lacking expression (≤2% positive) of hematopoietic markers such as CD45, CD34, CD31, CD11b, or CD19 and HLA-DR [81] [82]. This signature is not merely descriptive; it is intrinsically linked to the cells' core functionalities, including their immunomodulatory capacity, a key therapeutic mechanism whereby ADSCs can suppress lymphocyte proliferation and modulate immune responses [83]. Consequently, any significant alteration to this immunophenotype could compromise the validity of research data and the efficacy and safety of clinical applications.

Impact of Cryopreservation on ADSC Immunophenotype: Evidence and Data

A body of evidence demonstrates that the ADSC immunophenotype is largely well-preserved following cryopreservation and thawing, even over extended periods. The key is the use of standardized, controlled protocols. Studies have shown that when cryopreserved with cryoprotective agents (CPAs) like Dimethyl Sulfoxide (DMSO), ADSCs maintain high expression levels of characteristic surface markers.

Table 1: Summary of Key Studies on Cryopreservation's Impact on ADSC Immunophenotype

Study Duration	Post-Thaw Viability	Key Markers Maintained (≥95%)	Key Markers Absent (≤2%)	Reference
Average 12 years	High viability confirmed	CD90, CD73, CD105, CD166, NOTCH1, STRO-1	N/A	[84]
3 months	High viability comparable to controls	CD90, CD73, CD105, CD44, HLA-ABC	CD14, CD19, CD34, CD45, HLA-DR	[85]
3-10+ years	78-79% viability	CD29, CD90, CD105, CD44, CD73	CD31, CD34, CD45, CD146	[82]

The data indicates that long-term cryopreservation (up to 12 years) does not fundamentally alter the ADSC immunophenotype. Cells remain positive for classic mesenchymal markers like CD90, CD73, and CD105, and negative for hematopoietic lineage markers [84] [82]. Furthermore, research shows that reduced concentrations of DMSO (e.g., 5%) can be as effective as the traditional 10% concentration in preserving cell viability and phenotype, which is a significant finding given the desire to minimize DMSO-related cytotoxicity in clinical settings [85]. The consistency between freshly isolated and cryopreserved ADSCs extends to functional properties, as cryopreserved cells retain their multilineage differentiation potential into adipogenic, osteogenic, and chondrogenic lineages, confirming that their core biological identity remains intact post-thaw [84] [85] [82].

Quantitative Marker Expression Post-Cryopreservation

The following table compiles quantitative data from multiple studies to provide a clear comparison of marker expression levels before and after the cryopreservation process.

Table 2: Quantitative Analysis of Marker Expression in Fresh vs. Cryopreserved ADSCs

Surface Marker	Fresh ADSCs (% Positive)	Cryopreserved ADSCs (% Positive)	CPA Used	Storage Duration
CD90	>99% [85]	>99% [85] [82]	5-10% DMSO ± FBS	3 mo - 10+ yrs
CD73	>99% [85]	>99% [85] [82]	5-10% DMSO ± FBS	3 mo - 10+ yrs
CD105	>99% [85]	>99% [85] [82]	5-10% DMSO ± FBS	3 mo - 10+ yrs
CD44	>99% [82]	>99% [82]	10% DMSO	3-10+ yrs
CD29	>99% [82]	>99% [82]	10% DMSO	3-10+ yrs
CD34	<2% [82]	<2% [82]	10% DMSO	3-10+ yrs
CD45	<2% [85] [82]	<2% [85] [82]	5-10% DMSO ± FBS	3 mo - 10+ yrs

Detailed Experimental Protocols for Immunophenotype Assessment

To ensure the reliability and reproducibility of data concerning cryopreserved ADSCs, adherence to detailed, standardized protocols is essential. The following sections outline critical methodologies.

Standard Cryopreservation and Thawing Protocol

This protocol is adapted from established methodologies used in key studies [84] [85] [82].

Cryopreservation:

• Harvesting: Culture ADSCs to the desired passage (e.g., passage 2-3). Detach the cells using a clinical-grade enzyme such as TrypLE Select to minimize antigen disruption.
• Preparation: Centrifuge the cell suspension and resuspend the pellet in a cryopreservation medium at a concentration of ~1x10^6 cells per cryovial.
• Cryomedium Formulation: The standard medium consists of a base medium (e.g., DMEM/Ham's F-12) supplemented with 10% DMSO and 20-90% Fetal Bovine Serum (FBS). For a xeno-free alternative, FBS can be replaced with human platelet lysate [86] [81].
• Controlled Freezing: Place cryovials in an isopropanol-filled freezing container (e.g., "Mr. Frosty") and store at -80°C for 24 hours. This apparatus ensures a consistent cooling rate of approximately -1°C/minute, which is critical for cell viability.
• Long-term Storage: After 24 hours, promptly transfer vials to a liquid nitrogen tank for long-term storage at or below -150°C.

Thawing and Recovery:

• Rapid Thaw: Retrieve the cryovial from liquid nitrogen and immediately place it in a 37°C water bath with gentle agitation until only a small ice crystal remains.
• Dilution: Transfer the cell suspension to a sterile tube and slowly dilute the cryoprotectant (1:10) drop-wise with pre-warmed culture medium to mitigate osmotic shock.
• Centrifugation: Centrifuge the cell suspension at 300-400 g for 5 minutes to pellet the cells and remove the CPA/DMSO-containing supernatant.
• Resuspension and Culture: Resuspend the cell pellet in fresh, complete culture medium and seed into an appropriate culture flask. It is recommended to allow the cells to recover for 24-48 hours before flow cytometric analysis to enable membrane repair and the re-establishment of surface markers.

Flow Cytometry Immunophenotyping Protocol

This protocol is critical for accurately assessing the immunophenotype post-thaw [85] [82].

• Cell Preparation: Harvest the recovered ADSCs (typically after 1-2 passages post-thaw) using a gentle dissociation enzyme. Wash the cells with PBS supplemented with 2% FBS.
• Staining: Aliquot approximately 1x10^5 cells per tube. Incubate the cells with fluorochrome-conjugated antibodies (typically at a dilution of 1:50-1:100) for 30 minutes on ice to prevent internalization of surface markers. Include appropriate isotype controls and single-stain controls for compensation.
• Washing and Fixation: Wash the cells twice with cold PBS/2% FBS to remove unbound antibody. The cell pellet can then be resuspended in a fixation buffer (e.g., 1% paraformaldehyde) if analysis is not immediate.
• Data Acquisition and Analysis: Acquire a minimum of 10,000 events per sample on a flow cytometer (e.g., BD FACS Canto II). Analyze the data using specialized software (e.g., FlowJo), gating on the live cell population based on forward and side scatter characteristics, and report the percentage of positive cells for each marker.

Diagram 1: ADSC Immunophenotyping Workflow

Critical Factors Influencing Post-Thaw Immunophenotype

While the immunophenotype is generally stable, several technical factors can introduce variability and must be rigorously controlled.

• Cryoprotectant Agent (CPA) Composition: The type and concentration of CPA are paramount. While 10% DMSO is the historical gold standard, evidence shows that 5% DMSO can be equally effective in preserving phenotype and viability, reducing potential cytotoxic effects [85]. Furthermore, research into alternatives like trehalose is ongoing. However, trehalose is a non-permeating sugar and requires specialized methods for intracellular delivery to be comparable to DMSO [87].

• Freezing Rate Control: An uncontrolled, rapid freezing rate is detrimental to cell survival and can compromise membrane integrity, potentially affecting surface marker detection. The use of a controlled-rate freezer or an isopropanol freezing container to maintain a slow cooling rate of -1°C/min is essential for optimal results [85] [82].

• Donor Variability and Tissue Source: Intrinsic biological factors such as donor age, body mass index (BMI), and the anatomical source of the adipose tissue (e.g., abdomen vs. thigh) can influence the initial yield and characteristics of ADSCs. This inherent variability can also affect how cells respond to cryopreservation, underscoring the need for careful donor selection and stratification in study design [81].

The Scientist's Toolkit: Essential Reagents and Materials

Table 3: Key Research Reagents for ADSC Cryopreservation and Immunophenotyping

Reagent/Material	Function	Example Products & Clinical-Grade Notes
Collagenase / GIDzyme-2	Enzymatic digestion of adipose tissue to isolate Stromal Vascular Fraction (SVF).	Collagenase NB6 (Serva), GIDzyme-2 (GID Inc.) - clinical-grade enzymes are recommended for translational work [86].
DMSO (Dimethyl Sulfoxide)	Permeating cryoprotectant; prevents intracellular ice crystal formation.	Must be high-quality, cell culture tested. Use at 5-10% concentration; wash out post-thaw due to cytotoxicity [85] [87].
Human Platelet Lysate (hPL)	Xeno-free alternative to FBS for cell culture and cryopreservation media.	PLT-Max (Mill Creek), Stemulate (Cook) - eliminates xenogeneic immune response risks [86] [81].
Flow Cytometry Antibodies	Immunophenotyping; identification of positive and negative marker expression.	Antibodies against CD73, CD90, CD105 (positive) and CD45, CD34, CD31 (negative) from suppliers like BD Biosciences [85] [82].
Controlled-Rate Freezing Container	Ensures a consistent, slow freezing rate (~-1°C/min) to maximize cell viability.	"Mr. Frosty" (Nalgene) or programmable controlled-rate freezers [82].

In summary, the immunophenotype of ADSCs, as defined by the expression of characteristic surface markers, is robust and remains largely unaltered by properly executed cryopreservation and thawing processes. The key to this stability lies in the meticulous application of standardized protocols for freezing, storage, and post-thaw recovery. The data confirms that cryopreserved ADSCs not only maintain their defining surface marker profile but also retain their critical differentiation capabilities. For researchers and drug developers, this validates the use of cryopreserved ADSCs as a reliable and flexible cellular resource. By adhering to the detailed methodologies and considerations outlined in this guide, scientists can confidently utilize cryopreserved ADSCs, ensuring that their flow cytometry data is accurate, reproducible, and meaningful for both basic research and clinical translation.

The purification and characterization of adipose-derived mesenchymal stem cells (ADSCs) are critical steps in ensuring the efficacy and safety of cell-based therapies. Flow cytometry, particularly fluorescence-activated cell sorting (FACS), has long been the gold standard for isolating and analyzing these cells based on surface marker expression. However, the field of regenerative medicine is rapidly evolving, with emerging technologies offering new possibilities for purifying ADSCs with greater precision, efficiency, and minimal manipulation. This technical guide explores these innovative purification techniques—specifically microfluidic and nanoparticle-based sorting—and examines their integration into the broader context of ADSC characterization for research and therapeutic development.

The Established Standard: ADSC Characterization and FACS

Adipose tissue is a rich source of mesenchymal stem cells, offering a yield of stem cells up to 500 times greater than that of bone marrow [88]. The International Society for Cellular Therapy (ISCT) has established minimal criteria for defining MSCs, which include:

• Plastic adherence under standard culture conditions.
• Specific surface marker expression: Positive for CD73, CD90, and CD105 (≥95%), and negative for hematopoietic markers (CD34, CD45, CD14 or CD11b, CD79α or CD19, and HLA-DR) (≤2%) [89] [41].
• Multilineage differentiation potential: The ability to differentiate into osteoblasts, adipocytes, and chondrocytes in vitro [89].

FACS has been the cornerstone technique for verifying these criteria, enabling the high-throughput, multi-parameter sorting of living cells based on the presence or absence of these specific surface markers. This process is fundamental for obtaining a well-characterized, pure population of ADSCs for downstream applications.

Limitations of FACS and the Drive for Innovation

Despite its widespread use, FACS presents several challenges that have motivated the search for alternative methods:

• High cost and bulkiness of equipment.
• Potential for cellular damage due to high shear forces and pressure changes during sorting.
• Complex operation, requiring specialized expertise.
• Limitations in handling small sample volumes efficiently.
• Inability to fully resolve the functional heterogeneity that exists within ADSC populations, which transcriptomic analyses have revealed are composed of distinct subclusters with varying differentiation capacities and secretory profiles [90].

Emerging Purification Techniques

Microfluidic-Based Sorting

Microfluidic technologies manipulate fluids at the microscale, offering precise control over the cellular microenvironment for sorting. These systems can be categorized based on their operating principles.

Table 1: Comparison of Microfluidic Sorting Modalities

Sorting Modality	Principle	Key Advantages	Considerations
Label-Free (e.g., Inertial, Acoustic)	Utilizes intrinsic cell properties (size, density, deformability) within specially designed channels or acoustic fields.	Preserves native cell function; lower cost; avoids label-induced alterations.	May have lower purity compared to affinity-based methods; requires optimization for specific cell types.
Affinity-Based (Surface Marker)	Uses antibodies immobilized on channel surfaces to capture target cells, akin to fluorescence-activated cell sorting.	High specificity; directly targets well-established ADSC markers (CD73, CD90, CD105).	Requires validation of antibody immobilization; potential for non-specific binding.

The following diagram illustrates a generalized workflow for integrating microfluidic cell sorting into the ADSC processing pipeline.

Diagram 1: ADSC Processing with Microfluidic Sorting

Nanoparticle-Based Sorting

This technique leverages functionalized nanoparticles to isolate target cells. While the search results provided limited direct detail on its application for ADSCs, the principle is well-established in other cell types and holds significant promise.

• Principle: Nanoparticles (e.g., magnetic, gold, or polymeric) are conjugated with antibodies against specific ADSC surface markers (e.g., CD73, CD90, CD105).
• Magnetic-Activated Cell Sorting (MACS): A common implementation uses magnetic nanoparticles. The labeled cell-nanoparticle complex is passed through a column placed in a magnetic field. Target cells are retained and then eluted after the magnetic field is removed.
• Potential Advantages:
  • Scalability: Easily scaled from research to clinical-grade production.
  • Gentleness: Generally lower shear stress compared to FACS, potentially leading to higher cell viability.
  • Cost-Effectiveness: Lower instrumentation costs than FACS.

The primary challenge lies in the careful design and functionalization of nanoparticles to ensure high specificity and minimal non-specific binding, and to confirm that the nanoparticles do not adversely affect subsequent cell function or clinical application.

Experimental Protocols for Technique Validation

Protocol: Microfluidic Affinity-Based Sorting of ADSCs

This protocol outlines a method for using a custom-made microfluidic chip to purify ADSCs based on CD90 expression.

1. Chip Preparation:

• Microfluidic Chip Fabrication: Use standard soft lithography to create a polydimethylsiloxane (PDMS) chip with a herringbone mixer structure to enhance cell-antibody interaction.
• Antibody Immobilization: Functionalize the channel surface with a protein (e.g., recombinant Protein G) to orient antibodies correctly. Flush the channels with a 10 µg/mL solution of anti-CD90 antibody in PBS and incubate for 2 hours at room temperature. Block non-specific sites with 1% BSA for 1 hour.

2. Cell Sample Preparation:

• Isolate the stromal vascular fraction (SVF) from human lipoaspirate via collagenase digestion and centrifugation [41].
• Resuspend the SVF cells at a concentration of 1-5 x 10^6 cells/mL in ice-cold sorting buffer (PBS + 1% BSA).

3. Sorting Process:

• Introduce the cell suspension into the chip at a controlled flow rate (e.g., 1 µL/min) using a syringe pump.
• Allow cells to interact with the immobilized antibodies for sufficient residence time.
• Wash the chip with 10 volumes of sorting buffer to remove unbound cells.
• Elute the captured CD90+ ADSCs by introducing a low-pH glycine buffer (pH 2.5-3.0) or a gentle enzymatic solution (e.g., Accutase [41]), and immediately neutralize the eluent with Tris-HCl buffer.

4. Post-Sort Analysis:

• Assess cell viability using Trypan Blue exclusion.
• Characterize purity by flow cytometry, staining for the positive markers CD73, CD90, CD105 and negative markers CD34 and CD45.
• Validate functionality through tri-lineage differentiation assays (adipogenic, osteogenic, chondrogenic) [41].

Protocol: Nanoparticle-Based Magnetic Sorting of ADSCs

This protocol describes the use of magnetic nanoparticles for the positive selection of ADSCs.

1. Nanoparticle Conjugation:

• Use commercially available magnetic nanoparticles (e.g., superparamagnetic iron oxide nanoparticles, SPIONs) with a carboxylated surface.
• Activate the carboxyl groups using EDC/NHS chemistry.
• Incubate the activated nanoparticles with a purified anti-CD105 antibody (or an antibody cocktail) for 4 hours at room temperature.
• Purify the antibody-conjugated nanoparticles using size-exclusion chromatography or magnetic separation and resuspend in a storage buffer.

2. Cell Labeling and Separation:

• Incubate the SVF cell suspension with the conjugated nanoparticles at a ratio of 50 µg nanoparticles per 10^6 cells for 30 minutes on a rotator at 4°C.
• Apply the labeled cell suspension to a MACS column placed in a strong magnetic field.
• Wash the column with 3-5 column volumes of sorting buffer to remove unlabeled cells.
• Remove the column from the magnetic field and elute the positively selected ADSCs by flushing with buffer.

3. Post-Sort Analysis:

• Analyze the sorted population as described in Section 4.1 to determine purity, viability, and differentiation potential.

Table 2: Key Research Reagent Solutions for ADSC Sorting

Reagent / Material	Function / Description	Example in Protocol
Collagenase D	Enzymatic digestion of adipose tissue to release the stromal vascular fraction (SVF).	Initial isolation of SVF from lipoaspirate [41].
Anti-CD90 / CD105 Antibody	Primary capture ligand for specific isolation of ADSCs via surface markers.	Immobilized in microfluidic chip or conjugated to magnetic nanoparticles.
Magnetic Nanoparticles	Solid phase for affinity binding; enables separation via magnetic field.	Superparamagnetic iron oxide nanoparticles for MACS.
Protein G	Enhances orientation and binding efficiency of immobilized antibodies on surfaces.	Used for microfluidic chip surface functionalization.
Accutase	Gentle cell detachment enzyme; used for eluting live cells from surfaces.	Elution of captured cells from microfluidic chip [41].
BSA (Bovine Serum Albumin)	Blocking agent to prevent non-specific binding of cells to surfaces.	Used in sorting buffer and for blocking microfluidic channels.

Integration with Broader ADSC Characterization

The adoption of emerging purification techniques does not render flow cytometry obsolete; rather, it redefines its role. FACS transitions from a primary sorting tool to an essential validation and high-resolution analysis tool. A modern, comprehensive characterization workflow for ADSCs should be multi-modal.

Diagram 2: Integrated ADSC Characterization Workflow

This integrated approach allows researchers to not only isolate a pure population of cells but also to understand their functional potency, transcriptional heterogeneity, and paracrine signaling mechanisms—the latter being increasingly attributed to the effects of extracellular vesicles (EVs) secreted by ADSCs [88] [91]. These vesicles carry a diverse cargo of proteins, lipids, and regulatory RNAs that mirror the therapeutic potential of the parent cells [88] [90] [92].

The field of ADSC purification is advancing beyond the limitations of FACS. Techniques like microfluidic and nanoparticle-based sorting offer powerful, complementary tools that provide gentler, potentially more scalable, and functionally relevant methods for isolating these promising cells. The future of ADSC characterization lies not in a single technology, but in a synergistic pipeline. This pipeline begins with efficient, label-free, or gentle affinity-based primary purification, and is followed by rigorous multi-parametric validation and deep functional analysis using flow cytometry, 'omics' technologies, and functional assays. By adopting this integrated approach, researchers and drug developers can better elucidate the therapeutic mechanisms of ADSCs and accelerate the development of robust and effective cell-based advanced therapies.

Ensuring Quality and Clinical Relevance of ADSC Products

The clinical translation of Mesenchymal Stromal Cells (MSCs), particularly those derived from adipose tissue (AMSCs), represents a frontier in regenerative medicine. However, variability in biological source and manufacturing processes can significantly impact therapeutic outcomes, making comprehensive product characterization a critical regulatory requirement [12]. Within Good Manufacturing Practice (GMP)-compliant production, establishing well-defined release criteria is not optional but fundamental to ensuring that every cell product batch is safe, potent, and consistent. Among the analytical techniques available, flow cytometry emerges as a powerful and indispensable tool for providing this critical quality data. It enables rigorous assessment of cell identity, purity, and viability—key parameters for product release [93] [94]. This technical guide details the establishment of flow cytometry-based release criteria for clinical-grade AMSCs, providing researchers and drug development professionals with the methodologies and standards needed for translational science.

Flow Cytometry Fundamentals for GMP Environments

Core Principles and Data Interpretation

Flow cytometry operates by measuring the optical properties of individual cells as they pass in a fluid stream through a laser beam. It simultaneously measures forward scatter (FSC), indicating cell size, and side scatter (SSC), indicating cell granularity or complexity [50]. When antibodies conjugated to fluorochromes bind to specific cell surface markers, the emitted fluorescence is detected, quantifying antigen expression.

• Data Visualization: Data can be represented as single-parameter histograms or multi-parameter scatter plots.
  • Histograms display the distribution of a single marker's expression, allowing for easy visualization of positive and negative populations [57].
  • Scatter plots (e.g., dot plots, contour plots) correlate two or more parameters, enabling the identification of distinct cell subpopulations. Quadrant gates on these plots are commonly used to distinguish single-positive and double-positive populations [57].
• Gating Strategy: A logical, sequential gating strategy is essential for accurate analysis. This typically involves:
  • Removing debris based on FSC and SSC properties.
  • Selecting single cells by gating on FSC-Area vs. FSC-Height to exclude doublets.
  • Identifying viable cells using a viability dye (e.g., 7-AAD [93]).
  • Analyzing marker expression on the gated viable, single-cell population [50] [93].

GMP Compliance and Method Validation

In a GMP environment, the flow cytometry process itself must be standardized and validated. This includes:

• Use of Appropriate Controls: Isotype controls and fluorescence-minus-one (FMO) controls are crucial for distinguishing specific staining from background noise [57].
• Instrument Standardization: Regular calibration and performance tracking using standardized beads ensure day-to-day and instrument-to-instrument reproducibility [16].
• Robust SOPs: Detailed standard operating procedures (SOPs) must govern every step, from sample preparation and antibody staining to data acquisition and analysis [93].

Diagram 1: GMP-Compliant Flow Cytometry Workflow. Dashed lines indicate points where specific GMP documentation is required.

Establishing Identity and Purity: The Marker Panel

Classical and Non-Classical Marker Panels

Defining a cell product's identity is the primary function of release criteria. The International Society for Cellular Therapy (ISCT) has established minimum criteria for MSCs, including the positive expression of CD73, CD90, and CD105, and the absence of hematopoietic markers like CD45 [12]. These classical markers confirm a basic mesenchymal phenotype.

However, research on clinical-grade AMSCs expanded in human platelet lysate (hPL) has identified non-classical markers that provide a more nuanced characterization and may correlate with specific cellular functions [12]. The table below summarizes a comprehensive marker panel for AMSC characterization.

Table 1: Flow Cytometry Marker Panel for Adipose-Derived MSC Characterization

Marker	Classification	Expression in AMSCs	Functional/Biological Significance
CD73	Classical Positive	>95% Positive [12]	Ecto-5'-nucleotidase; immunomodulatory function
CD90	Classical Positive	>95% Positive [12]	Thy-1; cell-cell and cell-matrix interactions
CD105	Classical Positive	>95% Positive [12]	Endoglin; angiogenesis, TGF-β receptor complex
CD44	Classical Positive	>95% Positive [12]	Hyaluronic acid receptor; adhesion and migration
CD45	Classical Negative	<2% Positive [12]	Pan-hematopoietic marker; indicates purity
CD34	Non-Classical	Highly Variable [12] [93]	Progenitor cell marker; expression can depend on culture conditions and donor
CD146	Non-Classical	Highly Variable [12]	Pericyte marker; associated with vascular niche
CD271	Non-Classical	Highly Variable [12]	Nerve growth factor receptor; primitive MSC marker
CD200	Non-Classical	Highly Variable [12]	Immunomodulatory glycoprotein; may suppress immune responses
CD274 (PD-L1)	Non-Classical	Highly Variable [12]	Programmed death-ligand 1; key immunoinhibitory signal

Gating Strategy for AMSC Purity and Subpopulation Analysis

A reproducible gating strategy is vital. A typical workflow, as used in GMP-compliant studies, involves selecting nucleated cells using a DNA stain like Syto40, excluding doublets using FSC, and then gating on viable cells (7-AAD negative) [93]. Within this viable population, the purity of the AMSC product is determined by quantifying the percentage of cells that are CD45-/CD146-/CD34+, a phenotype identifying the ASC (Adipose-derived Stem Cell) population [93]. The non-classical markers can then be analyzed on this purified population to assess heterogeneity.

Diagram 2: Hierarchical Gating Strategy for AMSC Characterization. This logic is applied to flow cytometry data to isolate and analyze the target cell population.

Quantitative Release Criteria and Standards

Establishing Pass/Fail Benchmarks

For a batch of AMSCs to be released for clinical use, it must meet predefined specifications for identity, purity, and quality. The following table outlines potential release criteria based on published GMP studies.

Table 2: Proposed GMP Release Criteria for Clinical-Grade Adipose-Derived MSCs

Parameter	Release Criterion	Analytical Method	Rationale
Viability	>70% to >95% [94] [93]	Viability dye (e.g., 7-AAD)	Ensures infusion of a viable, functional product.
Identity (Purity)	>95% positive for CD73, CD90, CD105 [12]	Flow Cytometry	Confirms mesenchymal lineage as per ISCT guidelines.
Identity (Purity)	<2% positive for CD45 [12]	Flow Cytometry	Confirms absence of hematopoietic contaminants.
Sterility	No microbial growth	BacT/Alert or equivalent [94]	Mandatory safety requirement for parenteral products.
Endotoxin	Below specified limit (e.g., <5 EU/kg/hr)	Endotoxin Assay [94]	Prevents pyrogenic reactions in patients.
Mycoplasma	Absent	Mycoplasma Assay [94]	Prevents contamination of cell culture systems.

The Scientist's Toolkit: Essential Reagents and Materials

The following table lists key reagents and instruments critical for implementing GMP-compliant flow cytometry for AMSC release.

Table 3: Research Reagent Solutions for GMP Flow Cytometry

Item	Function/Application	Example Products/Catalogs
GMP-Grade Enzymes	Isolation of SVF/AMSCs from adipose tissue; must be animal-origin free.	Liberase, Celase [93]
GMP-Grade Cell Culture Media	Xeno-free expansion of AMSCs while maintaining phenotype and potency.	MSC-Brew GMP Medium [94], MesenCult-ACF Plus Medium [94]
Validated Antibody Panels	Standardized, pre-configured kits for MSC surface marker characterization.	BD Stemflow Human MSC Analysis Kit [94]
Viability Dyes	Discrimination of live/dead cells during flow analysis to ensure accuracy.	7-AAD [93], Syto40 [93]
Flow Cytometers	Instrumentation for data acquisition; requires regular QC and calibration.	BD FACS Fortessa [94], Beckman Coulter Navios [93]
Automated Cell Counters	Determination of total cell count and viability post-processing.	Nucleocounter NC-100 [93]

Flow cytometry is the cornerstone of quality control in the GMP-compliant production of adipose-derived MSCs. By implementing a rigorous, validated flow cytometry protocol that leverages both classical and novel biomarkers, manufacturers can establish scientifically sound release criteria. This ensures that every cellular product administered to patients is well-defined, pure, potent, and safe, thereby upholding the highest standards of clinical translation and paving the way for successful advanced therapy medicinal products (ATMPs). As the field evolves, the integration of more complex cytometry data and functional assays into release specifications will further enhance the predictability and efficacy of MSC-based therapies.

Within the rapidly advancing field of regenerative medicine, mesenchymal stromal cells (MSCs) have emerged as a cornerstone for therapeutic development. While MSCs can be isolated from numerous tissues, those derived from adipose tissue (ADSCs), bone marrow (BMSCs), dental pulp (DPSCs), and umbilical cord (UC-MSCs) are among the most extensively studied. Accurate characterization through flow cytometry is fundamental to understanding the intrinsic biological differences between these cell populations, which in turn dictates their suitability for specific clinical applications. This whitepaper provides an in-depth comparative phenotyping of ADSCs against other common MSC sources, delivering a technical guide framed within the context of flow cytometry research for scientists, researchers, and drug development professionals. We synthesize current research to highlight how ontogeny and tissue source shape MSC identity, focusing on surface marker expression, differentiation potential, proliferation capacity, and secretome profiles.

Essential Flow Cytometry Protocols for MSC Characterization

Standardized flow cytometry protocols are critical for the consistent isolation and phenotyping of MSCs from various sources. The following section details the core methodologies employed in the comparative studies cited throughout this document.

Cell Preparation and Staining

MSCs from all sources are typically cultured until passage 3-6 to ensure a purified population free from hematopoietic contaminants. For analysis, cells are harvested using trypsin/EDTA, washed with phosphate-buffered saline (PBS) containing a protein carrier like BSA, and resuspended at a concentration of 1x10^6 cells/mL [95] [96]. Aliquots of 100 µL (approximately 10^5 cells) are incubated with fluorochrome-conjugated antibodies for 20-30 minutes at room temperature in the dark. Isotype-matched control antibodies are used in parallel to define background staining and set appropriate gating boundaries [97] [96]. Following incubation, cells are washed twice to remove unbound antibody and resuspended in a suitable buffer for flow cytometric analysis.

Instrumentation and Data Analysis

Analysis is performed using instruments such as the FACSCalibur or Becton-Dickinson FACSAria, with data acquisition and analysis software like CellQuest Pro [98] [96]. The MSC population is first identified based on forward scatter (FSC) and side scatter (SSC) parameters, which correlate with cell size and granularity, respectively. A live analysis gate is set around this population to exclude debris and dead cells. Expression levels of surface markers are quantified as the percentage of positively stained cells within this gated population, with thresholds established based on isotype controls [8] [96].

Comparative Phenotypic Analysis of MSC Populations

The following tables summarize key quantitative differences in marker expression, functional capacities, and secretome profiles among MSC types, as established by side-by-side comparative studies.

Table 1: Surface Marker Expression Profile of MSCs from Different Sources

Surface Marker	ADSCs	BMSCs	DPSCs	UC-MSCs
CD44, CD73, CD90, CD105	>95% Positive [99]	>95% Positive [99]	>95% Positive [99]	>95% Positive [99]
CD34	Variable/Positive (early passage) [27]	Negative [99]	Negative [96]	Negative [99]
CD45, CD11b, CD14, CD19, HLA-DR	Negative (<2% positive) [99]	Negative (<2% positive) [99]	Negative (<2% positive) [96] [99]	Negative (<2% positive) [99]
CD106 (VCAM-1)	Low/Negative [99]	Not Reported	Low/Negative [99]	Moderately Positive (12%) [99]
CD146	Positive [96]	Not Reported	Positive (Different Intensity vs. ADSCs) [96]	Not Reported

Table 2: Functional Characteristics of MSCs from Different Sources

Functional Assay	ADSCs	BMSCs	DPSCs	UC-MSCs
Proliferation Capacity	High [95] [97]	Moderate [100] [97]	Very High [95]	Highest [99]
Adipogenic Differentiation	Strong [98] [101]	Moderate [98]	Limited/Absent [95]	Moderate [98]
Osteogenic Differentiation	Strong [101]	Strong [98]	Strong [95]	Strong [98] [99]
Chondrogenic Differentiation	Strong [101]	Can be induced [100]	Strong [95]	Strong [99]
Neuro-Marker Induction	Up-regulates markers, but immature morphology [101]	Not Reported	Up-regulates markers [101]	Up-regulates markers, but immature morphology [101]

Table 3: Secretome and Immunomodulatory Profile

Parameter	ADSCs	BMSCs	DPSCs	UC-MSCs
General Cytokine Secretion	Pro-angiogenic and immunoregulatory profiles [95] [27]	Not directly compared	Distinct profile from ADSCs; miRNAs involved in oxidative stress [95]	More prominent secretion profile than ADSCs [98]
Specific Factor Secretion	High HGF, Moderate VEGF [99]	Not Reported	Not Reported	High IGF-I, Ang-1, VEGF [99]
Extracellular Vesicle (EV) Production	Produces high numbers of small exosomes [95]	Not Reported	Produces EVs [95]	Not Reported

Experimental Workflow for Comparative Phenotyping

The following diagram illustrates a generalized experimental workflow for the side-by-side isolation, culture, and phenotyping of MSCs from different tissue sources.

Sca-1-Based Mouse ADSC Purification Workflow

Recent methodological advances highlight the importance of purification protocols for reducing heterogeneity, particularly for mouse ADSCs. The following diagram details a high-purity isolation method based on the Sca-1 marker.

The Scientist's Toolkit: Key Research Reagents

The following table catalogs essential reagents and their functions for the flow cytometry-based characterization and functional analysis of MSCs, as derived from the cited methodologies.

Table 4: Essential Research Reagents for MSC Characterization

Reagent / Kit	Function / Application	Specific Example
Collagenase Type I / II	Enzymatic digestion of tissue for primary cell isolation.	Digestion of adipose tissue [100] [97] and umbilical cord [98].
Mesenchymal Stem Cell Medium (MSCM)	Basal medium for MSC expansion and maintenance.	Sciencell MSCM used for rat ADSC/BMSC culture [97].
Fetal Bovine Serum (FBS)	Standard supplement for cell culture media.	10% FBS in DMEM/F12 for rat MSC culture [100].
Flow Cytometry Antibodies (CD markers)	Identification and phenotyping of MSC populations.	Anti-human CD73, CD90, CD105 (positive); CD34, CD45, HLA-DR (negative) [99].
Trilineage Differentiation Kits	Inducing adipogenic, osteogenic, and chondrogenic differentiation.	Commercial kits used to assess multipotency per ISCT criteria [95] [99].
Nanoparticle Tracking Analysis (NTA)	Quantifying concentration and size of extracellular vesicles.	NanoSight NS300 for characterizing MSC-EVs [9].
Cell Counting Kit-8 (CCK-8)	Colorimetric assay for assessing cell viability and proliferation.	Used to compare proliferation of ADSCs vs. BMSCs [100].

The comparative data unequivocally demonstrate that while all MSC populations adhere to the minimal criteria set by the ISCT, their biological and functional properties are significantly influenced by their tissue of origin. ADSCs distinguish themselves with a robust capacity for adipogenic differentiation and a secretome conducive to angiogenesis and immune regulation. BMSCs remain a well-characterized benchmark. DPSCs exhibit exceptional proliferation and unique neural marker expression, whereas UC-MSCs from fetal tissue offer the most rapid expansion.

For researchers, the choice of MSC source must be strategically aligned with the therapeutic target. ADSCs present a compelling option for applications in soft tissue regeneration and conditions requiring potent immunomodulation. The continued refinement of flow cytometry panels, including markers like CD106 and CD146, along with standardized purification protocols, is paramount for reducing population heterogeneity and ensuring reproducible, reliable outcomes in both basic research and clinical drug development.

The translational potential of adipose-derived mesenchymal stem cells (ADSCs) in regenerative medicine and cellular agriculture is immense, yet hampered by significant heterogeneity in cell populations. This variability often leads to inconsistent experimental and clinical outcomes, underscoring an urgent need for standardized characterization protocols [102]. A critical challenge in the field is bridging the gap between the phenotypic identification of ADSCs through surface markers and their actual functional capabilities, including proliferation, trilineage differentiation potential, and paracrine activities. This guide provides researchers with a comprehensive technical framework for linking specific surface marker expression profiles to functional potency, enabling more precise isolation, characterization, and application of ADSCs across preclinical and clinical settings.

Surface Marker Profiles and Their Biological Significance

The identity and purity of ADSCs are primarily defined through the expression pattern of specific cell surface markers. International societies, including the International Society for Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics and Science (IFATS), have established consensus markers for human ADSCs, though a definitive consensus for mouse ADSCs is still evolving [27].

Table 1: Core Surface Markers for Adipose-Derived Mesenchymal Stem Cells

Surface Marker	Alternative/Gene Name	Expression in ADSCs	Primary Function
CD73	NT5E, 5'-nucleotidase ecto	Positive [103]	Catalyzes conversion of extracellular nucleotides to nucleosides; lymphocyte differentiation [103].
CD90	THY1, Thy-1 cell surface antigen	Positive [103]	Cell adhesion and communication, particularly in immune and nervous systems [103].
CD105	ENG, Endoglin	Positive (Variable) [103] [104]	Transmembrane protein that induces activation and proliferation of endothelial cells [103].
CD29	ITGB1, Integrin subunit beta 1	Positive [27] [104]	Mediates cell adhesion and migration [103].
CD44	CD44 molecule	Positive [103]	Cell adhesion, migration, and cell-cell interactions [103].
Sca-1	Ly-6A/E, Stem Cell Antigen-1	Positive (Mouse) [27]	Marker for enriching stem cells; linked to self-renewal and pluripotency in mice [27].
CD34	CD34 molecule	Variable/Unstable [27] [103]	Expressed in early culture phases; decreases with passaging. Useful in stromal vascular fraction (SVF) [27].
CD45	PTPRC, Protein Tyrosine Phosphatase Receptor Type C	Negative [27] [103] [104]	Pan-hematopoietic marker; absence excludes hematopoietic cells [27].
CD31	PECAM1, Platelet Endothelial Cell Adhesion Molecule	Negative [27]	Endothelial cell marker; absence excludes endothelial cells [27].
CD11b	ITGAM, Integrin Subunit Alpha M	Negative [103]	Regulates leukocyte adhesion and migration; part of the innate immune response [103].

The expression of these markers is not merely for identification; it is deeply intertwined with cell function. For instance, CD29 (Integrin β1) facilitates cell-matrix interactions crucial for adhesion and migration, while CD105 (Endoglin) is involved in TGF-β signaling and angiogenesis. The Sca-1 marker in mice is associated with enhanced proliferative activity, self-renewal potential, and long-term stability in culture, making it a valuable tool for purifying a potent subpopulation of mouse ADSCs [27]. It is also crucial to note that marker expression can be dynamic, influenced by factors such as culture passage, donor species, and the specific anatomical depot from which the adipose tissue is sourced [104].

Correlating Marker Expression with Functional Potency

Quantitative differences in surface marker expression often directly predict the functional performance of ADSC populations in vitro.

Proliferative Capacity

Studies have demonstrated a strong positive correlation between the purity of specific surface markers and enhanced proliferation. A 2025 study showed that mouse ADSCs purified for Sca-1 positivity exhibited uniform morphology and enhanced proliferation rates. Furthermore, a subpopulation isolated via adherence followed by magnetic sorting (ADSC-AM) expressed over 95% Sca-1 and CD29, correlating with superior growth properties [27]. Similarly, in bovine models, ADSCs from perirenal fat (P-AMSCs) exhibiting higher expression of certain markers demonstrated faster proliferation and shorter population doubling times compared to those from subcutaneous fat (S-AMSCs) [104].

Trilineage Differentiation Potential

The differentiation capacity of ADSCs is a cornerstone of their therapeutic application, and this potential is strongly linked to their phenotype.

• Adipogenesis: The Sca-1+ mouse ADSC population not only showed robust trilineage differentiation but also demonstrated enhanced adipogenesis specifically [27]. In cattle, P-AMSCs, which showed a distinct marker profile (including 26.3% CD105 expression versus 1.2% in S-AMSCs), displayed greater lipid accumulation and higher expression of adipogenic genes (PPARγ, FABP4, LPL, and FASN) after induction [104].
• Osteogenesis and Chondrogenesis: The same bovine P-AMSCs population showed stronger osteogenic (91.8% vs. 60.5% mineralization) and chondrogenic differentiation, with significant upregulation of lineage-specific genes [104]. This confirms that a specific surface marker signature can indicate multipotency.

Angiogenic and Immunomodulatory Potential

Beyond trilineage differentiation, advanced functional assays like RNA sequencing can reveal further correlations. The high-purity Sca-1+ CD29+ mouse ADSCs were found to possess unique potential in angiogenesis and immune regulation, linking their specific phenotype to critical therapeutic functions [27].

Table 2: Correlation Between Surface Marker Profile and Functional Outcomes in Select Studies

Study Model / Cell Type	Key Surface Marker Profile	Correlated Functional Outcome
Mouse ADSCs (ADSC-AM) [27]	>95% Sca-1, >95% CD29	Enhanced proliferation, uniform morphology, enhanced adipogenesis, unique angiogenesis, and immune regulation potential.
Bovine Perirenal ADSCs (P-AMSCs) [104]	CD105+ (26.3%), CD73+ (75.7%), CD29+ (80.1%)	Superior proliferation, adipogenesis, osteogenesis (91.8% mineralization), and chondrogenesis.
Bovine Subcutaneous ADSCs (S-AMSCs) [104]	CD105+ (1.2%), CD73+ (95%), CD29+ (94.7%)	Lower proliferation and differentiation potential compared to P-AMSCs.

Experimental Protocols for Phenotype-Function Correlation

Establishing a robust link between phenotype and function requires a structured experimental workflow. Below is a detailed protocol for a correlative study, using recent research as a benchmark.

Experimental Workflow

The following diagram outlines the key stages of an integrated phenotype-function analysis workflow.

Detailed Methodologies

Cell Isolation and Purification

• Adipose Tissue Harvest and Digestion: Euthanize mice following IACUC-approved protocols (e.g., CO₂ asphyxiation). Excise inguinal fat pads and rinse in PBS. Mince tissue into 1-2 mm³ fragments and digest using a solution of 0.25% collagenase type II at 37°C with agitation [27]. Neutralize digestion with culture medium containing serum (e.g., 10% FBS).
• Stromal Vascular Fraction (SVF) Isolation: Centrifuge the digest to pellet the SVF (e.g., 1200× g for 10 min). Resuspend the pellet in a red blood cell lysis buffer (e.g., 160 mM NH₄Cl), incubate, and centrifuge again to obtain a clean SVF [103].
• Purification Strategies:
  • Direct Adherence (ADSC-A): Plate the SVF directly and rely on plastic adherence to select for ADSCs [27].
  • Magnetic-Activated Cell Sorting (MACS): Use magnetic beads conjugated to an antibody against a specific marker like Sca-1 to positively select the target population from the SVF. This can be done before (ADSC-M) or after (ADSC-AM) an initial adherence culture period [27]. The ADSC-AM method (adherence to third generation followed by MACS) has been shown to yield over 95% purity for Sca-1 and CD29 [27].

Phenotypic Characterization by Flow Cytometry

• Cell Preparation: Harvest and wash cells. Aliquot approximately (1 \times 10^5 ) to (1 \times 10^6 ) cells per tube for staining.
• Staining Protocol: Resuspend cells in a buffer containing a viability dye (e.g., Zombie NIR). Incubate with fluorochrome-conjugated antibodies against target markers (e.g., Sca-1, CD29, CD73, CD90, CD105 for positive markers; CD31, CD45 for negative markers) for 20-30 minutes on ice in the dark. Include isotype controls for accurate gating [103].
• Data Acquisition and Analysis: Analyze stained cells using a flow cytometer. Collect a minimum of 10,000 events per sample. Use fluorescence minus one (FMO) controls to set positive gates. The population of interest should demonstrate high expression of positive markers (>80-95% for key markers like Sca-1 and CD29) and minimal expression of negative markers (<2% for CD31/CD45) [27] [103].

Functional Potency Assays

• Proliferation Assay: Seed cells at a low density and monitor over time using assays like MTS. High-purity Sca-1+ populations have shown significantly enhanced proliferation rates and higher cell counts in these assays [27] [104].
• Trilineage Differentiation Assays:
  • Adipogenesis: Culture cells in adipogenic induction medium (containing insulin, IBMX, dexamethasone, and indomethacin) for 14-21 days. Confirm differentiation with Oil Red O staining for lipid droplets and quantify extracted dye or analyze adipogenic gene expression (PPARγ, FABP4) via qPCR [27] [104].
  • Osteogenesis: Culture cells in osteogenic induction medium (containing ascorbic acid, β-glycerophosphate, and dexamethasone) for 21-28 days. Stain calcium deposits with Alizarin Red S and quantify extraction [104].
  • Chondrogenesis: Pellet cultures in chondrogenic medium (containing TGF-β3, ascorbic acid, and proline) for 21-28 days. Analyze sulfated proteoglycans with Alcian Blue staining and assess chondrogenic genes (SOX9, COL2A1) [104].
• Advanced Functional Analysis: For a deeper mechanistic understanding, employ RNA sequencing on purified populations. This can reveal enriched pathways, such as those related to angiogenesis and immune regulation, which are associated with specific phenotypes like Sca-1+ CD29+ ADSCs [27].

Visualization of Signaling Pathways

The functional properties of ADSCs are governed by complex intracellular signaling networks that are activated downstream of surface markers. The following diagram integrates key pathways linked to the potent Sca-1/CD29 phenotype.

The Scientist's Toolkit: Essential Research Reagents

Table 3: Key Reagent Solutions for ADSC Phenotype-Function Studies

Reagent / Tool	Function / Application	Specific Examples / Notes
Collagenase Type II	Enzymatic digestion of adipose tissue to isolate the Stromal Vascular Fraction (SVF).	Use at 0.075% - 0.25% concentration [27] [103]. Critical first step determining initial cell yield and viability.
Magnetic Cell Sorting (MACS)	Labeling and separation of cell populations based on surface marker expression.	Ideal for pre-enrichment of target populations (e.g., Sca-1+ cells) to achieve high purity (>95%) before functional assays [27].
Flow Cytometry Antibodies	Phenotypic characterization and purity check of ADSC populations.	Core panel: Anti-Sca-1 (mouse), CD29, CD73, CD90, CD105. Negative panel: Anti-CD31, CD45 [27] [103]. Isotype controls are essential.
Trilineage Differentiation Kits	Standardized induction of adipogenic, osteogenic, and chondrogenic lineages.	Provides optimized media components for reproducible differentiation. Quantification via Oil Red O, Alizarin Red, Alcian Blue [104].
MTS/Proliferation Assay	Colorimetric measurement of cell metabolic activity and proliferation.	Used to compare proliferative capacity between different purified populations [104].
RNA Sequencing	Unbiased analysis of transcriptional profiles and pathway enrichment.	Identifies molecular mechanisms (e.g., angiogenesis, immune pathways) underlying the superior function of specific phenotypes [27].

Adipose-derived mesenchymal stem cells (AD-MSCs) represent a heterogeneous population with diverse functional capabilities, making their therapeutic application challenging due to inconsistent outcomes. The characterization and validation of functionally distinct subpopulations within this heterogeneous mix is paramount for advancing reproducible and effective cell-based therapies. This whitepaper provides an in-depth technical guide for researchers and drug development professionals engaged in the flow cytometry characterization of AD-MSCs, focusing on three functionally critical subsets: angiogenic, immunomodulatory, and osteogenic. Within the broader context of AD-MSC research for regenerative medicine, validating these subpopulations ensures that cell products have predictable biological activities, thereby enhancing therapeutic efficacy and reliability. This document synthesizes current methodologies, quantitative datasets, and experimental protocols to establish a standardized framework for identifying and validating these functionally distinct cellular subsets using flow cytometry and complementary functional assays.

Angiogenic CD271+ AD-MSCs

Characterization and Key Findings

The CD271+ subpopulation of AD-MSCs demonstrates enhanced angiogenic potential compared to their CD271- counterparts. This subset exhibits a gene expression profile conducive to blood vessel formation and represents a promising candidate for therapies aimed at improving vascularization in engineered tissues and grafts.

Table 1: Quantitative Characteristics of CD271+ Angiogenic AD-MSCs

Parameter	CD271+ AD-MSCs	CD271- AD-MSCs	Measurement Method
Frequency in SVF	4–20% [65]	80–96% [65]	Flow Cytometry
Stem Cell Phenotype (CD45-/CD90+)	Higher proportion [65]	Lower proportion [65]	Flow Cytometry
Angiogenic Gene Expression	Higher [65]	Lower [65]	RT-qPCR, RNA-seq
Inflammatory Gene Expression	Lower [65]	Higher [65]	RT-qPCR, RNA-seq
Tubule Formation Support	More effective [65]	Less effective [65]	Co-culture with HUVECs

Experimental Protocol for Isolation and Validation

Magnetic-Activated Cell Sorting (MACS) of CD271+ Cells [65]

• Source Tissue: Obtain human adipose tissue (e.g., abdominal fat) with ethical approval and informed consent.
• SVF Isolation: Mince tissue finely and digest with 0.2% (w/v) collagenase I in HBSS for 1 hour at 37°C with agitation. Filter the digest through a 100-μm mesh, centrifuge, and lyse red blood cells. The resulting pellet is the SVF.
• MACS Labeling: Resuspend ~10 million SVF cells in 80 μL of MACS buffer (PBS with 0.5% BSA and 2 mM EDTA). Add 20 μL of CD271 microbeads and 20 μL of FcR blocking reagent. Incubate for 15 minutes at 4°C.
• Magnetic Separation: Wash cells, pass through a prepped magnetic column. The flow-through is the CD271- fraction. Remove the column from the magnet and flush to collect the CD271+ fraction.
• Flow Cytometry Validation: Analyze sorted populations using a flow cytometer. Stain cells with anti-CD271-APC, anti-CD45-PerCP, and anti-CD90-FITC to confirm purity and phenotype (CD271+/CD45-/CD90+).

Functional Validation: Endothelial Tubule Formation Assay [65]

• Co-culture Setup: Co-culture sorted CD271+ or CD271- AD-MSCs with human umbilical vein endothelial cells (HUVECs) on a suitable extracellular matrix (e.g., Matrigel).
• Incubation and Imaging: Incubate for 6–24 hours and capture images of the formed tubule networks.
• Quantitative Analysis: Measure total tubule length, number of branch points, and number of meshes using image analysis software (e.g., ImageJ). CD271+ AD-MSCs will promote more complex and extensive tubule networks.

Signaling Pathways in CD271+ Angiogenic Function

The enhanced angiogenic function of CD271+ AD-MSCs is driven by a distinct gene expression profile and interaction with key signaling pathways. These cells secrete higher levels of angiogenic factors which activate receptors on endothelial cells, promoting their proliferation, migration, and ultimate organization into new blood vessels.

Immunomodulatory AD-MSC Subpopulations

Characterization and Sex-Dependent Effects

The immunomodulatory capacity of AD-MSCs is not uniform and can be influenced by donor characteristics, most notably biological sex. Female-derived AD-MSCs (fMSCs) have been demonstrated to possess superior immunosuppressive capabilities in vitro compared to male-derived AD-MSCs (mMSCs) [105].

Table 2: Quantitative Comparison of Immunomodulatory Potency in Female vs. Male AD-MSCs

Parameter	Female AD-MSCs (fMSCs)	Male AD-MSCs (mMSCs)	Measurement Method
PBMC Proliferation Suppression	67.9 ± 10.4% (fPBMCs); 60.7 ± 15.6% (mPBMCs) [105]	29.4 ± 9.3% (fPBMCs); 22.5 ± 13.6% (mPBMCs) [105]	CFSE Dilution Assay
IDO1 Production	3301 pg/mL [105]	1699 pg/mL [105]	ELISA
PGE-2 Production	6142 pg/mL [105]	2448 pg/mL [105]	ELISA
IL-1RA Production	1025 pg/mL [105]	701 pg/mL [105]	Multiplex Assay
G-CSF Production	503 pg/mL [105]	806 pg/mL [105]	Multiplex Assay

Experimental Protocol for Evaluating Immunomodulation

Lymphocyte Suppression Assay [105] [106]

• PBMC Isolation: Isolate Peripheral Blood Mononuclear Cells (PBMCs) from healthy donors via density gradient centrifugation (e.g., using Ficoll-Paque).
• MSC Preparation: Culture fMSCs and mMSCs (Passage 4) to ~80% confluence. Optionally "prime" MSCs by culturing for 24–48 hours with 10 ng/mL TNF-α and 100 ng/mL IFN-γ to mimic an inflammatory microenvironment.
• Co-culture Setup: Label PBMCs with carboxyfluorescein succinimidyl ester (CFSE, 10 μM). Co-culture CFSE-labeled PBMCs (2×10⁵ cells) with irradiated MSCs (e.g., at MSC:PBMC ratios from 1:10 to 1:1) in a 96-well plate. Stimulate PBMCs using anti-CD2/CD3/CD28 coated microbeads.
• Incubation and Analysis: Incubate for 5–6 days. Harvest cells and analyze CFSE dilution by flow cytometry to measure T-cell proliferation. Suppression is calculated as: (1 - (% divided T cells with MSCs / % divided T cells without MSCs)) × 100.

Analysis of Soluble Mediators

• Sample Collection: Collect cell culture supernatant after the co-culture period.
• Protein Quantification: Quantify concentrations of key immunomodulatory factors like IDO1, PGE-2, IL-1RA, and G-CSF using ELISA or multiplex bead-based assays.

Immunomodulatory Signaling Pathways

The superior immunosuppression by fMSCs is mediated through the heightened production of specific soluble factors in response to inflammatory signals from the microenvironment. These factors act on T-cells to suppress their proliferation and activation.

Osteogenic AD-MSC Subpopulations

Characterization of Early Osteogenic Commitment

Osteogenic differentiation of AD-MSCs is a gradual process. Early commitment is characterized by subtle shifts in gene expression related to cell adhesion and proliferation, rather than immediate upregulation of classic bone markers, which occurs over longer timeframes [107].

Table 3: Gene Expression Profile During Early Osteogenic Induction in hASCs

Gene Category	Regulation at 24h	Significance / Function	Analysis Method
Differentially Expressed Genes (DEGs)	586 in polysomal fraction; 433 in total RNA fraction [107]	Indicates early transcriptional & translational response	RNA-seq
Classic Osteogenic Markers	Not significantly upregulated at 24h [107]	Confirms lineage commitment is not immediate	RNA-seq
Cell Adhesion & Proliferation Genes	Significantly regulated [107]	Manages initial cell behavior in culture	GO Term Analysis

Experimental Protocol for Tracking Early Osteogenesis

Polysomal Profiling and RNA-seq for Early Differentiation [107]

• Cell Culture and Induction: Culture characterized hASCs. Induce osteogenesis in test groups with commercial osteogenic differentiation medium (typically containing dexamethasone, ascorbate-2-phosphate, and β-glycerophosphate). Maintain control groups in standard growth medium.
• Harvesting: At 24 hours post-induction, harvest cells and treat with cycloheximide to freeze translating ribosomes.
• Sucrose Gradient Centrifugation: Lyse cells and layer cytoplasmic extracts onto a 10–50% sucrose density gradient. Ultracentrifuge to separate ribosomal fractions.
• RNA Extraction: Fractionate the gradient and isolate RNA from the polysome-associated (actively translated) fraction and the total RNA fraction.
• RNA-seq and Analysis: Perform RNA sequencing on both fractions. Analyze data for differentially expressed genes (DEGs) and perform Gene Ontology (GO) enrichment analysis to identify regulated biological processes.

Flow Cytometry for Surface Marker Analysis While not a focus of the cited study, tracking surface proteins like CD73, CD90, and CD105 (positive markers) and CD31 and CD45 (negative markers) by flow cytometry during differentiation confirms the maintenance of MSC identity at the start of the experiment [18] [107].

Osteogenic Differentiation Signaling Pathway

The early stages of osteogenic differentiation are characterized by the activation of key signaling pathways that manage cell behavior and begin to prime the cells for bone matrix production. These pathways regulate transcriptional activators that drive the expression of bone-specific genes at later stages.

The Scientist's Toolkit: Essential Research Reagents

Table 4: Key Research Reagent Solutions for AD-MSC Subpopulation Validation

Reagent / Kit	Primary Function	Specific Application
Collagenase Type I/II	Enzymatic digestion of adipose tissue	Isolation of Stromal Vascular Fraction (SVF) [65] [105]
MACS CD271 Microbeads	Magnetic labeling of target cells	Positive selection of CD271+ angiogenic subpopulation [65]
Sca-1 Antibodies (Mouse)	Magnetic or fluorescent labeling	Purification of mouse ADSCs (Sca-1+ subset) [27]
Anti-CD2/CD3/CD28 Microbeads	Polyclonal T-cell activation	Functional validation of immunomodulatory potential [108] [105]
Osteogenic Differentiation Kit	Induces bone lineage differentiation	In vitro functional validation of osteogenic potential [107] [61]
CFSE Cell Proliferation Kit	Fluorescent cell labeling	Tracking and quantifying lymphocyte proliferation [105]
Flow Cytometry Antibody Panels	Cell surface and intracellular staining	Phenotypic characterization (e.g., CD73, CD90, CD105, CD34, CD45, HLA-DR) [18] [107]

The functional validation of AD-MSC subpopulations—angiogenic (CD271+), immunomodulatory (sex-dependent), and osteogenic—is a critical step in developing reproducible and potent cell-based therapeutics. The methodologies detailed herein, centered on flow cytometry and coupled with robust functional assays, provide a framework for researchers to move beyond characterizing heterogeneous cell mixtures. By rigorously identifying and validating these distinct functional subsets, the field can advance toward more predictable clinical outcomes, enabling the development of tailored cellular products for specific regenerative applications.

Within the framework of adipose-derived mesenchymal stromal cell (AD-MSC) research, ensuring the quality and consistency of cell products is paramount for both research reproducibility and clinical translation. AD-MSCs, harvested from adipose tissue, possess immense regenerative and immunomodulatory potential [103]. However, their heterogeneity and sensitivity to culture conditions create significant challenges for manufacturing consistent cell populations [109] [31]. Flow cytometry emerges as a critical, versatile tool in this context, enabling researchers to quantitatively assess cell identity, purity, and stability across multiple batches and over time. This technical guide outlines comprehensive strategies for employing flow cytometry to establish robust batch-to-batch consistency and stability studies, providing a foundational pillar for characterizing AD-MSCs in both basic research and advanced therapeutic medicinal product (ATMP) development.

Regulatory Framework and Standardization

The production of AD-MSCs for clinical applications classifies them as Advanced Therapy Medicinal Products (ATMPs) in the European Union and as cell-based products under the U.S. FDA regulation, necessitating strict adherence to Good Manufacturing Practice (GMP) guidelines [109]. This regulatory landscape mandates rigorous quality control (QC) protocols where flow cytometry is central to defining critical quality attributes (CQAs). The International Society for Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics and Science (IFATS) have provided consensus on marker expression for AD-MSCs, recommending a panel of positive and negative surface markers for basic characterization [103] [12]. A GMP-compliant workflow must be validated to ensure the safety, identity, purity, and potency of the final cell product, with flow cytometry data serving as a key release criterion [109] [110].

Core Marker Panels for AD-MSC Characterization

Classical and Non-Classical Marker Panels

The standard immunophenotypic identity of AD-MSCs is defined by the high expression (>80-95%) of specific positive markers and minimal expression (<2%) of negative markers, typically associated with the hematopoietic and endothelial lineages [103] [12]. The table below summarizes the essential markers for AD-MSC characterization.

Table 1: Core Surface Markers for Adipose-Derived MSCs Characterization

Surface Marker	Gene	Name	Expression in AD-MSCs	Primary Function
CD73	NT5E	5'-nucleotidase ecto	Positive (>80%)	Catalyzes conversion of nucleotides to nucleosides [103]
CD90	THY1	Thy-1 cell surface antigen	Positive (>80%)	Cell adhesion and communication [103]
CD105	ENG	Endoglin	Positive (>80%)	Activation and proliferation of endothelial cells [103]
CD44	CD44	CD44 molecule	Positive	Cell adhesion and migration [103]
CD29	ITGB1	Integrin subunit beta 1	Positive	Cell adhesion [103]
CD13	ANPEP	Alanyl aminopeptidase, membrane	Positive (Stable)	Peptide digestion; stable expression [103]
CD45	PTPRC	Protein tyrosine phosphatase, receptor type C	Negative (<2%)	Hematopoietic lineage marker [103] [12]
CD31	PECAM1	Platelet and endothelial cell adhesion molecule 1	Negative (<2%)	Endothelial lineage marker [103] [12]
CD34	CD34	CD34 molecule	Variable (Context-Dependent)	Early culture positivity; decreases with passages [103] [27]
CD11b	ITGAM	Integrin subunit alpha M	Negative (<2%)	Leukocyte adhesion and migration [103]
CD19	CD19	CD19 molecule	Negative (<2%)	B lymphocyte marker [103]
CD14	CD14	CD14 molecule	Negative (<2%)	Monocyte/macrophage marker [103]
HLA-DR	HLA-DR	Human Leukocyte Antigen - DR isotype	Negative (<2%)	Antigen presentation marker [103]

For enhanced characterization, especially in a GMP environment, non-classical markers provide deeper insights into functional heterogeneity and potency. These include CD36, CD163, CD271, CD200, CD273 (PD-L2), CD274 (PD-L1), CD146, CD248, and CD140b (PDGFRβ) [12]. Their expression can vary between donors and culture conditions, offering valuable information for manufacturing control.

Species-Specific Considerations: The Case of Mouse AD-MSCs

Preclinical research frequently utilizes mouse models, but it is critical to note that marker consensus defined for human AD-MSCs does not directly translate. The mouse AD-MSC phenotype is less defined, contributing to significant heterogeneity in study outcomes [27]. Stem cell antigen-1 (Sca-1, Ly-6A/E) is a widely accepted positive marker for enriching mouse mesenchymal stem cells, including those from adipose tissue [27]. Studies show that Sca-1+ mouse AD-MSCs demonstrate enhanced proliferation, self-renewal, and trilineage differentiation potential compared to unselected populations. A combination of positive markers (e.g., Sca-1, CD29, CD44, CD90) and negative markers (CD31, CD45) is recommended for purifying and characterizing mouse AD-MSCs [27].

Experimental Design and Workflow

A robust flow cytometry QC protocol for batch-to-batch consistency involves a standardized workflow from cell preparation to data analysis, ensuring comparability across different production batches and time points.

Diagram 1: Flow Cytometry QC Workflow for AD-MSCs.

Detailed Staining and Acquisition Protocol

Materials:

• Cells: AD-MSCs at passage 3-4 (or a standardized passage number).
• Staining Buffer: Phosphate-Buffered Saline (PBS) supplemented with 0.5-2% Bovine Serum Albumin (BSA) or Fetal Bovine Serum (FBS).
• Viability Dye: e.g., 7-AAD, Propidium Iodide (PI), or a fixable viability dye (e.g., Zombie Aqua).
• Antibodies: Directly conjugated monoclonal antibodies against target antigens. Validate antibodies for specificity and titrate for optimal signal-to-noise ratio.
• Fc Receptor Blocking Solution: Human or species-specific Fc block to reduce non-specific binding.
• Flow Cytometer: Instrument calibrated using standardized beads (e.g., CS&T or Cytometer Setup and Tracking beads).

Step-by-Step Method:

• Cell Harvest: Harvest cells at ~80% confluency using a standardized dissociation reagent (e.g., TrypLE Express for animal-origin-free protocols) [111] [110]. Neutralize the enzyme with complete medium.
• Cell Counting and Viability Assessment: Perform cell counting and viability analysis using a hemocytometer with Trypan Blue exclusion or an automated cell counter. Only proceed with samples demonstrating >95% viability [110].
• Aliquot and Wash: Aliquot 1-5 x 10^5 cells per test tube. Pellet cells by centrifugation (e.g., 300-400 x g for 5 minutes) and wash once with staining buffer.
• Fc Receptor Blocking: Resuspend the cell pellet in an appropriate volume of Fc receptor blocking solution. Incubate for 5-10 minutes at 2-8°C.
• Antibody Staining: Add pre-titrated antibody cocktails directly to the tube without washing. Include:
  • An unstained control for autofluorescence.
  • A viability dye-only control.
  • Single-color stained controls for compensation.
  • Fluorescence Minus One (FMO) controls for accurate gating. Incubate for 20-30 minutes in the dark at 2-8°C.
• Washing and Fixation: Wash cells twice with cold staining buffer. If required for biosafety or delayed acquisition, resuspend the cell pellet in a fixation buffer (e.g., 1-4% paraformaldehyde). Otherwise, resuspend in an adequate volume of staining buffer for acquisition.
• Data Acquisition: Acquire data on a flow cytometer within 24 hours if fixed, or immediately if live. Acquire a minimum of 10,000 events per sample from the viable cell gate. Ensure compensation is correctly applied using single-stain controls.

Gating Strategy and Data Analysis

Table 2: Standardized Gating Hierarchy for AD-MSC Immunophenotyping

Gating Step	Purpose	Typical Marker/Parameter	Acceptance Criterion
1. FSC-A vs. SSC-A	Identify the main cell population based on size and granularity, excluding debris.	Forward Scatter (FSC), Side Scatter (SSC)	Clear, distinct population.
2. Singlets Gate	Exclude cell doublets or aggregates to ensure analysis of single cells.	FSC-H vs. FSC-A	Well-defined diagonal population.
3. Viable Cells Gate	Select living cells for analysis, excluding dead/dying cells.	Viability Dye (e.g., negative for PI/7-AAD)	>95% of singlets should be viable.
4. Positive Marker Analysis	Quantify the percentage of cells expressing MSC markers.	CD73, CD90, CD105, CD44, CD29	>80-95% of viable cells should be positive.
5. Negative Marker Analysis	Quantify the percentage of contaminating cells.	CD45, CD31, CD11b, CD19, HLA-DR	<2% of viable cells should be positive.

Implementing Batch and Stability Studies

Batch-to-Batch Consistency Testing

To ensure manufacturing reproducibility, analyze a minimum of three consecutive batches of AD-MSCs under identical culture conditions. The acceptance criteria for consistency should be pre-defined, for example:

• Identity: The mean fluorescence intensity (MFI) and percentage of positive cells for classical markers (e.g., CD73, CD90, CD105) should not vary by more than ±10-15% between batches.
• Purity: The percentage of cells expressing negative markers must consistently remain below 2% in all batches.
• Viability: Post-thaw or harvest viability should consistently be >90-95% [110].

Stability Studies

Stability studies assess how the AD-MSC phenotype is maintained over time under specific conditions, which is critical for determining product shelf-life.

• In-Process Stability: Evaluate cells at different time points after harvest (e.g., 0, 6, 24, 48 hours) when stored in the intended administration formulation at 2-8°C. This defines the permissible hold time before patient infusion.
• Post-Thaw Stability: Assess cell phenotype and viability immediately after thawing (time 0) and after a defined post-thaw holding period (e.g., 4-24 hours) to establish the window for use after cryopreservation.
• Long-Term & Shelf-Life Stability: For cryopreserved products, test the phenotype and viability of AD-MSCs stored in the final container at cryogenic temperatures over several months (e.g., 1, 3, 6, 12 months) to establish the expiration date [110].

Table 3: Example Stability Study Schedule and Specifications

Study Type	Test Time Points	Key Parameters to Monitor	Proposed Acceptance Criteria
In-Process Stability	0, 6, 12, 24 hours post-harvest	Viability, %CD73+/CD90+/CD105+, %CD45-/CD31-	Viability ≥85%; Positive markers ≥80%; Negative markers ≤2%
Post-Thaw Stability	0 and 4 hours post-thaw	Viability, %CD73+/CD90+/CD105+	Viability ≥70% (minimum), target ≥90%; Positive markers ≥80% [110]
Long-Term Stability	0, 30, 90, 180 days in vapor phase LN₂	Viability, Sterility, Phenotype, Endotoxin	All release criteria met (viability, phenotype, sterility) [110]

The Scientist's Toolkit: Essential Reagents and Materials

Table 4: Key Research Reagent Solutions for Flow Cytometry of AD-MSCs

Item Category	Specific Examples	Function & Importance
Culture Media	MSC-Brew GMP Medium (Miltenyi), StemPro MSC SFM XenoFree (Thermo), MesenCult-ACF Plus (StemCell)	GMP-compliant, serum/xeno-free media for expansion, ensuring clinical relevance and reducing batch variability [111] [110].
Dissociation Reagent	TrypLE Express (Thermo)	Animal-origin-free, recombinant enzyme for cell harvesting, enhancing GMP compliance [111].
Viability Dye	7-AAD, Propidium Iodide, Fixable Viability Dyes (e.g., Zombie Aqua)	Distinguishes live from dead cells, critical for accurate immunophenotyping by excluding non-viable events.
Core Antibody Panel	Anti-human CD73, CD90, CD105, CD44, CD45, CD31 (Multiple vendors, e.g., BD, Miltenyi)	Defines the fundamental identity and purity of AD-MSCs according to ISCT/IFATS guidelines [103] [12].
Validation Antibodies	Anti-human CD36, CD146, CD200, CD273/PD-L2, CD274/PD-L1	Non-classical markers for deep phenotyping and potentially correlating with specific functional potencies [12].
Calibration Beads	CS&T Beads (BD), Cyto-Cal Beads (Thermo)	Ensures day-to-day instrument performance consistency, laser alignment, and photomultiplier tube (PMT) voltage stability.
Flow Cytometer	BD FACSymphony, Beckman CytoFLEX, BD FACSFortessa	High-performance instruments capable of multi-color analysis for comprehensive immunophenotyping.

Advanced Applications and Future Directions

Flow cytometry's utility extends beyond basic characterization. As the field progresses, it is increasingly used for potency assays, where specific surface markers (e.g., CD274/PD-L1 for immunomodulation) or intracellular proteins are measured to predict therapeutic efficacy [12]. Furthermore, high-parameter spectral flow cytometry allows for the simultaneous assessment of dozens of markers, enabling deep profiling of AD-MSC subpopulations and revealing functional heterogeneity that may impact clinical outcomes [31]. Integrating flow cytometry data with other OMICs technologies, such as single-cell RNA sequencing (scRNA-seq), will further refine our understanding of AD-MSC biology and lead to more sophisticated and predictive quality control metrics for cell-based therapies.

Conclusion

Flow cytometry is an indispensable and versatile tool that extends far beyond simple characterization of ADSCs. It is fundamental for confirming identity, assessing purity, and uncovering functional heterogeneity within cell populations. Success hinges on a deep understanding of both the foundational ISCT criteria and the more nuanced, non-classical markers that may predict therapeutic potency. As the field advances toward more personalized cell therapies, the ability to reliably identify, isolate, and validate specific ADSC subpopulations using optimized flow cytometry panels will be crucial. Future efforts must focus on standardizing protocols across laboratories, further investigating the direct link between immunophenotype and in vivo function, and integrating flow cytometric data with other omics technologies to fully realize the clinical potential of adipose-derived mesenchymal stromal cells in regenerative medicine and drug development.

References

• 1. Evolution of cell therapies derived from adipose tissue [https://pmc.ncbi.nlm.nih.gov/articles/PMC12382222/]
• 2. Adipose-derived stem cell exosomes: emerging roles and ... [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1637342/full]
• 3. Current progress and limitations of research regarding the ... [https://link.springer.com/article/10.1007/s43994-024-00147-9]
• 4. Adipose derived stem cells – Sources, differentiation ... [https://www.sciencedirect.com/science/article/pii/S0753332225002306]
• 5. Optimal Sca-1-based procedure for purifying mouse ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1566670/full]
• 6. Mesenchymal stem cells: opening a new chapter in the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12465317/]
• 7. Adipose-derived mesenchymal stem cells and their ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1617157/full]
• 8. Flow Cytometry: a versatile tool for stem cell research [https://www.sciencedirect.com/science/article/abs/pii/S0006291X25017498]
• 9. Extracellular vesicles isolated from adipose tissue-derived ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04435-x]
• 10. An Overview of Mesenchymal Stem Cell Heterogeneity and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10975472/]
• 11. Minimal criteria for defining multipotent mesenchymal ... [https://www.sciencedirect.com/science/article/abs/pii/S1465324906708817]
• 12. Identification and validation of multiple cell surface markers of ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-016-0370-8]
• 13. Purification and characterization of human adipose ... [https://www.nature.com/articles/s41598-022-05760-4]
• 14. Phenotypic Characterization and In Vivo Localization of ... [https://www.sciencedirect.com/science/article/pii/S101684782305269X]
• 15. ICCS Quality & Standards Committee Modules [https://www.cytometry.org/web/quality.php]
• 16. Guidelines for the use of flow cytometry and cell sorting in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9165548/]
• 17. Characterization of human adipose-derived stem cells ... [https://pubmed.ncbi.nlm.nih.gov/21082399/]
• 18. Adipose-derived mesenchymal stromal/stem cells [https://pmc.ncbi.nlm.nih.gov/articles/PMC4131268/]
• 19. Phenotypic Characterization of Mesenchymal Stem Cells ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3083285/]
• 20. Immunophenotypic analysis of human adipose-derived ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10266955/]
• 21. Guidelines for preparation and flow cytometry analysis of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11739683/]
• 22. Identification and validation of multiple cell surface markers of ... [https://pubmed.ncbi.nlm.nih.gov/27515308/]
• 23. Distinct Dominant Lineage from In Vitro Expanded Adipose ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8998068/]
• 24. Flow cytometric characterization of cell surface markers to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10507789/]
• 25. Flow cytometric characterization of cell surface markers to ... [https://www.archivesofmedicalscience.com/Flow-cytometric-characterization-of-cell-surface-markers-to-differentiate-between,131088,0,2.html]
• 26. The heterogeneity of mesenchymal stem cells: an important ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-023-03587-y]
• 27. Optimal Sca-1-based procedure for purifying mouse adipose ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12122437/]
• 28. Adipose-Derived Mesenchymal Stromal/Stem Cells [https://pmc.ncbi.nlm.nih.gov/articles/PMC3345279/]
• 29. CD31 defines a subpopulation of human adipose-derived ... [https://www.nature.com/articles/s41598-023-41535-1]
• 30. Isolation, culture and identification of human adipose ... [https://www.spandidos-publications.com/10.3892/etm.2017.4069]
• 31. Adipose-derived mesenchymal stromal cells in clinical trials [https://www.sciencedirect.com/science/article/pii/S0024320524003515]
• 32. Vasculogenic potential of adipose tissue derived stem cells ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12423250/]
• 33. Best Practices for Multiparametric Flow Cytometry [https://www.thermofisher.com/us/en/home/references/newsletters-and-journals/bioprobes-journal-of-cell-biology-applications/bioprobes-79/best-practices-multiparametric-flow-cytometry.html]
• 34. Multiplex Analysis of Adipose-Derived Stem Cell (ASC) ... [https://www.mdpi.com/2073-4409/10/2/218]
• 35. Best Practices In Flow Cytometry Compensation Methodologies [https://expertcytometry.com/best-practices-in-flow-cytometry-compensation-methodologies/]
• 36. Impact of Panel Size, Fluorochrome Selection, and ... [https://pubmed.ncbi.nlm.nih.gov/40960432/]
• 37. Spectral Flow Cytometry Panel Controls and Sample ... [https://www.thermofisher.com/us/en/home/life-science/cell-analysis/flow-cytometry/flow-cytometry-learning-center/flow-cytometry-resource-library/flow-cytometry-methods/spectral-flow-cytometry-panel-controls-sample-preparation.html]
• 38. Recommended controls for flow cytometry [https://www.abcam.com/en-us/technical-resources/guides/flow-cytometry-guide/recommended-controls-for-flow-cytometry]
• 39. Sample Preparation - USF Health - University of South Florida [https://health.usf.edu/medicine/corefacilities/flowcytometry/sample-preparation]
• 40. Flow Cytometry Blood Cell Identification - StatPearls - NCBI [https://www.ncbi.nlm.nih.gov/books/NBK608011/]
• 41. Human Adipose-Derived Mesenchymal Stem/Stromal Cells ... [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2018.00033/full]
• 42. Therapeatic evaluation and single cell analysis of adipose ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12595830/]
• 43. Mechanical isolation of stromal vascular fraction from adipose ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04641-7]
• 44. Human adipose tissue–derived mesenchymal stromal cells ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8742185/]
• 45. Clinical Protocol of Producing Adipose Tissue-Derived ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6235368/]
• 46. Characterization of adipose-derived stem cells of anatomical ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4156637/]
• 47. Flow cytometry analysis of adrenoceptors expression in ... [https://www.nature.com/articles/sdata2018196]
• 48. The influence of inflammation on the characteristics of adipose ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-023-03532-z]
• 49. Identifying differentiation markers between dermal fibroblasts ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04185-w]
• 50. Data analysis in flow cytometry [https://www.abcam.com/en-us/technical-resources/guides/flow-cytometry-guide/data-analysis-in-flow-cytometry]
• 51. Impact of cell culture transition on adipose-derived ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12270734/]
• 52. Protocol to examine murine visceral adipose tissue ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11456973/]
• 53. Characterisation of Mesenchymal Stromal Cells (MSCs) ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12112012/]
• 54. Seventeen-colour flow cytometry: unravelling the immune ... [https://www.nature.com/articles/nri1416]
• 55. Murine bone-derived mesenchymal stem cells undergo ... [https://www.nature.com/articles/s41598-024-63009-8]
• 56. Extracellular vesicles isolated from adipose tissue-derived ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12168270/]
• 57. How to Interpret Flow Cytometry Data [https://www.fortislife.com/resources/antibody-resources/how-to-interpret-flow-cytometry-data]
• 58. Continuous collection of human mesenchymal-stromal-cell ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04341-2]
• 59. Isolation of murine adipose-derived stromal/stem cells for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6391981/]
• 60. Effect of adipose-derived mesenchymal stromal/stem cells ... [https://www.sciencedirect.com/science/article/pii/S2452318625000418]
• 61. Optimization of Human Adipose-Derived Mesenchymal ... [https://bmrat.org/index.php/BMRAT/article/view/988]
• 62. Unveiling heterogeneity in MSCs: exploring marker-based ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11094970/]
• 63. Adipose Tissue: Understanding the Heterogeneity of Stem ... [https://www.mdpi.com/2218-273X/11/7/918]
• 64. Ex Vivo Human Adipose Tissue Derived Mesenchymal ... [https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.01695/full]
• 65. The angiogenic potential of CD271+ human adipose tissue ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7927269/]
• 66. Purification and differentiation of human adipose-derived ... [https://www.nature.com/articles/srep40069]
• 67. Adipose-derived and bone marrow mesenchymal stem cells [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-018-0914-1]
• 68. Is CD34 truly a negative marker for mesenchymal stromal ... [https://www.sciencedirect.com/science/article/abs/pii/S1465324912712343]
• 69. Is CD34 Truly a Negative Marker for Mesenchymal Stem ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3846603/]
• 70. Human adipose-derived mesenchymal stromal cells from ... [https://www.sciencedirect.com/science/article/abs/pii/S0014482721002937]
• 71. Phenotypic Characterization of Adherent Cells Population ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5405783/]
• 72. and Late-Passage Adipose-Derived Mesenchymal Stem ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7519987/]
• 73. Endothelial CD34 expression and regulation of immune ... [https://www.nature.com/articles/s41598-023-40622-7]
• 74. Tracing genomic instability in induced mesenchymal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12046023/]
• 75. Adipose-Derived Mesenchymal Stromal Cells in Basic ... [https://www.mdpi.com/1422-0067/24/4/3888]
• 76. Adipose-derived mesenchymal stem cells from liposuction ... [https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-017-0258-9]
• 77. High-resolution analysis of genetic stability of human ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3822542/]
• 78. Flow Cytometry Rare Cell Detection and Analysis Guide [https://www.thermofisher.com/us/en/home/life-science/cell-analysis/flow-cytometry/flow-cytometry-learning-center/flow-cytometry-resource-library/flow-cytometry-methods/flow-cytometry-rare-cell-analysis.html]
• 79. Detection of low abundance RNA molecules in individual ... [https://pubmed.ncbi.nlm.nih.gov/23441230/]
• 80. Detection of Low Abundance RNA Molecules in Individual ... [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057002]
• 81. Adipose-Derived Stem Cells: Current Applications and Future ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7787857/]
• 82. Effects of Decade Long Freezing Storage on Adipose ... [https://www.nature.com/articles/s41598-018-26546-7]
• 83. Immunomodulatory Effect of Adipose-Derived Stem Cells [https://pmc.ncbi.nlm.nih.gov/articles/PMC7180192/]
• 84. Fidelity of Long-Term Cryopreserved Adipose-Derived Stem ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6938680/]
• 85. Phenotypic and Functional Characterization of Long-Term ... [https://www.nature.com/articles/srep09596]
• 86. Overview of current adipose-derived stem cell ( ADSCs ) processing... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-02006-w]
• 87. Cryopreservation of Human Adipose Tissues and ... [https://www.mdpi.com/2073-4409/10/7/1837]
• 88. Therapeutic potential and mechanistic insights into adipose ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12659562/]
• 89. Mesenchymal stem cells in treating human diseases [https://www.nature.com/articles/s41392-025-02313-9]
• 90. Omics characteristics and epigenetic modifications of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12590281/]
• 91. Extracellular vesicle-based drug overview [https://www.nature.com/articles/s41392-025-02312-w]
• 92. Mesenchymal stem cell-derived extracellular vesicles [https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2025.1626996/full]
• 93. Processing Adipose Tissue Samples in a GMP Environment Standardizes the Use of SVF in Cell Therapy Treatments: Data on 302 Patients - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC10525825/]
• 94. Optimizing mesenchymal stem cell therapy: from isolation to GMP-compliant expansion for clinical application - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC12054297/]
• 95. Comparative analysis of human Mesenchymal Stromal ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12616983/]
• 96. Phenotypic Characterizations and Comparison of Adult Dental ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3075526/]
• 97. A comparison of the use of adipose-derived and bone ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-020-01661-3]
• 98. Side-by-Side Comparison of the Biological Characteristics of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC3722850/]
• 99. Comparison of the Biological Characteristics ... [https://www.nature.com/articles/s41598-018-23396-1]
• 100. Comparison of the differentiation abilities of bone marrow ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8343765/]
• 101. Phenotype and differentiation potential of human somatic ... [https://www.sciencedirect.com/science/article/pii/S1873506115000458]
• 102. Bridging the gap: clinical translation of adipose-derived stem ... [https://stemcellres.biomedcentral.com/articles/10.1186/s13287-025-04405-3]
• 103. Adipose-Derived Mesenchymal Stromal Cells in Basic ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9962639/]
• 104. Comparative Analysis of the Proliferation and ... [https://www.sciencedirect.com/science/article/abs/pii/S2212429225019716]
• 105. Immune modulation via adipose derived Mesenchymal ... [https://www.nature.com/articles/s41598-021-91870-4]
• 106. Characteristics and Immunomodulating Functions of ... [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01642/full]
• 107. Gene expression analysis of human adipose tissue ... [https://www.nature.com/articles/s41598-018-22991-6]
• 108. Immunomodulatory Potential of Human Adipose ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC4220146/]
• 109. Optimization of Mesenchymal Stromal Cell (MSC ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9261977/]
• 110. Optimizing mesenchymal stem cell therapy: from isolation to ... [https://bmcmolcellbiol.biomedcentral.com/articles/10.1186/s12860-025-00539-7]
• 111. Housekeeping Gene Stability in Adipose Mesenchymal ... [https://www.mdpi.com/2073-4409/13/2/167]